National Institute for Health and Clinical Excellence

Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (part review of TA86)

Assessment Report

Commercial in Confidence stripped version for consultation

Produced by: Aberdeen Health Technology Assessment Group

Systematic review of the clinical and cost-effectiveness of imatinib at escalated doses of 600 mg/day or 800 mg/day for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours which have progressed on treatment at a dose of 400 mg/day

Produced by:

[1]Health Services Research Unit
[2]Health Economics Research Unit
Institute of Applied Health Sciences
University of Aberdeen

[3]Division of Applied Medicine, School of Medicine and Dentistry, University of Aberdeen and Aberdeen Royal Infirmary, NHS Grampian

Authors:

[1]Jenni Hislop
[2]Zahidul Quayyum
[1]Andrew Elders
[1]Cynthia Fraser
[1]David Jenkinson
[1]Graham Mowatt
[1]Pawana Sharma
[1,2]Luke Vale
[3]Russell Petty

Correspondence to:

Jenni Hislop
Health Services Research Unit
University of Aberdeen
3rd Floor, Health Sciences Building
Foresterhill
Aberdeen AB25 2ZD

Date completed: March 2010

Version: 1

Source of funding

This report was commissioned by the NIHR HTA Programme as project number 09/21/01.

Declared competing interests of authors

None

Acknowledgements

We thank the study authors we contacted who provided additional details of their studies, and Lara Kemp for secretarial support. The Health Services Research Unit, and Health Economics Research Unit, Institute of Applied Health Sciences, University of Aberdeen are both core-funded by the Chief Scientist Office of the Scottish Government Health Directorates. The views expressed are those of the authors and not necessarily those of the funding bodies. Any errors are the responsibility of the authors.

Rider on responsibility for report

The views expressed in this report are those of the authors and not necessarily those of the Chief Scientist Office of the Scottish Government Health Directorates or of the NIHR HTA Programme. Any errors are the responsibility of the authors.

This report should be referenced as follows:

Hislop J, Quayyum Z, Elders A, Fraser C, Jenkinson D, Mowatt G, Sharma P, Vale L, Petty R. Systematic review of the clinical and cost-effectiveness of imatinib at escalated doses of 600 mg/day or 800 mg/day for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours which have progressed on treatment at a dose of 400 mg/day. Aberdeen HTA Group, Institute of Applied Health Sciences, University of Aberdeen, 2010.

Contributions of authors

Jenni Hislop (Research Fellow) and Pawana Sharma (Research Fellow) screened the search results for clinical effectiveness, assessed full text studies for inclusion, and undertook data extraction and quality assessment. Jenni Hislop drafted the chapters of the report other than the background and cost-effectiveness chapters, and coordinated the review. Pawana Sharma contributed to the chapter on clinical effectiveness, and appendices. Graham Mowatt (Senior Research Fellow) and Luke Vale (Professor of Health Technology Assessment) commented on drafts. Zahidul Quayyum (Research Fellow) screened the search results on cost-effectiveness, undertook data extraction and quality assessment, drafted the chapter on cost-effectiveness and developed the economic model, supervised by Luke Vale. Russell Petty (Clinical Senior Lecturer in Medical Oncology) drafted the background chapter, and provided

expert advice on clinical aspects of the review. David Jenkinson and Andrew Elders (Statisticians) contributed to the data analysis section of the assessment of clinical effectiveness and conducted the statistical analysis. Cynthia Fraser (Information Officer) developed and ran the search strategies, obtained papers and formatted the references. All authors assisted in preparing the manuscript and commenting on drafts. Graham Mowatt is guarantor.

CONTENTS

LIST OF TABLES

LIST OF FIGURES

LIST OF APPENDICES

1 LIST OF ABBREVIATIONS

AGITG	Australasian Gastrointestinal Trials Group
ATP	Adenosine triphosphate
BNF	British National Formulary
BSC	Best supportive care
CEA	Cost effective analysis
CI	Confidence interval
c-KIT	Cytokine- tyrosine kinase receptor
CT	Computer tomography
ECOG	Eastern Cooperative Oncology Group
EORTC	European Organization for Research and Treatment of Cancer
EQ-5D	EuroQol-5D
ESMO	European Society for Medical Oncology
FDG-PET	Fluorodeoxy glucose - positron emission tomography
GI	Gastrointestinal
GIST	Gastrointestinal stromal tumours
HR	Hazard ratio
HRQOL	Health related quality of life
ICC	Interstitial cells of Cajal
ICER	Incremental cost effective ratio
ICUR	Incremental cost utility ratio
IM	Imatinib
IQR	Interquartile range
ISG	Italian Sarcoma Group
KIT	Tyrosine kinase
LYG	Life year gain
LYS	Life year saved
NCCN	National Comprehensive Cancer Network
NICE	National Institute for Health and Clinical Excellence
NIHR	National Institute for Health Research
OS	Overall survival
PD	Progressive disease
PDGFRA	Platelet-derived growth factor receptor alpha
PFM	Progression free month
PFS	Progression free survival
PR	Partial response

QALY	Quality adjusted life year
QoL	Quality of life
RCT	Randomised controlled trial
REBIP	Review Body of Interventional Procedures
RECIST	Response Evaluation Criteria in Solid Tumors
RR	Relative risk
SCF	Stem cell factor
SD	Stable disease
SMC	Scottish Medicine Consortium
VEGFR	Vascular endothelial growth factor receptor
WHO	World Health Organization
WMD	Weighted mean difference

2 EXECUTIVE SUMMARY

Background

Less than 1% of all cancers in the gastrointestinal (GI) tract are gastrointestinal stromal tumours (GISTs). The median age of patients at diagnosis is between 50 and 60 years old and diagnosis typically depends upon morphological and clinical features being consistent with positive KIT/CD117 protein expression. Surgical resection is potentially curative but some patients will have unresectable and/or metastatic disease. Conventional chemotherapy and radiotherapy are ineffective in the management of unresectable and/or metastatic GIST and symptom control through best supportive care was the main treatment available. Imatinib (Glivec®) at a dose of 400 mg/day was recommended in NICE's 2004 guidance as first line management for those with KIT (CD117)-positive unresectable and/or metastatic GIST. Dose escalation upon disease progression after initially responding at the 400 mg/day dose was not recommended, although other recent guidelines have recommended dose escalation to a maximum dose of 800 mg/day, particularly for those patients with unresectable and/or metastatic GIST who also have specific exon mutations in the KIT gene. Since the 2004 guidance sunitinib malate (SUTENT), another tyrosine kinase inhibitor, has been licensed for the treatment of people with unresectable and/or metastatic GIST. NICE guidance recommends sunitinib as a treatment option for people with unresectable and/or metastatic malignant GISTs if imatinib treatment has failed because of resistance or intolerance, and the drug cost of sunitinib for the first treatment cycle is met by the manufacturer.

Objectives

The aim was to assess the effectiveness and cost-effectiveness of imatinib at escalated doses of 600 mg/day and 800 mg/day following progression of disease at a dose of 400 mg/day, with sunitinib, or the provision of best supportive care only for patients with unresectable and/or metastatic GISTs. Particular subgroups of interest were patients with specific KIT mutations.

Methods

Electronic searches were undertaken to identify published and ongoing randomised controlled trials (RCTs), non-randomised comparative studies and case series. Participants were adult patients with unresectable and/or metastatic GISTs whose disease had progressed on an imatinib dose of 400mg/day. The interventions considered were imatinib at a dose of 600 mg/day and 800 mg/day, sunitinib, or best supportive care only. Outcomes considered included overall response, overall survival, disease-free survival, progression-free survival, time to treatment failure, health related quality of life, and adverse effects.

The titles and abstracts of all identified reports were screened and full text reports of potentially relevant studies assessed. Data were extracted from included studies, including details of study design, participants, interventions, comparators and outcomes. These studies were quality assessed using a checklist developed for non-randomised studies and case series, adapted from several sources, including the Centre for Reviews and Dissemination's guidance for those carrying out or commissioning reviews, Verhagen and colleagues, Downs and Black, and the Generic Appraisal Tool for Epidemiology (GATE). The Cochrane Collaboration's risk of bias tool, was also used to evaluate the quality of sequence generation and allocation concealment of RCTs. Data analysis was confined to a comparison of data extracted from published Kaplan-Meier curves, and a narrative synthesis of results was presented.

For the review of economic evaluations, electronic searches were undertaken to identify cost or cost-effectiveness analyses relevant to the study question. Selection of relevant papers used similar methods to the review of clinical effectiveness. For included studies, data were extracted and critically appraised according to the guidelines produced by the Centre of Reviews and Dissemination for the critical appraisal of economic evaluations, and guidelines relevant to modelling studies. A Markov model was developed to compare the cost-effectiveness of seven clinically plausible alternative care pathways. The data used to populate the model were derived from the review of clinical effectiveness as well as the review of economic studies. Within the model people were assumed to move to the next therapy specified for a care pathway unless they had responded to treatment. All pathways ended with best supportive care, which patients would enter if they had exhausted all other treatments in a pathway. Both deterministic and probabilistic sensitivity analysiswere conducted. The latter was restricted to considering distributions for the probability of death and non-response to focus attention on uncertainty in these data.

Results

Clinical effectiveness

Five studies (n = 2032) met the inclusion criteria, with four (n = 318) reporting outcomes for patients who received escalated doses of imatinib and one (n = 351) reported outcomes for patients who received sunitinib. No studies meeting our inclusion criteria were identified for best supportive care. The included studies were essentially observational in nature and subject to the biases associated with such data, consisting mostly of reporting of subgroups of patients who had been enrolled in RCTs that were not designed to assess the effects of dose escalation

on patients with advanced and/or metastatic GIST whose disease had progressed on the 400 mg/day dose. Therefore the selection of patients was neither randomised nor consecutive.

At an escalated dose of 600 mg/day between 26% and 42% of patients showed either a partial response or stable disease. Median time to progression was 1.7 months (range 0.7 to 24.9 months). No data on other outcomes were available.

At an escalated dose of 800 mg/day between 29% and 33% of patients showed either a partial response or stable disease. The median overall survival was 19 months (95% CI 13 to 23 months). Progression-free survival ranged from 81 days to 5 months (95% CI 2 to 10 months). The median duration of response was 153 days (range 37 to 574 days). Treatment progression led to 88% discontinuations but between 16% and 31% of patients required a dose reduction, and 23% required a dose delay. There was a statistically significant increase in the severity of fatigue ($p<0.001$) and anaemia ($p=0.015$) following dose escalation.

For sunitinib, median overall survival was 90 weeks (95% CI 73 to 106 weeks). No data were available for other outcomes.

Insufficient data were available on the subgroup population of interest with KIT mutations, and these were not considered in the economic analysis.

Cost-effectiveness

Although seven economic studies were identified only one full-text study and one abstract, comparing imatinib at an escalated dose, sunitinib and best supportive care were identified. Neither were based on a UK context. The definition of best supportive care was not consistent across the studies, and the pattern of resources (including drugs for treatment) and measures of effectiveness also varied.

Within the model, Path – 1, best supportive care, (which was assumed to include continuing medication to prevent tumour flare) was the least costly and least effective. It would be the care pathway most likely to be cost-effective when the cost per QALY threshold was less than £25,000. Path – 4, imatinib at 600 mg/day was most likely to be cost-effective at a threshold between £25,000 and £45,000. Imatinib at 600 mg/day followed by further escalation, followed by sunitinib was most likely to be cost-effective at a threshold over £45,000.

Sensitivity analysis

The results did not greatly alter under the majority of the sensitivity analyses conducted. However, all the economic data were based upon point estimates for mortality and response rates that were in turn based upon sparse and potentially biased data.

It was also not possible, due to lack of data, to make alternative assumptions about probabilities of death and response change over time, or reductions in utility associated with adverse effects of treatment. Further assumptions that were required to be made in the model were that patients who move on to best supportive care would remain on treatment with imatinib at 400 mg/day to prevent tumour flare, but that this would have no impact on effectiveness.

Discussion

Relatively little relevant data were identified for this review and what data were available are essentially observational and non-comparative. Such data are potentially biased, with both the magnitude and direction of the bias being uncertain. Therefore, all results should be interpreted with caution.

Approximately one third of unresectable and/or metastatic GIST patients who receive dose escalated imatinib show either response or stable disease, which can be maintained over several months. However, few data were available for imatinib at 600 mg/day and median overall survival for imatinib at 800 mg/day and sunitinib was less than 24 months. Few data were available on adverse events but up to one third of patients may need a dose reduction or a dose delay. Patients may see a significant worsening of anaemia and/or fatigue upon dose escalation.

The results of the economics model showed that pathways involving dose escalation would be cost-effective should the cost per QALY threshold be £30,000 or above. Treatment with sunitinib after progressing on imatinib at 400mg/day was not likely to be cost-effective. However, this result was based on limited non-comparative data for this treatment and is probably unreliable.

There are a number of remaining uncertainties, including:

- The results are suggestive of a benefit from dose escalation but the non-randomised, non-comparative data available for review are potentially biased. This limits the usefulness of both the review of effectiveness and the economic model.

- There was a lack of evidence on quality of life outcomes, which would have informed the economic model, but would also be of importance to patients.
- There was little evidence on response and survival on escalated doses of imatinib, specifically for those with different mutations in the KIT gene.
- There is uncertainty surrounding the effects of dose modifications and potential differential effects of sunitinib for both the population being given this drug because of intolerance to imatinib and those receiving sunitinib after failure on imatinib.
- There is also uncertainty surrounding the nature and severity of adverse events and their impact on quality and quantity of life and costs.

Conclusions

Implications for service provision

- There was very limited evidence available from very few studies on the effects of escalated doses of imatinib or treatment with sunitinib for the target population. The evidence that was available was essentially observational in nature and subject to the biases associated with such data, consisting mostly of reporting of subgroups of patients in RCTs that were not designed to assess the effects of dose escalation.
- The limited evidence base suggests that around one third of patients with unresectable and/or metastatic GIST who have failed on a dose of 400 mg/day, may show response or stable disease with escalated doses of imatinib, and those who do respond may have a reasonable chance of maintaining this response over a longer period of time than would otherwise have been the case.
- For all patients receiving either dose escalated imatinib, or sunitinib, median overall survival, where reported, was less than two years.
- Although the results should be interpreted with caution due to the limitations of the evidence base, should society's threshold for willingness to pay be less than £25,000 per QALY a pathway of best supportive care only has the highest probability of being cost-effective. Between a threshold of £25,000 and £45,000 provision of an escalated dose of imatinib would be most likely to be cost-effective. Above a threshold of £45,000 a threshold a pathway of escalated doses of imatinib followed by sunitinib, if necessary would most likely to be cost-effective.

Recommendations for research

Suggested priorities for further research are made:

- An RCT involving patients who progress on 400 mg/day imatinib where patients are randomised to pathways describing alternative combinations of dose escalation with imatinib and the use of sunitinib should be performed. The pathways most likely to be cost-effective at thresholds society might be willing to pay and hence potentially the most useful to assess were: dose escalation with imatinib and dose escalation with imatinib followed by sunitinib if necessary. A trial should include an economic evaluation and measurement of health state utilities and have sufficiently long enough follow-up to capture all outcomes of interest.
- Where possible further studies should also report outcomes for subgroups of patients with specific KIT mutations.
- In any prospective comparative study a wider perspective on the consideration of costs might also be informative (e.g. costs that fall on personal social services, which would be relevant for NICE to consider, and costs for patients and their families, which goes beyond NICE's reference case).

3 BACKGROUND

3.1 Description of health problem

3.1.1 Introduction

Gastrointestinal stromal tumours (GISTs) are tumours of mesenchymal origin that arise in the gastrointestinal tract (GI tract). Historically and based upon morphological appearance alone, GISTs were considered to be of smooth muscle origin and regarded as leiomyomas or leiomyosarcomas. Subsequently, electron microscopic and molecular analysis has demonstrated that GISTs are a distinct tumour type arising from the interstitial cells of Cajal (ICC), and characterised by the expression of receptor tyrosine kinase KIT (CD117) protein demonstrated by immunohistochemistry.[1] CD117/KIT immunoreactivity now provides the diagnostic criteria for GISTs, although there is recognition that a small proportion of GISTs (4%) are KIT immunoreactive negative.[2,3]

3.1.2 Aetiology, pathology, and prognosis

Recent investigation has provided clinically significant insights into the molecular pathogenesis of GISTs. This has allowed the rational development of systemic therapies (including imatinib and sunitinib); provided robust diagnostic criteria for GISTs; and demonstrated the ability of certain pathogenic gene mutations to predict clinical behaviour and response to therapy in GISTs which therefore have potential application as predictive biomarkers.

Activating mutations in the *KIT* proto-oncogene are an early and key event in the pathogenesis of GISTs, and present in up to 95% of cases.[4-10] The protein product is a member of the receptor tyrosine kinase family and a transmembrane receptor for stem cell factor (SCF).[11] Extracellular binding of SCF to the receptor results in dimerisation of KIT and subsequent activation of the intracellular KIT kinase domain[9] leading to activation of intracellular signaling cascades controlling cell proliferation, adhesion, and differentiation. *KIT* mutation is necessary but not sufficient for GISTs pathogenesis, other mutations are essential, and KIT mutation is absent in a minority of cases (<5%).[12,13] In the majority of KIT mutation negative cases, mutational activation of the closely related tyrosine kinase Platelet Derived Growth Factor Receptor Alpha (PDGFRA) is the pathogenic event and KIT and PDGFRA activation have similar biological effects.[12,13]

It has been demonstrated that KIT and PDGFRA gene mutations are mutually exclusive[7,8,10,14] and GISTs with no *KIT* mutations have either PDGFRA-activating mutations or no identified kinase mutations.[13] GISTs that lack *KIT* mutations may still have high KIT kinase activity

and so may have *KIT* mutations that are not detected by conventional screening methods. Alternatively, KIT kinase activation may be due to non-mutational mechanisms.[6]

Diagnosis of GIST is made when morphological and clinical features of the tumour are consistent and the tumour has positive KIT/CD117 protein expression.[15] However, as noted above, approximately 4% of GISTs have clinical and morphological features of GIST but have negative KIT immunoreactivity.[2] These KIT negative GISTs are more likely to contain PDGFRA mutations.[2] It is important in these cases, when KIT/CD117 staining is negative, that other markers are investigated to confirm GIST diagnosis. Recent studies have shown that a novel protein DOG1, is highly expressed in both *KIT* and *PDGFRA* mutant GISTs [16,17] and immunostaining for DOG1 can be used in conjunction with CD117 staining, and diagnosis of GIST made on the basis of KIT and/or DOG1 immunoreactivity.[15] PDGRFA immunohistochemistry should also be performed and positivity can assist with diagnosis. Mutational analysis also plays a role in the diagnosis of KIT/CD117 negative suspected GISTs, as with consistent morphological and clinical features, positive mutation analysis for either KIT or PDGFRA is diagnostic.[15]

Without treatment GISTs are progressive and will eventually metastasise to distant organs and so are invariably fatal without any intervention. GISTs are resistant to 'conventional' oncology treatments of cytotoxic chemotherapy and radiotherapy. Prognosis is highly dependent on the resectability of the tumour, however only 50% of GIST patients have resectable disease at first presentation.[18,19] Ten year survival for resectable/non-metastatic tumours is 30-50%, and at least 50% will relapse within 5 years of surgery, but for unresectable tumours, prognosis is very poor with survival generally less than 2 years without further treatment.[18,19]

3.1.3 Epidemiology and incidence

While GISTs are the most common mesenchymal tumour of the GI tract, overall they are a rare cancer accounting for less than 1% of all cancers of the GI tract.[20] GISTs can occur anywhere in the GI tract from the oesophagus to the rectum, but most arise in the stomach or small intestine.[21] They are rare before the age of 40 years and very rare in children with a median age at diagnosis of 50-60 years.[22,23] Some data show a slight male predominance but this is not a consistent finding.[22,24,25]

Retrospective studies carried out using KIT immunoreactivity as a diagnostic criterion have shown that GISTs have been under-diagnosed in the past.[26,27] These retrospective population-

based reclassification studies provide the most reliable and accurate current estimate of an annual incidence of 15 cases per million, which would equate to 900 cases in the UK. [15]

3.1.4 Impact of health problem

The symptoms of GISTs depend on the size and location of the primary tumour and any metastatic deposits. While one third of cases are asymptomatic and discovered incidentally during investigations or surgical procedures for unrelated disease, severe and debilitating symptoms occur in many patients and are invariable in those patients who have (or develop) metastatic disease.[28]

GISTs less than 2 cm in size with no metastatic disease are usually asymptomatic. Larger primary tumours and those of patients with metastatic disease are usually symptomatic and the most common symptom is GI tract bleeding, which occurs in 50% of patients, 25% of these patients presenting as emergencies with acute GI haemorrhage, either into the intestine or peritoneum.[29] Abdominal discomfort is a feature of larger tumours.[30] Oesophageal GISTs typically present with dysphagia, which represents the main symptomatic problem in these cases and colorectal GISTs may cause bowel obstruction. In metastatic disease debilitating systemic symptoms such as fever, night sweats, and weight loss are common.

3.2 Current service provision

3.2.1 Management of disease

There is wide consensus that the management of GISTs should be undertaken in the context of discussion of individual cases by a multidisciplinary team.[15,31]

3.2.1.1 Management of resectable disease

Surgical resection is the primary treatment for GISTs and offers the only possibility of cure. Surgical resection is undertaken with the aim of achieving a complete microscopic resection (R0 resection). Evaluation of the suitability and possibility of a complete microscopic resection of a GIST is made after appropriate pre-operative assessment to determine stage and also the fitness of the patient for the procedure required. Preoperative assessment for staging includes (as a minimum) a CT scan of the chest, abdomen and pelvis, and in specific circumstances there is a role for endoscopic ultrasound, laparoscopy and angiography.

After resection patients are followed up with protocols involving clinical examination and/or surveillance imaging, based upon relapse risk stratification by means of histopathological criteria of the resected tumour.[15,32] Preliminary results from one randomised, placebo-controlled phase III trial suggest that adjuvant therapy with imatinib (400mg/day for one year)

increases recurrence-free survival following resection, and it is therefore suggested that adjuvant imatinib may have an important role to play in the prevention of recurrence of GISTs after resection.[33] The results of other similar adjuvant trials are awaited.[15] At present UK guidelines recommend adjuvant imatinib (400mg/day) in patients considered to be of moderate or high-risk of relapse, according to histopathological criteria.[15] However it is acknowledged that, until more data are available from ongoing adjuvant studies, there is still uncertainty regarding the optimal duration of treatment, and also the sub-groups of patients who may or may not benefit from adjuvant therapy. The use of imatinib as an adjuvant therapy may have implications, for example with regard to the development of drug resistance, for the subsequent systemic treatment of GISTs upon recurrence.[34]

Studies are ongoing to determine the role of imatinib as preoperative therapy in resectable tumours.[35] Nevertheless, the use of imatinib preoperatively to downstage tumours from unresectable to resectable is considered safe and clinically worthwhile.[15] Similarly, preoperative imatinib has also been recommended to limit the extent and (accordingly) morbidity of resection in specific circumstances, for example to facilitate sphincter sparing resection in rectal GISTs.

3.2.1.2 Management of unresectable and metastatic disease

Conventional cytotoxic chemotherapy and radiotherapy are ineffective in the treatment of advanced GISTs. Similarly, initial debulking surgery is not recommended unless there is an immediate clinical need, such as to remove an obstructing tumour.

Imatinib (Glivec®) is a rationally-designed small molecule inhibitor of several tyrosine kinases including KIT and PDGFRA and has provided the first clinically effective systemic therapy for GISTs. The European license for imatinib was based on a phase II study of 147 patients who were randomised to receive either imatinib at 400 mg or 600 mg orally taken once daily.[36] The treatment was well tolerated, objective response rate was the primary efficacy outcome and an overall partial response rate of 67% was demonstrated with no difference between treatment arms. Long-term results revealed median survival of 57 months for all patients.[37] A concurrent study investigated dose escalation and established 800 mg daily as the maximum tolerated dose.[38] Phase III trials performed both in Europe and Australasia (EORTC 62005 study), and in North America (S0033 Intergroup study) confirmed the efficacy of imatinib in a larger patient population, and established the starting dose of 400mg orally per day.[39,40]

Primary resistance to imatinib is uncommon, but acquired resistance is inevitable, and manifest clinically by the observation of disease progression.[39-43] Guidelines suggest that patients should have a CT scan every three months while on therapy.[15] Measurement of response by conventional criteria such as Response Evaluation Criteria in Solid Tumors (RECIST), based on objectively measured changes in tumour size, may not occur, or may only happen after many months of treatment. This means that definitive evidence of patient response, and therefore clinical benefit, can be difficult to ascertain (at least initially). This has been addressed by the development of alternate methods of GIST response assessment, such as the 'Choi criteria' based upon tumour density as well as tumour size.[44,45] Similarly, FDG-PET has demonstrated some efficacy in predicting early response to imatinib therapy.[46]

In addition, the assessment of progression of GISTs may be problematic, based on RECIST based tumour size criteria as tumour liquefaction (cystic degeneration) can occur which may give the appearance of progressive disease although the tumour is actually responding.[45] Accordingly, it is recognised that experienced radiologists should assess CTs before confirming progression.

It has been demonstrated that interruption of treatment results in rapid disease progression in many patients with advanced GISTs.[43] This includes patients with disease progression where a symptomatic worsening or 'flare' has been described.[47] Therefore continuation of imatinib in these patients has been common practice despite progression, as part of best supportive care.

Several studies have reported further disease control after progression on an initial imatinib dose of 400 mg orally per day, with dose escalation of imatinib to 800 mg orally per day and this has also become common practice.[37,42] However, it should be noted that current NICE guidelines for imatinib do not actually recommend dose escalation for unresectable and/or metastatic GIST patients who progress on an initial dose of 400 mg/day.[48]

Recently, additional molecular-based treatments for GIST have become available, including sunitinib (Sutent®), which has been approved by NICE for patients with unresectable and/or metastatic GIST who have progressed on treatment imatinib.[49] The NICE advice follows a randomised, double-blind, placebo-controlled, multicentre phase II trial in which 312 patients who were resistant or intolerant to imatinib, received either sunitinib (50 mg starting dose in 6 week cycles; 4 weeks on and 2 weeks off treatment) or placebo,[50] was unblinded early when interim analysis showed a significantly longer time to tumour progression (the primary endpoint) with sunitinib.

To date, no randomised trial has been conducted comparing imatinib and sunitinib. One had been planned but was stopped due to poor recruitment.[51] As new options for management of patients with unresectable and/or metastatic GIST have developed since the initial 2004 publication of NICE guidance for GIST treatment with imatinib, a review of the evidence available on treatments currently used in clinical practice is required.

3.2.2 Current service cost and anticipated costs associated with the intervention

As GIST affects mostly the middle aged and older age population, the loss of productivity from the middle age population suffering from GIST is of concern. The median age of the GIST patients was found to be between 50-60 years,[22,23] and incidence of GIST was found to increase with increase in age.[52] The cost of different treatment strategies needs thorough investigation in a robust economic evaluation.

Treatment with imatinib per patient within an NHS setting has been estimated at £18,896 and £24,368 for patients on 400 mg/day and 600 mg/day respectively[53] Other associated annual costs of treatment (including the treatment of adverse events) were estimated at £2730 (price year not stated). Estimates from previous disease models suggest that in two years it would cost the NHS approximately £31,160 to treat a patient with imatinib, and for ten years this figure would be £56,146 (2002 price year).[52,53] It has also been suggested that the total cost of treatment with imatinib in the NHS (England and Wales), would be between £5.6 million and £11.2 million.[53] Costs would differ when patients who fail to respond to imatinib are provided with higher doses, or alternative treatments (e.g. sunitinib).[48]

The costs of treating unresecetable and/or metastatic GIST using imatinib were estimated at between £1557 and £3115 per month per patient, resulting in a cost to NHS (England and Wales) of between approximately £5.6 million and £11.2 million per year (2002 price year).[53] NICE estimates suggest the number of new cases of unresectable and/or metastatic GISTs to be around 240 people per year. Another study estimates that the total costs over ten years for managing GIST patients with molecularly-targeted treatment would be between £47,521 and £56,146 per patient compared with a cost of between £4047 and £4230 per patient with best supportive care (price year not stated).[52]

3.2.3 Variation in service and uncertainty about best practice

The treatment of GISTs after progression on imatinib is generally decided on a case by case basis by multidisciplinary teams, and the alternatives are; dose escalation of imatinib; sunitinib 50mg/day (4 weeks out of 6), or alternatively best supportive care only (although due to the 'symptomatic flare' already mentioned this may include continuation of imatinib at

400mg/day). Many clinicians advocate initial dose escalation of imatinib and then consider sunitinb on subsequent progression, but there will be variation in clinical practice depending on the specific needs of individual patients.

3.2.4 Relevant national guidelines

UK guidelines recommend the dose escalation of imatinib, and/or sunitinib following imatinib failure,[15,54] but also suggest clinical decisions are made on an individual case by case basis, reflecting uncertainty regarding optimal practice.

3.3 Description of technology under assessment

3.3.1 Summary of intervention

3.3.1.1 Imatinib

Imatinib (Glivec®) is a rationally designed small molecule inhibitor of several oncogenic tyrosine kinases - c-Abl, ARG, PDGFR, and the KIT tyrosine kinases. Its therapeutic activity in GISTs relates to inhibition of KIT, although in cases with no KIT mutation, inhibition of PDGFRA is likely to be of therapeutic importance[2] Imatinib is a derivative of 2-phenylaminopyrimidine, and a competitive antagonist of ATP binding which blocks the ability of KIT to transfer phosphate groups from ATP to tyrosine residues on substrate proteins. This interrupts KIT-mediated signal transduction which is the key pathogenic driver for many GISTs. The inhibitory activity of imatinib on KIT is highly selective, and minimal inhibition of other kinases that are important in normal cell function occurs, thereby affording a good toxicity and safety profile.

Imatinib is licensed and approved for use in the NHS in KIT immunoreactive positive advanced/unresectable GISTs.[48,55]

3.3.1.2 Sunitinib

Sunitinib malate (SUTENT), is a tyrosine kinase inhibitor targeting KIT, PDGFRA, all three isoforms of vascular endothelial growth factor receptor (VEGFR), FMS-like tyrosine kinase 3 (FLT3) colony-stimulating factor 1 receptor (CSF-1R) and glial cell line-derived neurotrophic factor receptor.[56] Sunitinib activity in GISTs may predominantly relate to inhibition of KIT and/or PDGFRA, and ex-vivo investigation has shown that sunitinib can inhibit the kinase activity of KIT molecules harbouring secondary mutations conferring imatinib resistance.[57] However the potent anti-angiogenic activity of suntinib as a consequence of strong VEGFR inhibition may also be important for clinical activity in GISTs.

3.3.1.3 Best supportive care

Best supportive care is not well defined or standardised, and can also be referred to as "supportive care" or "active symptom control".[53] It usually involves interventions to manage pain; treat fever, anaemia (due to GI haemorrhage) and GI obstruction[48] and can include palliative measures.[58] A Cochrane review of supportive care for gastrointestinal cancer patients defined supportive care as "the multi-professional attention to the individual's overall physical, psychosocial, spiritual and cultural needs".[59] It was argued that this type of care should ethically be made available to all treatment groups, meaning that in clinical practice for GIST patients, treatment with imatinib or sunitinib could not be provided without concomitant supportive care as well, though it is possible that treatment with best supportive care could be provided without additional drug treatment with either imatinib or sunitinib.

3.3.2 Identification of important subgroups

The differential benefit from imatinib and sunitinib in subgroups of GIST patients whose tumours have different primary and secondary KIT mutations has suggested possible benefits in personalising first and second line therapy.

Primary KIT mutations are those that are pathogenic and present before any systemic treatment, while secondary mutations are those that have been identified after imatinib treatment and confer resistance to imatinib. Identification of secondary mutations requires rebiopsy of tumours, and studies have suggested that the emergence of secondary (or acquired) imatinib resistance is polyclonal, so GIST patients may acquire more than one secondary KIT mutation.[60]

A meta-analysis of 1640 patients revealed that patients with *KIT* exon 9 primary mutations have a better outcome if treated at the escalated dose of 800 mg daily.[61] Similarly, objective response rates to imatinib 400mg/day are higher in patients with exon 11 primary mutations compared to those with exon 9 mutations, or those with no detectable KIT or PDGFR mutation.[14,39] Therefore, advanced GIST patients with exon 9 mutations may benefit from immediate dose escalation of imatinib, and the benefit of dose escalation on progression may be more significant in this subgroup of patients and thereby have implications for therapeutic alternatives and choices on progression in different groups of patients defined by KIT mutations.

Secondary mutations in KIT exons 13, 14, 17 and 18 are associated with acquired resistance to imatinib.[41] Sunitinib activity after progression on imatinib has been demonstrated in GIST patients with imatinib resistance conferring secondary KIT mutations.[60] However, both the

primary KIT mutation genotype and secondary KIT mutations may influence the clinical benefit effect of sunitinib in GIST patients who have progressed on imatinib.[60] Interestingly, in contrast to imatinib, greater benefit from sunitinib (after imatinib failure) is seen in patients with primary exon 9 mutations or wild-type KIT as opposed to primary exon 11 mutations.[60] However it is not clear how dose escalated imatinib (800mg/day) compares to sunitinib in patients with primary exon 9 KIT mutation. While the polyclonal emergence of resistance is an investigational and clinical challenge, it appears that GIST patients with secondary *KIT* mutations associated with acquired imatinib resistance in exons 13 or 14 (which involve the KIT-adenosine triphosphate binding pocket) appear to gain greater clinical benefit from sunitinib after imatinib failure, than those patients with exon 17 or 18 imatinib resistance secondary mutations (which involve the KIT activation loop).[60]

Changes in FDG (F-2-fluoro-deoxy-D-glucose) avidity of GISTs measured by FDG-PET occur earlier than anatomical changes in GISTs and so may also have a role as a predictive biomarker for imatinib response, and also for detecting early disease progression.[47]

3.3.3 Current usage in the NHS

Current practice is to commence patients at imatinib 400mg/day, and on confirmed disease progression the options are dose escalation of imatinib up to 800mg/day or sunitinib, or best supportive care only. Practice is variable, and decided on a case-by-case basis. Some clinicians proceed with dose escalation of imatinib initially and then on further progression, use sunitinib. Some guidelines and clinicians advocate returning to imatinib for symptomatic benefit, when there are no other therapeutic options, and the cessation of imatinib in the absence of alternative treatment options is not recommended due to the tumour flare phenomenon, with rapid deterioration in symptoms observed in some patients.

4 DEFINITION OF THE DECISION PROBLEM

4.1 Decision problem

Specific information on the population, interventions, comparators and relevant outcomes considered for this review are discussed in detail in Section 6.1.1

Until the licensing of imatinib, the prognosis for people with unresectable and/or metastatic GISTs was poor.[19] Since 2002, the clinical effectiveness of treatment for GIST with imatinib at a dose of 400 mg/day has been well documented.[48,53] There is also clinical trial evidence showing that patients with unresectable and/or metastatic GIST can also respond to higher doses of imatinib, up to a maximum tolerated dose of 800 mg/day,[38] and that patients with different exon mutations in the KIT gene may differ in their response to imatinib at both standard and escalated doses.[14]

NICE guidance does not currently recommend the prescription of escalated doses of imatinib upon progression on the standard 400 mg/day dose,[48] although it is common in clinical practice.[15,32] Most of the evidence relating to dose-escalated imatinib comes from randomised trials where participants were randomised to doses greater that 400 mg/day, as opposed to receiving these higher doses upon disease progression on the 400 mg/day dose. However evidence suggests that tolerability of higher doses may depend on the extent of prior exposure to the drug,[62] and if in clinical practice, escalated doses are prescribed upon progression, these trial data may not provide reliable estimates of response, progression-free and overall survival, quality of life effects or the extent of adverse event occurrence. In addition, if patients with unresectable and/or metastatic GIST are likely to attain different levels of clinical benefit from different imatinib doses, clinicians' decision-making on appropriate dosages for individual patients should be informed by the best available evidence.

The development of imatinib has represented a paradigm shift in the treatment of unresectable and/or metastatic GIST, as prior to its introduction onto the market, the only available treatment remaining for this population group was best supportive care, which, given the severity of this disease, represents essentially palliative intervention. Since the introduction of imatinib, other new treatments for unresectable and/or metastatic GIST have become available, including sunitinib, which has been recommended by NICE as the second line treatment for the population of interest, after failure on treatment with imatinib.[49] As there are now various options available for treating unresectable and/or metastatic GIST, and it is therefore necessary to review the available evidence on imatinib at escalated doses, when

compared with sunitinib, for patients with unresectable and/or metastatic GIST whose disease has progressed on the standard imatinib dose of 400 mg/day.

4.2 Overall aims and objectives

The aim of this review was to assess the clinical and cost-effectiveness of imatinib at escalated doses (i.e. 600 mg/day or 800 mg/day) within its licensed indication,[63] for the treatment of patients with unresectable and/or metastatic GISTs, who have progressed on imatinib at a dose of 400 mg/day.

The objectives of this review will help facilitate decision-making on the most appropriate treatment(s) for patients with unresectable and/or metastatic GIST who have progressed on imatinib at a dose of 400 mg/day, by:

- Conducting a systematic review of the evidence available on the clinical effectiveness of imatinib at dosages of 600 mg/day, or 800 mg/day compared with sunitinib and/or best supportive care
- Conducting a systematic review of the cost-effectiveness of imatinib at dosages of 600 mg/day or 800 mg/day compared with sunitinib and/or best supportive care
- Analysing available outcome data for particular sub-groups of interest (e.g. patients with different KIT mutations) in order to establish any differences in clinical effectiveness for specific groups
- Develop an economic model to compare the cost-effectiveness and cost-utility of using imatinib at a dose of 600 mg/day or 800 mg/day, with sunitinib (within its recommended dose range) or best supportive care only

5 CRITIQUE OF THE MANUFACTURER SUBMISSION

The manufacturer of imatinib (Novartis) did not provide an economic analysis in their submission, stating that due to the limited amount of data available from the key clinical studies and the dearth of data comparing imatinib dose escalation with sunitinib and best supportive care, they were unable to submit a sufficiently robust economic analysis which met the scope for the appraisal. However, they did provide a summary of clinical evidence and implications for the economic analysis. With the exception of the Executive Summary section, and most of the References section, a large proportion of the submission document was highlighted as commercial in confidence. Electronic copies of all the papers cited in the References section, including two labelled as commercial in confidence by the manufacturer, were provided. Apart from both of the commercial in confidence documents, these studies had already been retrieved by our searching process and are discussed in Chapter 6.

Of the two commercial in confidence reports provided, one [redacted] was a report on the randomised, phase II, B2222 trial comparing imatinib at doses of 400 mg/day and 600 mg/day. Patient data from this trial that is relevant to this review has since been published by Blanke and colleagues in the Journal of Clinical Oncology.[37] The remaining commercial in confidence report [redacted] provided a meta-analysis of data from the randomised, phase III, intergroup S0033 trial comparing imatinib at doses of 400 mg/day and 800 mg/day, and the randomised, phase III, EORTC-ISG-AGITG trial also comparing imatinib at these doses. Crossover data from the S0033 trial have been published separately,[39,64] as have crossover data from the EORTC-ISG-AGITG trial.[42] [redacted]

All relevant results pertaining to the population of interest for this review have been provided in Chapter 6 (Assessment of Clinical Effectiveness). [redacted] but as more recent results for the study population of interest has been published, only study characteristics information was used in Chapter 6 (Assessment of Clinical Effectiveness) of this review.

The key points made in the manufacturer submission were as follows:

- The limited amount of data available from the key clinical studies and the paucity of data comparing imatinib dose escalation with sunitinib and best supportive care prevent, in the opinion of the manufacturer, the submission of a sufficiently robust economic analysis which meets the scope of the appraisal.
- There are currently no head-to-head trial data comparing imatinib with sunitinib.
- Sunitinib represents a third line treatment, rather than second line as per the scope of the evaluation, making it difficult, if not impossible, to conduct a robust and plausible indirect comparison of the two technologies. UK National GIST Guidelines recommend that changing treatment to sunitinib should only be considered after patients have shown progression on imatinib dose escalation.
- Since the publication of TA86 clinical practice has evolved to consider dose escalation to a daily dose of 600 mg or 800 mg, when patients progress on the standard daily dose of 400 mg, and this change in clinical practice is reflected within UK National GIST Guidelines.[54]

[redacted]

6 ASSESSMENT OF CLINICAL EFFECTIVENESS

6.1 Methods for reviewing effectiveness

6.1.1 Identification of studies

Extensive sensitive electronic searches were conducted to identify reports of published and ongoing studies on the clinical effectiveness of imatinib. The searches were also designed to retrieve clinical effectiveness studies of the comparator treatments (sunitinib and best supportive care). In addition, reference lists of retrieved papers and submissions from industry and other consultees were scrutinised to identify additional potentially relevant studies.

The databases searched were: Medline (1966 - September Wk 3 2009), Medline In-Process (25th September 2009), Embase (1980 – Week 39 2009), CINAHL (September 2009), Science Citation Index (2000 - 26th September 2009), Biosis (2000 - 24th September 2009), Health Management Information Consortium (September 2009), and the Cochrane Controlled Trials Register for primary research and the Database of Abstracts of Reviews of Effects (DARE) (October 2009), the Cochrane Database of Systematic Reviews (CDSR) (Issue 3 2009) and the HTA database for relevant evidence syntheses (October 2009).

Ongoing and recently completed trials were searched in the following databases: current research registers, including Clinical Trials, Current Controlled Trials, NIHR Portfolio, WHO International Clinical Trials Registry Platform, IFPMA Clinical Trials and the ABPI database. Recent conference proceedings of key oncology and gastrointestinal organisations, including the American Society for Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO) and the European Cancer Organisation. Websites of the GIST Support International, and the drug manufacturers Pfizer and Novartis were also scrutinised.

Full details of the search strategies used are reproduced in Appendix 1.

6.1.2 Inclusion and exclusion criteria

Types of studies

An initial scoping search suggested that there would be few studies looking specifically at either of the named interventions (imatinib 600 mg/day or 800 mg/day). Therefore we considered all of the following types of studies for the assessment of clinical effectiveness:

1. RCTs;
2. Non-randomised comparative studies; and
3. Case series.

If the number of studies meeting our inclusion criteria was sufficiently large, consideration was to be given to limiting them by type of study design, and also possibly other factors (e.g. sample size). Additionally, it was planned to exclude non-English language papers, and/or reports published as meeting abstracts if the evidence base of English language and/or full text reports was sufficiently large.

- ***Types of participants***

Participants considered were people with KIT (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST), whose disease had progressed on treatment with imatinib at a dose of 400 mg/day. If sufficient evidence was available, sub-group analysis was to be undertaken for those patients with different mutations of CD117, as there is some evidence to suggest this may affect their response to escalated doses of imatinib[14,39,61]- see background section 3.3.2. In addition, sub-group analysis was also to be undertaken on methods used to identify response or resistance (e.g. FDG-PET or CT scanning) and the use of imatinib in a neoadjuvant or adjuvant setting for patients with previously resectable GIST, where sufficient data were available.

- ***Types of intervention and comparators***

The interventions considered were imatinib at escalated doses of 600 mg/day and 800 mg/day respectively, being prescribed with best supportive care. The comparators considered were sunitinib, prescribed within its recommended dose range of 27-75 mg and provided with best supportive care, and best supportive care only. As previously stated, best supportive care is defined as "the multi-professional attention to the individual's overall physical, psychosocial, spiritual and cultural needs".[59]

- ***Types of outcomes***

For the assessment of clinical effectiveness, the following outcomes were considered:

- Overall response
- Overall survival
- Disease-free survival
- Progression-free survival
- Time to treatment failure
- Health-related quality of life (e.g. EQ-5D scores)
- Adverse effects of treatment (e.g. number of discontinuations due to adverse events)

- ***Exclusion criteria***

We excluded studies of animal models, preclinical and biological studies, reviews, editorials, opinions, case reports, and reports investigating technical aspects of the interventions.

6.1.3 Data extraction strategy

The titles and abstracts (where available) of all records identified by the search strategy were screened by two reviewers independently. Full-text copies of all potentially relevant reports were retrieved. The full-text reports were assessed against the inclusion and exclusion criteria by two reviewers independently. Full-text papers and conference abstracts were assessed using a screening form that was developed and piloted for this purpose. Any disagreements were resolved by consensus or arbitration by a third party. A copy of the screening form used can be found in Appendix 2.

A data extraction form was developed and piloted (Appendix 3). One reviewer extracted details of the study design, participants, intervention, comparator and outcomes and a second reviewer checked the data extraction for accuracy. Any disagreements were resolved by consensus or arbitration by a third party.

6.1.4 Quality assessment strategy

Two reviewers independently assessed the methodological quality of the included full-text studies. Non–randomised comparative studies were assessed using an 18-question checklist, with the same checklist minus four questions used to assess the methodological quality of case series. The checklist for non-randomised studies and case series was adapted from several sources, including the Centre for Reviews and Dissemination's guidance for those carrying out or commissioning reviews,[65] Verhagen and colleagues,[66] Downs and Black,[67] and the Generic Appraisal Tool for Epidemiology (GATE). It assesses bias and generalisability, sample definition and selection, description of the intervention, outcome assessment, adequacy of follow-up, and performance of the analysis. The checklist was developed through the Review Body for Interventional Procedures (ReBIP). ReBIP is a joint venture between Health Services Research at Sheffield University and the Health Services Research Unit at the University of Aberdeen and works under the auspices of the National Institute for Health and Clinical Excellence (NICE) Interventional Procedures Programme.

We planned to assess the quality of RCTs using the Cochrane Collaboration's tool for assessing risk of bias.[68] The tool addresses six specific domains: sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting and other issues. Each quality assessment item had three possible responses; "Yes", "No" or "Unclear", with space

for additional comments. Disagreements between reviewers over study quality were to be resolved by consensus and if necessary, arbitration by a third party. Abstracts were not quality assessed because they were considered unlikely to provide sufficient methodological information to enable an accurate assessment of study quality. Methodological quality did not form part of the criteria for the inclusion or exclusion of studies. A copy of the quality assessment tool can be found in Appendix 4.

6.1.5 Data analysis

The type of data analysis considered was dependent on the number of studies meeting the specified inclusion criteria, and study design. Where a quantitative synthesis was considered inappropriate or not feasible, it was planned that a narrative synthesis of results would be provided instead.

For relevant outcomes from randomised comparisons, it was decided that meta-analysis (where appropriate) was to be employed to estimate a summary measure of effect. Dichotomous outcome data for the overall response outcome would be combined using the Mantel-Haenszel relative risk (RR) method, and continuous outcomes by using the inverse-variance weighted mean difference (WMD) method. For both of these estimates, 95% confidence intervals (CIs) and p-values would also be calculated. Chi-squared tests and I-squared statistics were to be used to explore statistical heterogeneity across studies, with possible reasons for heterogeneity explored using sensitivity analysis. Where no obvious reason for heterogeneity was found, the implications would be explored using random effects methods.

The pooled weighted ratio of median survival was to be derived for overall, disease-free and progression-free survival. The hazard ratio (HR) is the most appropriate statistic for time-to-event outcomes (i.e. for time to treatment failure). If available, the HR would be extracted directly from the trial publications, but if not reported it would be extracted if possible from other available summary statistics or from data extracted from published Kaplan-Meier curves using methods described by Parmar and colleagues.[69] A pooled HR from available RCTs could then be obtained by combining the observed (O) minus expected (E) number of events and the variance obtained for each trial using a fixed effects model.[70] A weighted average of survival duration across studies was to be calculated. The chi square test for heterogeneity was to be used to test for statistical heterogeneity between studies.

Where no RCT data were available, but non-randomised studies had reported relevant data for survival outcomes, assessment of the risk of bias and heterogeneity was to be undertaken using meta-regression analysis.

It was expected that few studies, if any would report direct comparisons of the intervention and comparators, so (depending on feasibility, and appropriateness) it was decided that where non-randomised evidence was available, meta-analysis models would be used to model survival rates for interventions and comparators. A "cross design" approach was to be adopted to allow non-randomised evidence to be included, whilst avoiding the strong assumption of the equivalence of studies. Evidence suggests that this approach would allow data from RCTs, non-randomised comparative studies and case-series to be included.[71] Differences between treatments for survival outcomes were to be assessed via the corresponding odds ratio and 95% credible intervals. These results are "unadjusted odds ratios", but meta-analysis models adjusting for study type were also to be used. The results from these models produce "adjusted" odds ratios.[72] WinBUGS software was to be used for the analysis.

Any reported data on adverse effects of treatment and quality of life (QoL) that were collected were to be combined, using standardised mean difference, where appropriate.

In addition, and taking into account the type of evidence, the feasibility of using a mixed treatment comparison model for indirect comparisons was to be considered.

6.2 Results

6.2.1 Number of studies identified

We identified 3366 records from the primary searches for the review of clinical effectiveness. After title and abstract screening, 2441 articles were considered not to be relevant for this review and were excluded. The full text papers of 925 records were obtained and screened. One hundred and twenty-three of these full-text papers were non-English language publications. In total, six full-text papers and ten abstracts reporting four separate clinical trials and one additional retrospective cohort, met our inclusion criteria. An additional 49 papers were retained for background information. The reasons for exclusion of assessed full-text papers are given in Table 1. A flow diagram of the screening process is outlined in Figure 1 below. Information on the reasons for excluding individual studies is provided in Appendix 5.

Figure 1 Flow diagram outlining the screening process for the review of clinical effectiveness



6.2.2 Included studies

See Appendix 6 for a list of studies that were included in the review of clinical effectiveness. We did not identify any RCTs, or non-randomised comparative studies comparing the effectiveness of escalated doses of imatinib (600 mg/day or 800 mg/day) with sunitinib or best supportive care, that met our inclusion criteria. One on-going trial was identified comparing imatinib and sunitinib. However, this study was stopped due to poor recruitment. We identified five full-text reports of three randomised trials of imatinib that contained relevant data for this review.[14,36,37,39,42] The studies by Zalcberg and colleagues,[42] Blanke and colleagues (S0033)[39] and Blanke and colleagues (B2222)[37] were designated as the primary reports for the EORTC-ISG-AGITG (62005) trial, the S0033 trial and the B2222 trial respectively. The study by Debiec-Rychter and colleagues[14] met our inclusion criteria and provided additional information from the EORTC-ISG-AGITG (62005) study on response following crossover, whilst the study by Demetri and colleagues[50] met our inclusion criteria and provided interim data from the B2222 trial on response following crossover.

An additional three abstracts were identified, with two[64,74] reporting interim data for the S0033 trial, and one reporting interim data for the EORTC-ISG-AGITG 62005 trial.[75]

All of these included studies contained a treatment arm of 400 mg/day, and reported data separately for participants who received an escalated dose of imatinib upon progression at this randomised dose. One additional full-text paper detailing the results of a non-randomised retrospective study by Park and colleagues[73] was also included. This study met our inclusion

criteria as it also provided separate outcome data for metastatic or unresectable GIST patients who received escalated doses of imatinib on progression at an initial dose of 400 mg/day.

For the comparator treatment of sunitinib, we identified seven abstract reports meeting our inclusion criteria. All were interim results of an on-going, open-label sunitinib trial reporting information on participants recruited to the trial following failure at different doses of imatinib, including doses of ≤400 mg/day.[76-82] We designated the abstract by Seddon and colleagues[82] to be the primary report for this trial, as it was thought to contain its most recent results.

For the comparator treatment of best supportive care, no randomised, non-randomised or case series studies were identified that compared either of the interventions (imatinib at a dose of 600 mg/day or imatinib at 800 mg/day) with best supportive care, or provided data on relevant outcomes for the population of interest for best supportive care only. It should be noted that studies published on the clinical effectiveness of best supportive care prior to the licensing of imatinib[18,19] were not eligible for this review as our population of interest was those who had failed on imatinib at 400 mg/day, therefore all studies published prior to the availability of imatinib automatically failed to meet our inclusion criteria because best supportive care at that time could not possibly have been provided following failure of treatment with imatinib at a dose of 400 mg/day.

Corresponding authors for each of the included trials were contacted in order to determine whether any additional data could be provided specifically for the population of interest (i.e. those participants failing on an imatinib dose of 400 mg/day and receiving either an escalated dose of imatinib 600 mg/day or 800 mg/day, or alternatively, sunitinib). For the ongoing, open-label sunitinib study, the corresponding author replied that no further information could be provided as the study was an official, ongoing trial by the manufacturer (Pfizer). For the imatinib trials, in the case of both studies by Blanke and colleagues[37,39] our requests for information were forwarded to the statistics team involved in the trials. The requested data for the S0033 trial were provided on the 17th February 2010. For the study by Zalcberg and colleagues, a response to our request was received, explaining that an official data request form must be completed. This has been submitted and we are presently awaiting a response.

Two additional reports [redacted] to the ones identified through our search strategy were provided for this review by the manufacturer and have been

discussed in Chapter 5, and are also discussed below. Both of these reports were marked as commercial in confidence.

6.2.3 Excluded studies

A list of 340 studies, originally identified as potentially relevant but subsequently failing to meet our inclusion criteria is provided in Appendix 5. The studies were excluded because they failed to meet one or more of the inclusion criteria in terms of the type of study, participants, intervention, comparator, or outcomes reported. In addition, the types of participants were limited to an adult population; therefore studies involving paediatric GIST patients were excluded. However, it should be noted that the age range provided in the baseline data for the included study by Seddon and colleagues[82] indicates that at least one child was recruited onto this trial, but as the median age reported indicates that the majority of patients in this trial were adults, the study was not excluded.

Studies with a relevant population of fewer than ten patients were also excluded. Changes to our original protocol were reported to NIHR in a progress report submitted on the 9th of December 2009.

In addition to the included studies identified above, nine studies (reported in 14 papers) reported sufficient information with regard to our inclusion criteria to be considered for potential inclusion in this review, subject to clarification from the study authors regarding specific aspects of the study. Corresponding authors for each of the nine studies were therefore contacted. Responses were received from four corresponding authors [personal communication, GD Demetri, YK Kang, P Rutkowski, and P Wolter]. In the cases of two responses, this resulted in the exclusion of the studies (five papers in total) from the review.[personal communication, P Rutkowski and P Wolter] In the remaining two studies (four papers), the responses did not result in clarification, as the authors requested that we wait for a further response from them or their colleagues.[personal communication, GD Demetri and YK Kang]. In the case of correspondance with YK Kang, it was decided that the study by Park and colleagues[73] could be included in the review without further clarification from the corresponding author.

Of the correspondences that did not result in responses, one email could not be sent successfully[83] and the remaining four authors did not respond.[84-87]

Table 1 Reasons for exclusion of studies

Reason for exclusion	Number of studies excluded
Patient had resectable GIST	24
Outcomes not reported separately for GIST patients	11
<10 patients in relevant study population	46
Imatinib dose is 400 mg/day	13
No/insufficient data reported for escalated dose patients	66
No imatinib dose reported	83
No relevant interventions	15
Treatment not evaluated	11
No outcomes of relevance	10
Other reason	61
	340
Retained for background information	49
Review articles	169
Letter/editorial/correspondence/symposium articles/meeting reports/expert views/comments	117
Case study/ case series<10 patients	64
Non-English language exclusions	123
Not obtained	47
Total	***909***

6.2.4 Characteristics of the included studies

Study characteristics data were available for the four full-text included imatinib studies[37,39,42,73] and the primary report of the included sunitinib trial.[82] However, of these studies, only the studies by Zalcberg and colleagues, and Park and colleagues gave specific baseline information for the crossover subgroup of interest. Therefore, Table 2 provides details of all characteristics information provided for each crossover group, whilst Table 3 provides details of the same characteristics for all patients in the treatment arms of interest (initial randomisation to a dose of 400 mg/day). In the case of the EORTC-ISG-AGITG trial reported by Zalcberg and colleagues, relevant study characteristic data for participants initially randomised to the 400 mg/day dose were not available. However, these data were reported in a paper by Verweij and colleagues,[40] for the same trial. The paper by Verweij and colleagues failed to meet the inclusion criteria for this review as it did not provide any outcome data for patients receiving an escalated dose of 800 mg/day imatinib upon

progression at a 400 mg/day dose, but as it provides information on the characteristics of all randomised patients (of whom a proportion went on to receive an escalated dose of 800 mg/day and formed the study population of the included study by Zalcberg and colleagues), it was felt that the baseline data from this excluded study could still be used.

Table 2 Characteristics of the included studies for the population of interest

	Zalcberg 2005[42]	Blanke S0033[39]	Blanke B2222[37]	Park 2009[73]	Seddon 2008[82]
Drug assessed:	Imatinib	Imatinib	Imatinib	Imatinib	Sunitinib
Doses given:	400 mg/day 800 mg/day	400 mg/day 800 mg/day	400 mg/day 600 mg/day	600mg/day 800mg/day	Cycle of 50 mg/day for 4 weeks, then 0 mg/day for 2 weeks
Start Date:	[redacted]	Dec 2000	July 2000	June 2001	Unspecified
End Date:	April 2004	[redacted]	May 2006	June 2006	Dec 2007
Study countries:	Australia, Belgium, Denmark, France, Germany, Italy, The Netherlands, New Zealand, Poland, Singapore, Spain, Switzerland, UK	Canada, US	Finland, US	Seoul, South Korea	Unspecified but "worldwide" and "multicenter"
Number of institutions involved (number of countries involved)	[redacted]	148 (2)	4 (2)	1 (1)	96 (33)
Length of follow up at time of analysis:	median of 25 months (max. of 35 months)	median of 4.5 years	Median of 63 months (max of 71 months)	median of 8 months (range 1.4 to 22.3)	median of 51 weeks (range 0.1 to 159)
Number receiving escalated dose of imatinib after failure of imatinib at 400 mg/day, out of all those randomised to receive 400 mg/day	133/473 (28.1%)	118/345 (34.2%)	43/73 (58.9%)	24/24 (100.0%)	N/A
Number receiving sunitinib after failure of imatinib at ≤400 mg/day, out of all those receiving sunitinib	N/A	N/A	N/A	N/A	351/1117

Four of the included trials reported data for imatinib,[37,39,42,73] whilst the remaining trial reported data for sunitinib.[82] Two of the imatinib trials randomised patients to imatinib doses of either 400 mg/day or 800 mg/day[39,42], one randomised patients to imatinib doses of either 400 mg/day or 600 mg/day.[37] and the other was a retrospective study looking only at GIST patients who had received escalated doses of imatinib at either 600 mg/day or 800 mg/day on progression at a dose of 400 mg/day.[73] The sunitinib trial is an ongoing, non-randomised, open-label study and participants are provided with a six-week cycle of sunitinib, at a dose of 50 mg/day for four weeks followed by two weeks without the drug.[82]

The study start date was reported for three out of the four included imatinib trials[37,39,73] and was made available for the study by Zalcberg and colleagues by the manufacturer [redacted] From this it can be seen that the earliest study start date is that of the study [redacted][37] [redacted]. The included sunitinib abstract did not report a start date.

Three out of the four included imatinib studies reported an end date,[37,42,73] or in the case of the study by Seddon and colleagues, a date for the most recent analysis.[82] The manufacturer also made this information available for the study by Blanke and colleagues [redacted]. The on-going sunitinib trial has the most recent update, whilst the study by Zalcberg and colleagues was completed first, in April 2004.[42]

With the exception of the study by Park and colleagues,[73] which involved one centre in one country, all trials were international and multicentre.[37,39,42,82] with the sunitinib trial involving the most countries[81] and the S0033 trial involving the most institutions.[39] The B2222 trial involved the fewest countries and fewest institutions.[37]

The longest length of follow up occurred in the B2222 trial reported by Blanke and colleagues[37] where patients were followed up for a median of 63 months, whilst the shortest length of follow up was found in the study by Park and colleagues[73] which gave a median follow up for the study population of 8 months.

Among the imatinib trials, 133/473 (28.1%), 118/345 (34.2%), and 43/73 (58.9%) of those initially randomised to imatinib at 400 mg/day progressed and were given an escalated dose.[37,39,42] In the imatinib study by Park and colleagues,[73] the study population comprised only those who were given escalated doses of imatinib so 24/24 (100%) received an escalated dose. In the sunitinib study by Seddon and colleagues, 351/1117 (31.4%) of those who failed on imatinib and were entered into the trial, had failed on a dose of 400 mg/day or less.

Therefore the study with the largest relevant population was the sunitinib trial,[82] whilst the study by Park and colleagues had the smallest study population.[73]

Table 3 Characteristics of the included studies for all participants randomised

	EORTC-ISG-AGITG*[40]	Blanke S0033[39]	Blanke B2222[37]	Park 2009[73]	Seddon 2008[82]
Included in this analysis	**All those randomised to 400 mg/day**	**All those randomised to 400 mg/day**	**All those randomised to 400 mg/day**	**All those who received escalated doses of imatinib on progression at a dose of 400 mg/day†**	**All those receiving sunitinib**
Number included	473	345	73	24	1117
Age in years – median (range)	59 (49-67)	61.9 (18-87)		52 (31-73)	59 (10-92)
Sex (M/F)	283/190	187/158		18/6	665/451
ECOG/WHO Performance Status Score					
0	217			4	420
1	191			18	515
2	48			2	134
≤2	(456)	332			(1069)
>2	17	13			38
Missing					10
Race/ethnicity (N)	Not reported			Not reported	Not reported
White		273			
Black		37			
Asian		25			
Other/Unknown		10			
Number had previous chemotherapy	156 (32.9%)	Not reported		3 (12.5%)	225 (26.8%)
Number having previous radiotherapy	26 (5.5%)	Not reported		Not reported	78 (7.9%)
Number having prior surgery	410 (86.7%)			20 (83.3%)	Not reported

* Baseline data for only the crossover patients from this treatment arm were available and are reported in Appendix 8 (Characteristics of Included Studies)
† Participants in this study were part of a retrospective cohort. Treatment was not randomised. The population of interest received escalated imatinib doses

The Park study[73] had the youngest population, whilst the S0033 trial,[39] had the oldest study population. In [redacted] studies, the number of male patients was higher than the number of female patients, which concurs with the epidemiological trends in gender associated with this disease.

[redacted] studies reported data on the performance status score of participants although the study by Blanke and colleagues for the S0033 trial[39] had combined the ECOG performance status categories 0 to 2. Doing the same for the remaining studies shows that the vast majority of participants, 456/473 (96.4%), 332/345 (96.2%), [redacted], 24/24 (100%) and 1069/1107 (96.6%) in the EORTC-ISG-AGITG trial,[40] S0033 trial[39] B2222 trial, [redacted] Park study[73] and the sunitinib trial[82] respectively, had a performance status score of ≤ 2.

[redacted]

In terms of prior treatment, [redacted] two reported the number having previous radiotherapy,[40,82] [redacted] For the imatinib studies, 3/24 (12.5%), 156/473 (32.9%) and [redacted] of participants had undergone previous chemotherapy in the study by Park and colleagues[73] the EORTC-ISG-AGITG trial and the B2222 trial[40] [redacted] respectively, whilst 26.8% (225/1117) patients had received prior chemotherapy in the study by Seddon and colleagues.[82] With regard to radiotherapy, 26/473 (5.5%) of patients in the EORTC-ISG-AGITG trial[40] and 78/1117 (7.9%) of patients in the sunitinib trial[82] had received prior radiotherapy. [redacted] of participants involved in the B2222 trial reportedly had received prior surgery, [redacted] whilst this figure was 86.7% (410/473) for participants in the EORTC-ISG-AGITG trial,[40] and 83.3% (20/24) in the study by Park and colleagues.[73]

6.2.5 Quality of the included studies

Results of the quality assessment for all four included full-text papers, are summarised in Figure 2. No third party arbitration for quality assessment was required. The results of the quality assessment for each individual study are provided in Appendix 9. Three full-text studies assessed for quality assessment were included in the review because they provided crossover data on a subset of patients who were originally randomised to a dose of 400 mg/day, but progressed and received an escalated dose of either 600 mg/day[37] or 800 mg/day.[39,42] The fourth study[73] was assessed for quality because it included a retrospective analysis of a subgroup of a cohort of patients given treatment with imatinib at 400 mg/day. The subgroup were patients who received escalated doses of 600 mg/day and/or 800 mg/day after progression on the 400 mg/day dose.

As the study populations of interest were not the original randomised populations, but the crossover sub-group in three studies,[37,39,42] and a subgroup of consecutively treated patients in the remaining study,[73] quality was assessed using the checklist for non-randomised studies (detailed in the methods section above). Questions within this checklist which were specific to non-randomised comparative groups (i.e. Q6 and Q16) were not considered applicable to the crossover subset population included in our review, and were therefore not summarised.

However, two specific domains were assessed using the Cochrane Collaboration‘s tool for assessing risk of bias, namely sequence generation and allocation concealment, as these would check for selection bias at trial level.

Figure 2 Quality assessment results summary



Sample definition and selection

In three studies[37,39,42] the included subgroups of participants were randomised at trial level, but crossover patients were not randomly selected, and so it is unclear the extent to which this group can be considered representative of the relevant patient population (Q1). The other study provided inadequate information to allow judgement of the representativeness of sample of the relevant population.[73] With regard to the randomisation process at trial level, the studies by Blanke and colleagues[39] and Zalcberg and colleagues[42] used methods that adequately generated the allocation sequence to avoid influence of confounding factors whilst Blanke and colleagues[37] did not report sufficient data on the randomisation process. In the study by Zalcberg and colleagues,[42] allocation to treatment was not concealed. Both the B2222 and S0033 studies by Blanke and colleagues reported inadequate information on allocation concealment. All four studies adequately described inclusion and exclusion criteria (Q2). We considered the inclusion of only those participants who progressed on 400 mg imatinib with performance status of the disease to be at a similar point in their disease progression at the time of study entry. Three of the studies[37,39,73] involved participants whose performance status at the time of study entry was similar, while the study by Zalcberg and colleagues[42] included participants with different performance status at study entry (Q3), although most of the participants in all populations had an performance status of less than

two, meaning they were ambulatory and awake for at least 50% of their waking hours. None of the studies undertook consecutive selection of patients (Q4). Data were collected prospectively in all of the four studies (Q5).

Description of the intervention

The intervention was adequately defined by all studies (Q7). However, no study provided sufficient data describing supervision of the intervention (Q8) and no information was provided describing the types of staff involved, or the facilities used (Q9).

Outcome assessment

The quality of all four studies was similar in terms of outcome assessment (Q10). None of the studies had considered all the outcomes of interest, but all reported the objective response of escalated imatinib dosing in GIST patients while one[39] reported overall survival and two [39,42] measured progression-free survival. The study by Park and colleagues[73] reported time to progression, and the study by Zalcberg and colleagues was the only study which also reported adverse events for those on an escalated dose of imatinib. No study reported outcomes related to quality of life.

All four studies used valid and reliable outcome measures (Q11), such as Response Evaluation Criteria in Solid Tumors (RECIST) to assess objective response, or Kaplan-Meier methods to estimate survival curves minimising detection bias. Assessment of main outcomes was not blinded in any of the studies (Q12).

Follow up and attrition bias

Follow up was considered long enough to detect important effects on outcomes of interest in all but one study where follow up information was not provided and so this was unclear[73](Q13). Information on those lost to follow up was either not provided [37] or was not provided at a sufficient level of detail[39,42,73] to judge whether those lost to follow up would be likely to introduce bias (Q14 and Q15).

Performance of the analysis

For both studies by Blanke and colleagues, important prognostic factors such as sex, performance status, neutrophils counts etc were investigated and multivariate analyses was performed at trial level but this was not done for the subset of patient who crossed over.[37,39] Similarly, Park and colleagues[73] identified possible prognostic factors (but did not adjust for confounding factors during analysis). The study by Zalcberg and colleagues[42] also did not identify any prognostic factors, their effect on analyses, or adjust for confounding factors

(Q17 and Q18). Hence we considered the quality of reporting ambiguous in terms of the performance of the analyses.

6.2.6 Assessment of effectiveness

Response

For imatinib at an escalated dose of 600 mg/day following progression at a dose of 400 mg/day, response is reported in the B2222 study by Blanke and colleagues, [37] and the study by Park and colleagues.[73] In the study by Blanke and colleagues, the median follow-up at this time was 63 months (maximum 71 months), and at that time, 43 patients had crossed over from 400 mg/day to 600 mg/day. Of these 43 patients, 11 (25.6%) showed either partial response or stable disease[i]. Some of the 43 patients who crossed over would have had an initial response to 400 mg/day before progression, as only 11 patients in the 400 mg/day arm showed a best response of progressive disease.[37] Interim data for this study population are provided in the study by Demetri and colleagues,[36] where, after a median follow up of 288 days (maximum nine months), nine patients had crossed over, with one showing partial response at that point, and two with stable disease.[36]

In the study by Park and colleagues,[73] median follow up was eight months (range 1.4 to 22.3 months) and of the 12 patients who received an escalated dose of of 600 mg/day of imatinib, five (41.7%) showed either partial response or stable disease.

With regard to response data provided by the manufacturer,

[redacted]

[redacted]. As a result, these data from the manufacturer's submission were not used in our review.

For imatinib at a dose of 800 mg/day following progression at a dose of 400 mg/day response data is available from the S0033 study by Blanke and colleagues,[39], the EORTC-ITG-AGITG trial by Zalcberg and colleagues,[42] and the study by Park and colleagues.[73] Of the crossover populations in S0033 and EORTC trials (117 and 133 patients respectively), three patients in each trial (i.e. six in total) had a partial response, whilst 33 patients in the S0033 trial and 36 patients in the EORTC-ISG-AGITG trial had stable disease as a best response. This means that out of a total of 250 patients, 75 (30%) had a response after escalation from 400 mg to 800 mg/day.

Response information from the study by Park and colleagues did not provide separate data for those with stable disease and those achieving partial responses. However, it did state that four out of the 12 patients (33.3%) receiving an escalated imatinib dose of 800 mg/day upon progression at the 400 mg/day dose, achieved either partial response or stable disease.[73]

Some of the patients receiving dose escalated imatinib to 800 mg/day would have had an initial response to the 400 mg/day dose, because only 42/345 patients (12.2%) in the S0033 trial 400mg arm had a best/only response of progressive disease (or "early death"),[39] and in the study by Zalcberg and colleagues this figure was 61/473 (12.9%).[40]

Interim data for the EORTC-ISG-AGITG trial was provided for a data cut-off point of 7th December 2003, at which point there were 2/97 (2.1%) patients showing a partial response, 30/97 (30.9%) patients with stable disease, and 65/97 (67.0%) patients with progressive disease.[75] Interim data for the S0033 trial, also from December 2003, showed that there were 5/68 (7.4%) patients with partial response, and 20/68 (29.4%) patients with stable disease, during crossover treatment with 800 mg/day of imatinib, following failure of treatment at 400 mg/day.[64]

In addition, secondary analysis for the EORTC-ISG-AGITG trial in the study by Debiec-Rychter and colleagues[14] indicated, without stating the number of patients involved, that response following crossover was significantly more likely to occur in patients with wild-type

[i] One patient only showed response after further escalation from 600 to 800mg

GIST than KIT exon 11 mutation (p=0.0012), and response following crossover was also significantly more likely to occur in patients with KIT exon nine mutation compared with exon 11 mutation (p=0.0017).[14]

No response data were provided for treatment with sunitinib at a dose of 50 mg/day (as part of a four weeks on treatment, two weeks off treatment, six week cycle), following progression on an imatinib dose of 400 mg/day.

Overall survival

For imatinib at an escalated dose of 600 mg/day following progression at a dose of 400 mg/day, overall survival data were not reported by Blanke and colleagues[37] [redacted] for the B2222 trial.

For imatinib at a dose of 800 mg/day following progression at a dose of 400 mg/day, the EORTC-ISG-AGITG trial by Zalcberg and colleagues,[42] did not report overall survival outcomes. However, the S0033 trial by Blanke and colleagues,[39] reported relevant outcome data, and at the time of the analysis (median follow up of 4.5 years) noted that, 76/118 (64.4%) of patients had died.[39] Median overall survival was 19 months (95% CI 13 to 23 months) starting from the commencement of crossover. Interim data for the S0033 trial was also provided in the study by Rankin and colleagues,[64] which stated median overall survival at December 2003 was 19 months.[64]

[redacted]

[redacted]



For sunitinib, overall survival data were available for those on 50 mg/day of sunitinib who failed on a prior imatinib dose of ≤400 mg/day, from two abstracts of the same trial, taken at different follow-up periods.[78,82] The data from the study by Reichardt and colleagues were analysed after a median of 4 cycles.[80] Median survival at this point was 93 weeks (95% CI 72-100 weeks) and 231/339 (68.1%) of patients were still alive.[78] The data from the report by Seddon and colleagues were analysed after a median of 51 weeks (range 0.1 to 159 weeks). Median survival at that time was 90 weeks (95% CI 73 to 106 weeks) and 193/351 (55%) were still alive.[82] It should also be noted that further interim overall survival data were provided in another study by Seddon and colleagues,[81] but although the date of analysis is the same month as that reported by the studies by Reichardt and colleagues[78] and Rutkowski and colleagues[79] the median overall survival reported differed, at 80.4 weeks (95% CI 60.3 to N/A weeks), whilst the population who had failed on doses of imatinib of ≤400 mg/day was also less (307 patients).[81]

It was possible to compare overall survival with an escalated dose of 800 mg/day, from the S0033 trial reported by Blanke and colleagues,[39] with sunitinib at a dose of 50 mg/day (provided in four weeks on/two weeks off cycles of six weeks), for patients who had progressed on imatinib at a dose of 400 mg/day. Quarterly overall survival estimates for the sunitinib participants reported in a Kaplan-Meier chart by Seddon and colleagues[82] were obtained using the method proposed by Parmar and colleagues[69] and compared with overall survival estimates for the S0033 trial provided by the authors. The results are provided in Figure 3.

Figure 3 Comparison of overall survival estimates for imatinib at 800 mg/day and sunitinib at 50 mg/day



The study by Zalcberg and colleagues did not report information on overall survival and was therefore not included in the comparison in Figure 3. However, data are available from the [redacted], and data from the study by Seddon and colleagues on treatment with sunitinib, are provided in Table 6.[redacted]

Table 6 Comparison of overall survival estimates for imatinib at 800 mg/day and sunitinib at 50 mg/day

	Seddon (N=351)			[redacted]		
Number of years elapsed	**Survival estimate**	**95% C.I.**		[redacted]		
1	0.684	0.626	0.741	[redacted]	[redacted]	[redacted]
2	0.441	0.379	0.503	[redacted]	[redacted]	[redacted]
3	0.200	0.140	0.261	[redacted]	[redacted]	[redacted]
4	Not reported			[redacted]	[redacted]	[redacted]

Disease-free survival

No data were reported for this outcome on account of no patient in any of the included studies having a complete response.

Progression-free survival

For imatinib at an escalated dose of 600 mg/day following progression at a dose of 400 mg/day, progression-free survival data were not reported by Blanke and colleagues[37] [redacted] for the B2222 trial.

For imatinib at an escalated dose of 800 mg/day following progression at a dose of 400 mg/day, data were reported for the S0033 trial by Blanke and colleagues,[39] and for the EORTC-ISG-AGITG trial by Zalcberg and colleagues.[42]

For the S0033 trial, at the time of the analysis, median follow up of four and a half years (54 months), 99/118 (83.9%) of the crossover cohort for whom data were available, had progressed.[39] Median progression-free survival was estimated to be five months (95% CI 2 to 10 months). Of the 99 patients who had progressive disease or had died at the time of the analysis, 23/99 (23.2%) had progressed but were still alive. Interim data from this trial, at a data cut-off point of December 2003, gave median progression-free survival to be four months following crossover, for 68[iv] patients.[64]

For the EORTC-ISG-AGITG trial, median follow up was 25 months (maximum follow-up was 35 months), and at that time, 108/133 (81.2%) of the cross-over cohort with data available had progressed. Median progression-free survival was 81 days. Sixty-seven patients (50.4%) had progressed or died within three months (Kaplan-Meier survival estimate 0.467). At one year, the Kaplan Meier survival estimate was 0.181.[42]

[redacted]

The estimates of progression-free survival provided at three month intervals by the authors of the S0033 study, and available as a Kaplan-Meier chart in the published paper of this study by Blanke and colleagues[39] were compared with progression-free survival estimates at three

month intervals that were measured from an enlarged copy of the plot of the Kaplan-Meier survival function estimate given in the paper by Zalcberg and colleagues.[42] The number of events in each time period was then calculated using the method proposed by Parmar and colleagues,[69] corrected to ensure that the total number of patients censored was consistent with the number reported in the published paper.[42] For both trials the standard error of the survival function estimates was estimated from the quarterly numbers for events and patients at risk using Greenwood's formula. Figure 4 shows the survival functions from each trial, together with 95% confidence intervals for each.

Figure 4 Kaplan-Meier plot for progression free survival with 800 mg/day imatinib



A meta-analysis of these two survival curves was attempted, using the methods described in Arends and colleagues.[88] However, no valid results could be achieved, due to the lack of data.

For sunitinib at a dose of 50 mg/day for a six week cycle, no progression data were available specifically for trial participants who had failed on a prior dose of imatinib at ≤400 mg/day.

Time to treatment failure

Data on the duration of response/time to treatment failure were available from the study by Park and colleagues[73] which showed that of the 12 patients who had their dose escalated to 600 mg/day following progression at the 400 mg/day dose, one patient died of a cause unrelated to both their disease and imatinib treatment, whilst the remaining 11 patients eventually progressed on imatinib treatment at the escalated dose after a median of 1.7 months (range 0.7 to 24.9 months).

For those receiving an escalated dose of 800 mg/day of imatinib following progression at an initial dose of 400 mg/day, data were available from the EORTC-ISG-AGITG trial showing that, of those who achieved partial response or stable disease after crossover, the median duration of "stabilisation" (i.e. partial response or stable disease after crossover) was 153 days

(range 37-574 days).[42] Interim data from this trial, (7th December 2003 data cut-off) gave a median time to progression of 78 days.[75]

For the sunitinib trial, the specific median treatment duration for those given sunitinib after failure on imatinib at a dose of ≤400 mg/day was not provided, but interim median treatment duration for the whole cohort was reported at 126 days (range 1-618), and at that time point (median follow up not stated) it was noted that median treatment duration "did not significantly differ based on the dose of prior imatinib therapy (≤400 vs > 400 mg/day).[76]

Health-related quality of life

No data were reported for this outcome by any of the included studies.

Adverse events

Data on adverse events were not reported for participants receiving an escalated dose of 600 mg/day of imatinib following progression at an initial dose of 400 mg/day.

For those receiving an escalated dose of 800 mg/day of imatinib following progression at an initial dose of 400 mg/day, data were available from the EORTC-ISG trial reported by Zalcberg and colleagues,[42] and there was some information on dose reductions in the S0033 trial report by Dileo and colleagues.[74]

The number of discontinuations due to adverse events is not explicitly stated for the EORTC-ISG-AGITG trial reported in the study by Zalcberg and colleagues, but they did report that the vast majority of discontinuations (88.4%, i.e. approximately 86/97 withdrawals) were due to disease progression, suggesting the maximum possible adverse event withdrawals possible would be 11.6% of all 97 withdrawals, i.e. 11 patients.[42] Interim data for this trial at a December 2003 data cut-off point showed that there were two toxicity withdrawals at that time.[75]

Data from this trial on specific adverse events following crossover is shown in Table 7 for those patients with 60 days follow up data.

Table 7 Adverse event data from the study by Zalcberg and colleagues[42]

Adverse event	Number with adverse event	Less severe after crossover	More severe after crossover	Number achieving new grade 3-4 level adverse event
Oedema	99	25/99 (25.3%)	33/99 (33.3%)	7
Skin rash	45	23/45 (51.1%)	19/45 (42.2%)	2
Fatigue	102	21/102 (20.6%)	47/102 (46.1%)	10 (p<0.001)
Dyspnoea	30	8/30 (26.7%)	14/30 (46.7%)	1
Infection	20	9/20 (45.0%)	9/20 (45.0%)	1
Nausea	82	38/82 (46.3%)	26/82 (31.7%)	3
Leucopenia	56	25/56 (44.6%)	16/56(28.6%)	0
Neutropenia	49	30/49 (61.2%)	13/49 (26.5%)	0 (p=0.002)
Thrombocytopenia	7	4/7 (57.1%)	2/7 (28.6%)	0
Anaemia	119	15/119 (12.6%)	51/119 (42.9%)	17 (p=0.015)

A higher proportion of those with skin rash, nausea, leucopenia, neutropenia and thrombocytopenia had reduced severity from these effects following crossover to the 800 mg/day dose of imatinib, compared with the proportion who had increased severity from these effects following crossover, (though with the exception of neutropenia these differences were not significant at the 0.05 level). The same proportion of people with infection had increased and decreased severity from this following crossover. For all other adverse events, a higher proportion of sufferers had increased severity from these effects than improvement, and in the case of anaemia and fatigue, the increase in severity following crossover was significant at the 0.05 level.[42]

Interim data reported by Zalcberg and colleagues for this trial show that 31% of patients (exact number not calculable) required a dose reduction (NB: stated as "cumulative incidence").[75] No information was provided on the dose given following dose reduction.

Interim data for the S0033 trial reported by Dileo and colleagues,[74] show that of the 77 patients who had crossed over from an imatinib dose of 400 mg/day to 800 mg/day at that time, 18 (23.3%) had at least one dose delay, and 12 (15.6%) had at least one dose reduction, due to oedema and rash. No information was provided on the dose given following dose reduction.

[redacted]



[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]					
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]					
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]					

[redacted]

[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]

[redacted]

For sunitinib at a dose of 50 mg/day for a six week cycle, no progression data were available specifically for trial participants who had failed on a prior dose of imatinib at ≤400 mg/day.
A summary of the results for all outcomes with the exception of adverse events, is provided in Table 10.

Table 10 Summary of results

Drug/dose	Median follow-up (range)	N (%) with partial response or stable disease	Duration of response/time to treatment failure	Median overall survival (95% CI)	N (%) still alive	Median progression - free survival (95%CI)	N (%) progression - free	Reference source
Sunitinib at 50mg/day	4.5 months (0 to 22.1 months)		median treatment duration did not differ based on prior imatinib dose					Kang 2007[76]
Sunitinib at 50mg/day	<6 months?			20.1 months (15.1 to N/A months)	?/307			Seddon 2007[81]
Sunitinib at 50mg/day	6 months			23.3 months (18 to 25 months)	231/339 (68.1%)			Reichardt 2008[78]
Imatinib at 600 mg/day	8 months	5/12 (41.6%)	1.7 months (range 0.7 to 24.9 months)					Park 2009[73]
Imatinib at 800 mg/day	8 months	4/12 (33.3%)						Park 2009[73]
Imatinib at 600mg/day	9.5 months (? to 9 months)	3/9 (33.3%)						Demetri 2002[36]
Sunitinib at 50mg/day	12 months (0 to 39.8 months)			22.5 months (18.3 to 26.5 months)	193/351 (55%)			Seddon 2008[82]
Imatinib at 800 mg/day	<25 months (<? to <35months)	32/65 (49.2%)	2.8 months					Zalcberg 2004[75]
Imatinib at 800 mg/day	25 months (? to 35 months)	39/133 (29.3%)	5.5 months (1.3 to 20.5 months)			2.9 months	25/133 (18.8%)	Zalcberg 2005[42]
Imatinib at 800 mg/day	<54 months	25/68 (36.8%)		19 months (not stated)				Rankin 2004[64]
Imatinib at 800 mg/day	54 months	36/117 (30.8%)		19 months (13 to 23 months)	42/118 (35.6%)	5 months (2 to 10 months)	19/118 (16.1%)	Blanke S0033[39]
Imatinib at 600mg/day	63 months (? to 71 months)	11/43 (25.6%)						Blanke B2222[37]
Imatinib at 800 mg/day		significantly more likely to occur in patients with wild-type and exon 9 mutations than exon 11						Debiec Rychter 2006[14]

NB: All units of measurement for time have been converted into months by dividing by 4 for weeks, dividing by 28 for days, and multiplying by 12 for years. All figures that were originally in units of measurement other than months are therefore approximate

7 ASSESSMENT OF COST-EFFECTIVENESS

The aim of this chapter is to assess the cost-effectiveness of alternative treatment strategies for people with KIT (CD117) positive unresectable and/or metastatic gastrointestinal stromal tumours (GISTs), whose disease has progressed on treatment with imatinib at a dose of 400 mg/day.

The specific objectives are:

a) To determine, by undertaking a systematic review of the literature, the cost-effectiveness of using imatinib at an escalated dose of 600 mg/day or 800 mg/day to treat patients with unresectable and/or metastatic GISTs (whose disease has progressed with imatinib at a dose of 400 mg/day), compared with treatment with sunitinib (within its recommended dose range) or best supportive care.

b) To develop an economic model to compare the cost-effectiveness and cost-utility of imatinib at a dose of 600 mg/day or 800 mg/day; the use of sunitinib (within its recommended dose range); or best supportive care only, for people with KIT (CD117) positive unresectable and/or metastatic GISTs whose disease has progressed on treatment with imatinib at a dose of 400 mg/day or those whose treatment with imatinib has failed due to intolerance.

7.1 Systematic review of existing cost-effectiveness evidence

The purpose of the review of economic evaluation studies was to identify published studies and assess their quality and usefulness for comparisons of treatments of GISTs; inform the methodology of the proposed economic model; and identify data on the parameters of the proposed economic model (e.g. utilities for different health states, costs and epidemiological data).

7.1.1 Methods

Search strategy for identification of published reports

A comprehensive search was undertaken to identify studies that assessed the cost or cost-effectiveness of the alternative treatments used for GISTs. Databases searched included: Medline, Medline In Process, Embase Science Citation Index, Health Management Information Consortium, NHS Economic Evaluations database, the HTA database, CEA Registry and RePeC. There were no language restrictions in the search strategy and all databases were searched from 2000 onwards.

The search strategy used is provided in Appendix 10. The abstracts of ISPOR conferences from 2006 were also searched and in addition, websites of key professional organisations, GIST Support International and the drug manufacturers Pfizer and Novartis were scrutinised.

The reference lists of all identified studies and evidence syntheses, as well as submissions from industry and other consultees were also checked for additional potentially relevant references. The methods for how the industry submissions were to be handled is described below, although as noted in Chapter 5 no industry submission was reviewed for this Technology Assessment Review. The full texts of potentially relevant reports were obtained and assessed in terms of their relevance to the economic evaluation or cost-analysis.

Quality assessment

Included studies were assessed using the guidelines of the Centre for Reviews and Dissemination.[65] Modelling studies were assessed against the Phillips checklist.[89]

Inclusion and exclusion criteria

To be included, studies had to include a cost-analysis, or a cost-effectiveness analysis of alternative treatments for GISTs. Non-English language studies were excluded.

Data extraction

Information and relevant data were extracted by an economist according to the guidelines produced by the Centre for Reviews and Dissemination for the critical appraisal of economic evaluations. Where an economic evaluation has been based on a modelling exercise, additional data extraction criteria developed by Phillips and colleagues were applied.[89,90]

Handling industry submissions

Information from the manufacturer was to be considered if it was submitted in accordance with the 3rd December 2009 deadline set by NICE. Any economic evaluations included in the company submission, provided they complied with NICE's guidance on presentation, would be assessed for clinical validity, reasonableness of assumptions and appropriateness of the data used in the economic model, using the methods outlined above. The strengths and weaknesses in terms of the methodology adopted, and reporting of results and conclusions, would be described. The conclusions derived from the company submissions were then to be compared with those provided by the review of the other existing evidence and the model reported in Section 7.2, highlighting any differences in results. Any 'commercial in confidence' data taken from a company submission were to be reported in accordance with NICE guidelines.[90]

Synthesising evidence

Data from the included studies on economic analysis and economic evaluation were summarised in order to identify common results, and to summarise the variations and differences between studies. The studies that used economic modelling were critically reviewed with regard to, for example, model structure use, and how these models dealt with uncertainties whilst predicting results.

7.1.2 Results

Results of literature search

In total there were 250 papers identified from the initial search (Table 11). Of these, 18 were selected as potentially relevant abstracts, and 13 were included for further screening. From these papers, nine were selected for the review. Appendix 11 summarises the included studies.

Table 11 Search results

Database	**Number retrieved**
Medline (2000 - Oct Wk 4 2009) Embase (2000 - Wk 44 2009) Medline In Process (3rd Nov 2009) (after de-duplication in Ovid)	227
Science Citation Index* (2000 to 3rd Nov 2009)	16
Health Management Information Consortium* (Sep 2009)	0
NHS Economic Evaluation Database* (Oct 2009) HTA Database (Oct 2009)	0
ISPOR conference abstracts 2006-2009	7
Total	**250**

* Numbers retrieved after de-duplication against Medline and Embase search

As already noted no submission was received from industry reporting relevant evidence.

Characteristics of included studies

Out of the nine studies, seven[53,91-96] reported a full economic evaluation which assessed both the costs and cost-effectiveness of the alternatives compared. Of the remaining two studies, the study by Reddy and colleagues[52] is a review reporting information related to costs and health outcomes reported in other studies and did not undertake an economic evaluation. The other study[97] which is also a review of the management of GIST with sunitinib, reports on,

amongst other things, the cost of treatment with sunitinib. Details of these two studies are reported in the main background section.

Five studies[53,91,92,95,96] conducted a modelling exercise rather than incorporating data from actual patient follow-up. Two studies[92,94] used non-randomised, or non-trial patient data (from retrospective cohorts) to inform their economic evaluations.

One study[53] reported an economic evaluation in a UK context, which was based on an industry submission to NICE for a previous TAR. Two studies[91,94] reported a Canadian context, and one study was from a US context.[93] The remaining three studies were conducted in the context of Mexico,[92] Spain[95] and Brazil[96] respectively. Table 12 summarises the main features of the included studies.

Comparative studies:

- *Imatinib vs. best supportive care*

Three studies[53,93,94] compared imatinib with best supportive care. The study by Wilson and colleagues[53] used the manufacturer submissions (Novartis model) and compared imatinib and best supportive care, but in the imatinib group allowed for escalation of doses from 400 mg/day to 600 mg/day for those who failed to response or were intolerant to imatinib at the 400 mg/day dose. The study by Mabasa and colleagues[94] noted that patients included from retrospective cohorts in their analysis were given imatinib 400 mg/day until disease progression, and later were allowed escalated doses of between 600-800 mg/day. Six out of fifty-six patients in the imatinib groups of patient considered in this economic evaluation were then allowed to switch to sunitinib therapy. The economic evaluation by Huse and colleagues[93] considered imatinib at 400 mg/day (Table 12).

Table 12 Characteristics of included cost-effectiveness analysis studies

Study	Country, Currency , Price Year	Perspectives	Comparisons					Patient failed on imatinib?	Outcomes Reported											Modelling
			Imatinib 400 mg/day	Imatinib 600 mg/day	Imatinib 800 mg/day	Best Supportive Care	Sunitinib		Overall Survival	Median Overall Survival	Survival Rate	Progression Free Survival	Progression Free Life Years	Time to Progression	PFM	Life Years Gain	QALY	Cost Effectiveness Ratio	ICER	
Chabot et al (2008)[91]	Canada Canadian $, 2005	Provincial Health Authority				✓	✓	Yes	✓			✓				✓	✓		✓	Markov Model
Contreras-Hernandez et al (2008)[92]	Mexico US $, 2006[2]	Health Insurance System			✓	✓	✓	Yes							✓	✓			✓	Markov model
Mabasa et al (2008)[94]	Canada Canadian $, 2006	British Columbia Cancer Agency (BCCA)	✓			✓		No	✓	✓		✓				✓			✓	CEA using cost effectiveness ratios and ICERs
Paz-Ares, L (2008) [95]	Spain €, 2007	Health Care System				✓	✓	Yes					✓		✓	✓	✓		✓	Markov Model
Huse et al (2007)[93]	USA US $, 2005	Societal perspective (Payers for Health Care)	✓			✓		N/A									✓	✓		CEA
Teich et al (2009)[96]	Brazil Brazilian R$, 2005 [3]	Health Care system			✓	✓	✓	Yes					✓			✓			✓	Markov Model
Wilson et al (2005)[53]	UK GB £, (2004?)	Health Care System	✓	✓		✓		Yes			✓						✓		✓	Markov Model

[2] 1 US$=11 Mexican pesos
[3] And US$ at PPP, 1US$=1.4 R$

Imatinib, sunitinib, and best supportive care

Two studies[92,96] compared sunitinib, escalated doses of imatinib, and best supportive or palliative care as comparators for their economic evaluations. The Contreras-Hernandez and colleagues[92] study compared treatment with imatinib, sunitinib and palliative care. Both treatments (sunitinib and imatinib) were compared with the same best supportive care in a model based analysis. The doses for both the treatments were clearly specified (imatinib at 800 mg/day and sunitinib at 50 mg/day) as the study was based on primary data collected from hospital records. The study did not include dose escalation with imatinib at a 600 mg/day dose. Teich and colleagues[96] compared sunitinib, imatinib at 800 mg/day and best supportive care (Table 12).

Sunitinib and best supportive care

The studies by Chabot and colleagues[91] and Paz-Ares and colleagues[95] compared treatment with sunitinib and best supportive care for GIST patients who were imatinib resistant or intolerant. Chabot and colleagues did not specify the dose of sunitinib used, or mention whether patients who were imatinib resistant or intolerant were initially treated with 400 mg/day and then with escalated imatinib doses (e.g. 600 or 800 mg/day). Paz-Ares and colleagues[95] specified a dose of 50 mg/day for the patients in the sunitinib group. The patients in the sunitinib group were provided with best supportive care. Therefore, this study compared sunitinib plus best supportive care with best supportive care alone. Best supportive care in this study included diagnostic tests and routine palliative treatment.[95]

The definition of best supportive care in the economic evaluation studies was not the same across the studies. Chabot and colleagues[91] did not clearly define what best supportive care included, while Contreras-Hernandez and colleagues[92] defined clearly that best supportive care included treatment with imatinib. Paz-Ares and colleagues[95] defined best supportive care as essentially consisting of diagnostic tests and routine palliative care. In the other three studies,[53,93,94] the control group of patients which are considered as effectively being treated with best supportive care were not provided with treatment with imatinib. As a full-text paper of the study by Teich and colleagues[96] was not available, information on how this study defined best supportive care was not available.

Escalated doses of imatinib at 600 or 800 mg/day, sunitinib and best supportive care

We did not find any studies that conducted an economic evaluation of all of the alternative treatments (e.g. escalated doses of imatinib 600 mg/day, imatinib 800 mg/day, sunitinib and BSC) for patients who failed or were intolerant to imatinib at a dose of 400 mg/day.

Study design

Among the seven studies that conducted a full economic evaluation, five used Markov modelling.[53,91,92,95,96] Huse and colleagues[93] used a very simple modelling framework and Mabasa and colleagues[94] also used patient level data and had 46 and 47 patients in their imatinib and best supportive care (historical group) groups respectively. Contreras-Hernandez and colleagues[92] also used patient level data (for 21 patients) collected at the *Hospital de Oncologia,* to estimate the costs of care associated with imatinib, best supportive care and other procedures, and used these costs in their model.

Perspective

Three studies[53,95,96] adopted the perspective of a National Health Care system. The study by Contreras-Hernandez and colleagues[92] was from Mexico's Health Insurance Systems' perspective. The study by Huse and colleagues did not specifically mention whether it was from a health insurance system perspective, however it mentioned that it had been conducted from a US societal perspective. The studies by Chabot and colleagues[91] and Mabasa and colleagues[94] considered a provincial health authority and a specialised agency (British Columbia Cancer Agency) perspective respectively for their economic evaluations. None of the seven studies[53,91-96] that conducted full economic evaluations reported indirect non-medical resource use, or indirect costs to society in terms of productivity loss, costs to carers, and other indirect costs associated with GIST.

Health outcome measures

The major outcome measures used in the seven studies reporting full economic evaluations were: progression free survival (PFS)[91,92,94-96] overall survival (OS)[91,94] life years gained[91,92,94-96] and quality adjusted life years (QALYs).[53,91,93,95] Four studies[53,91,93,95] reported the incremental cost per QALY gained. The remaining three studies [92,94,96] used incremental cost per life year gained, and incremental cost per progression-free life year gained.

Data sources

Most of the studies[91,92,95] which are based on modelling exercises used effectiveness or health outcome data from major trials[36,50,98-100] and adapted them for their specific contexts. The source of cost data were mainly from relevant patients' records, and health care cost databases. Wilson and colleagues[53] used data from an industry submission (Novartis Trial). Table 13 summarises the data sources used for the studies. A full paper of the study by Teich and colleagues[96] was not available and so information on the data sources used was unknown.

Table 13 Data sources

Study	Unit Costs	Resource Use for Treatment	Effective/Health Outcomes
Chabot et al (2008)[91]	Published literature and Canadian government benefit schedule and medical oncologist	Published literature and Canadian government benefit schedule and medical oncologist	Phase III trial NCT00075218 [50]
Contreras-Hernandez et al (2008)[92]	Hospital records (Hospital de Oncologia,) for 21 patients in Mexico, IMSS pricing and reimbursement procedure, and cost of sunitinib from Pfizer Laboratories	Patients medical charts, associated information from IMSS (Mexican Insurance system)	Phase III trial[50,100]
Mabasa et al (2008)[94]	British Columbia Cancer Agency (BCCA)	BCCA registry	Patients data in two arms (imatinib groups and 46 non-imatinib group) was compared with Demetri et al (2002[36]) and Verweij et al (2003) [98]
Paz-Ares, L (2008) [95]	Health costs database eSalud (for administration, radiotherapy, nephectomy and monitoring costs). General Council of Pharmacists Official Colleges for drug costs. Ojeda *et al* (2003) unit costs of adverse events	Data reported by expert panel on number of visits to oncology clinic, laboratory tests, CT scans, nurse visits, and visits to palliative units, and analgesic drugs	Demetri et al (2006) [50] Adverse events[101]
Huse et al (2007)[93]	Drug acquisition costs: Published average wholesale price, (Red Book: Pharmacy's Fundamental Reference 2005, Montvale (NJ): Thomson PDR, 2005 and Physicians' Desk References 2005. Montvale (NJ): Thomson PDR, 2005)	Based on the resources used by patients with pancreatic cancer (not advanced in US context) to determine the resources used for medical management in the absence of data on resource used by GIST patients	Demetri et al (2002)[36]Phase II and Blanke (2006)[99]
Wilson et al (2005)[53]	Industry submission: Novartis Model – Novartis Submission to NICE 2003	Novartis Model – Novartis Submission to NICE 2003	Quality of life based on ECOG data from B2222 trial[37], and Goss and colleagues study (data academic in confidence)

Time horizon

The studies that used models in their economic evaluations used different time horizons and treatment cycle lengths for the Markov model. The two studies[91,95] which had sunitinib and BSC as comparator treatments used a time horizon of six years and a treatment cycle length of six weeks in the modelling exercise. Of the other studies the study by Contreras-Hernandez and colleagues[92] which has sunitinib as a comparator along with imatinib and best supportive care, used a lifetime time horizon and also a six-week cycle of treatment (to be consistent with the sunitinib treatment cycle of six weeks). Huse and colleagues[93] used a ten year time horizon for the analysis, whilst Teich and colleagues[96] used a six year time horizon, and a six-week treatment cycle.

Discount rate

A 5% discount rate for cost and health outcomes was used in two studies.[91,92] Wilson and colleagues[53] in their model, discounted costs by 6% and QALYs by 1.5%, as per NICE methods guidance at the time the work was conducted. Paz-Ares and colleagues[95] and Huse and colleagues[93] used 3% and 3.5% respectively. Mabasa and colleagues [94] used 3% for discounting costs and outcomes. The abstract by Teich and colleagues[96] did not report the discount rate used in their modelling exercise.

Findings on costs and cost effectiveness

The cost of treatment and cost per different health outcome under different alternatives are presented in Table 14. As regards to cost in relation to the health outcomes, the incremental cost-effectiveness ratios from the studies are noted in the table with respect to the main outcomes, i.e. life year saved, progression free survival and QALYs. Although the Contreras-Hernandez and colleagues study[92] considered three alternative treatments (sunitinib, imatinib, and best supportive care), it did not report an ICER for imatinib versus best supportive care.

Table 14 Summary of cost of treatment from studies reviewed

Study	Comparator	Mean Cost of Treatment per patient	ICER1	ICER2
Chabot et al 2008[91]. *Costs in Can $ at 2005 prices*.	Sunitinib	Can $46,125	Sun vs. BSC Can$ 49,826 per Life Year Saved	Sun vs. BSC Can $79,884 per QALY
	BSC	Can $11,632		
Contreras-Hernandez et al (2008)[92] *Costs in US $ at 2006 prices*	Sunitinib	US $17,806 sd US $695 CI US $15377 to $19816	.	Sun vs. BSC $15,734 per patient treated with sunitinib and $56,612 per year of progression free survival, and $46,108 per life year gained
	Imatinib	US $35,057, sd US $1253 CI US $31,381 to 38,705		
	BSC	US $2071, sd 473 CI US $ 1543 to 2869		
Mabasa et al 2008[94] *Costs in Can $ at 2006 prices*	Imatinib	Can $79,839	Imatinib vs. BSC(control) Can$ 15,882 per life year	
	BSC	Can $1743		
Paz-Ares, L (2008)[95] *Costs in Euros at 2007 prices*	Sunitinib	€ 23,259	Sun. vs. BSC €30,242 per life year.	Sun. vs. BSC €4,090 per progression free month €49,090 per QALY gained.
	BSC	€1622		
Huse et al 2007[93] Cost in US $ at 2005. price	Imatinib	US $416,255		
	BSC	US$ 341,886		
Wilson et al 2005[53] *Cost in £ at.2004. prices*	Imatinib	£18,896 (400 mg/day) £24,368 (600 mg/day) Other cost of treatment £1,136		Cost per QALY £70,206 (yr 2), £51,514 (yr 3), £36,479 (yr 5), and £25,859 in yr 10
	BSC	£562		

BSC = best supportive care; Sun = sunitinib

Higher doses of imatinib versus best supportive care

The Contreras- Hernandez and colleagues[92] study suggested that a higher dose of imatinib (800 mg/day) may be cost-effective compared to best supportive care (where best supportive care includes treatment with imatinib at a lower dose). Wilson and colleagues[53] using the modified Novartis model in a UK context and from an NHS perspective estimated the incremental cost per QALY gained at £51,515 to £98,889 at two years, and £27,331 to £44,236 at five years compared with best supportive care.

Sunitinib versus higher dose of imatinib versus best supportive care

Sunitinib treatment was associated with an estimated gain of 0.7 years and 0.4 QALYs compared with best supportive care.[91] Sunitinib treatment also resulted in a higher number of progression free months than both the imatinib and best supportive care therapies. The mean progression free months was found to be 5.64 months for sunitinib while it was 5.28 and 2.58 months respectively for imatinib and best supportive care. The incremental effectiveness of sunitinib therapy compared with best supportive care was 3.1 progression free months and 0.3 progression free months compared with a high dose of imatinib. Over the five year treatment horizon, Contreras-Hernandez and colleagues[92] found that patients with sunitinib had a mean life year gain of 1.4 compared with 1.31 and 1.08 for imatinib and best supportive care respectively. The study also suggests that patients taking imatinib at a dose of 800 mg/day had the highest mean costs of treatment. Teich and colleagues[96] reported that sunitinib was cost-effective compared with imatinib at a dose of 800 mg/day for a six year time horizon. Their study suggested that sunitinib increases life years and progression free life years by 0.3 and 0.26 respectively, with an incremental cost of Brazil $86,756 (US $61,968 Purchasing Power Parity 2005) in comparison with best supportive care. They found that sunitinib was both more effective showing a gain in life years of 0.02 and progression free life years of 0.47, and less costly than imatinib over six years.

Assessment of uncertainty

All six full-text studies[53,91-95] used some form of sensitivity analysis. Chabot and colleagues[91] varied the most influential model parameters, i.e. utility of progression and no progression, overall survival (hazard ratio), progression free survival, positron-emission tomography (PET) at initiation of sunitinib treatment, the cost of palliative care and the cost of PET. The model assumed the acquisition cost of sunitinib was certain and did not vary this in the sensitivity analysis. The sensitivity analysis suggested that results of the economic evaluation were most sensitive to health-state utility value and rate of overall survival and progression free survival. The sensitivity analysis also suggested that the results were robust. Contreras-

Hernandez and colleagues[92] conducted probabilistic sensitivity analysis with data obtained from the Markov model. An acceptability curve was derived and reported the cost-effectiveness ratios for sunitinib in comparison with palliative care. In the absence of any threshold for cancer therapy in Mexico, they used three hypothetical re-imbursement cut points equivalent to US$27,723, US$36,364, and US$45,455 to derive acceptability curves. These hypothetical values were based on taking 5%, 14% and 40% of the upper threshold that NICE reimburses for imatinib as first-line treatment. Mabasa and colleagues[94] varied the median overall survival rate, the rate of progression free survival and years of life expectancy, and conducted univariate sensitivity analysis. They found that the model used for the analysis remained robust. The ICER for each median life year gained was found to be within the range of Can $0 to Can $550, and for each median progression free year it ranged from Can $0 to Can $75,505. Paz-Ares and colleagues[95] also conducted univariate sensitivity analysis. Their model results were calculated in a probabilistic analysis considering the impact of uncertainty on the values of each variable included in the model, by assuming different distributions of these variables. The study conducted sensitivity analysis of the results by adding the cost of imatinib to the best supportive care group by assuming all patients in the palliative care group would be given imatinib 400mg/day. The most sensitive variables affecting the results were efficacy of treatment, and the unit cost of sunitinib. The study by Huse and colleagues[93] also used univariate sensitivity analysis and examined the impact of considering the upper and lower values of the cost of the drugs, the cost of treatment, the utilities of successful treatment and progressive disease, the time horizon, and the annual rate of discount, in their analysis. They used imatinib at a 600 mg/day dose to examine the impact of results variation as an alternative scenario for the sensitivity analysis. The study by Wilson and colleagues[53] fitted a Weibull curve to estimate progression and death due to GIST, in their sensitivity analysis, and found that the ICER based on a Weibull curve was £26,427 and with an exponential fitting was £21,707.

7.1.3 Summary of the review

We found that most of the economic evaluation studies reviewed used modelling exercise However, only two studies[92,96] compared both imatinib and sunitinib with best supportive care for patients who had failed or become resistant to imatinib 400 mg/day. The full paper for only one of these[92] was available. Among the five studies[53,91,92,95,96] which used modelling exercises, Contreras-Hernandez and colleagues[92] and Teich and colleagues[96] did not use QALYs as health outcome measures. Although Contreras-Hernandez and colleagues[92] used patient level data as the basis of their cost estimates, they used survival and progression free survival as effectiveness measures in their model, which was based on the studies by Motzer and colleagues[100] and Demetri and colleagues.[50]

The two studies[91,95] which used modelling exercises to compare the cost-effectiveness of sunitinib only with best supportive care used the same trial data (A6181004).[50] Their utility data were based on responses to the EQ-5D instrument provided by participants in this trial.

In our review we did not identify any published economic evaluation studies in a UK context comparing all the relevant interventions. The study that included an economic evaluation of higher dose imatinib in a UK context[53] did not actually have as a comparator those who failed with imatinib 400 mg/day, rather the model allowed patients who failed on 400 mg to cross over to a higher dose of imatinib 600 mg/day rather than 800 mg/day.

The definition of best supportive care in the economic evaluation studies reviewed was not the same across the studies and cost-effectiveness of treatments compared with best supportive care cannot be easily compared. In addition, the pattern of resources including the drugs for treatment was reported in different ways in different studies.

For a comprehensive economic evaluation of the alternative treatment of GIST patients who failed on or became resistant to imatinib 400 mg/day, further evidence is needed to fill in gaps in the evidence base. The challenge is to obtain appropriate and sufficient information on survival rates and responses to treatments with escalated doses of imatinib, and sunitinib. The economic evaluations which were identified based on modelling exercises have limitations. For example, all extrapolated clinical trial data from a short time horizon, to predict cost-effectiveness results for a longer period. There is a need for empirical patient-level data for future economic evaluations. The outcome measures for disease severity can be considered as important surrogate endpoints. In cases where the patients in placebo groups or in best supportive care arms of trials are allowed to cross over to an experimental group (either escalated doses of imatinib or sunitinib) it could be argued that an intention to treat analysis would result in an underestimation of the survival benefit of patients randomised in the treatment groups, and the cost of the treatment for these patients who were assigned to placebo/best supportive care groups is often not accounted for in economic evaluations.

There has been no consideration of the patients' and society's costs/ resource use in the studies reviewed. A wider perspective might be informative but to consider this costs and resource use falling outside the NHS (e.g. on personal social services and patients and their families) would be helpful.

7.2 Economic modelling

7.2.1 Model structure

The structure of the model was informed by the modelling studies identified as part of the systematic review of economic evaluations, the review of clinical effectiveness, and other existing evidence including previous NICE TARs. We have also drawn upon advice from health care professionals within the research team in this regard.

The model is developed to compare the alternative treatment strategies for people with KIT (CD117) positive unresectable and/or metastatic gastrointestinal stromal tumours (GISTs) whose disease has progressed on treatment with imatinib at a dose of 400 mg/day or those whose treatment with imatinib has failed due to intolerance. According to the scope for the review the treatment strategies to be compared in the models were:

i) Treatment with an escalated dose of 600 mg/day, regulating symptoms with best supportive care
ii) Treatment with an escalated dose of 800 mg/day, regulating symptoms with best supportive care
iii) Treatment with sunitinib (within its recommended dose range), regulating symptoms with best supportive care
iv) Regulating symptoms with best supportive care only

The assumed pathway of the model

We considered a range of different alternative pathways for patients who progressed on imatinib at a dose of 400 mg/day, which led to the creation of nine alternative pathways and following advice from our clinical advisers, we determined seven clinically plausible pathways (Figure 5). The model is based on these seven clinically plausible care pathways. Circles represent health states that individuals may return to, rectangles represent health states during which treatment is administered, and the arrows show the possible directions in which individuals could move at the end of each cycle, depending on the transition probabilities. The states considered in the model were those thought to reflect care pathways for people with GIST. Patients entering the pathways are those who failed on imatinib 400 mg/day. The alternative treatments considered dose T1= imatinib 600 mg/day, T2 = imatinib 800 mg/day, T3 = sunitinib (with recommended dose 50 mg/day), BSC = Best Supportive Care.

Figure 5 **Markov model for GIST patients who have failed with imatinib 400 mg per day.**



A Markov model was developed to model these care pathways using Tree Age Pro 2009.[102] In this model, patients whose disease has progressed on treatment with imatinib at a dose of 400 mg/day or those whose treatment with imatinib has failed due to intolerance, enter one of the seven care pathways. Figure 6 is an illustrative example of the model structure for pathway 4 where patients are treated with imatinib, 600 mg/day and if the disease progresses on this treatment the patients are treated with best supportive care. Appendix 12 illustrates the model for all the seven pathways of alternative treatments.

Figure 6 Example of model structure for care pathway 4 (imatinib 600 mg/day – best supportive care)



Pathway 1, shows the patients with the BSC treatment. It is assumed that the patients with best supportive care are still treated with imatinib and palliative care. Pathway 2 represents treatment options where escalated doses of imatinib (600 and 800 mg/day) and treatment with sunitinib are provided to the cohort of patients. All patients start the treatment with imatinib 600 mg/day. If they survive and respond to imatinib 600 mg/day, then they will continue with the dose until they move to a state of stable condition with complete response or partial response (CR/Stable IM 600). From this point, a proportion of patients will survive and continue to respond to treatment. Dose is escalated to imatinib 800 mg/day if they failed to respond. Those who stop responding to imatinib 600 mg/day move to a state where they receive imatinib 800 mg/day (PD at IM 800). A proportion of patients will remain with the escalated doses of imatinib 800 mg daily (CR/Stable IM 800). If patients fail to respond on imatinib 800 mg daily, they are switched to treatment with sunitinib (PD with sunitinib). If they respond to sunitinib then they will continue with the treatment and move to a state of stable condition with complete response or partial response (CR/Stable with sunitinib). From this point, a proportion of patients might continue to respond to the treatment and remain stable, or they may stop responding to sunitinib and now receive best supportive care for the remainder of their life.

Pathway 3 represents treatment options where an escalated dose of imatinib (imatinib 600 mg/day only) and treatment with sunitinib are provided. In this pathway, all patients also start the treatment with imatinib 600 mg/day (PD initial treatment IM600). If they respond to imatinib 600 mg/day, then they will continue with the dose and move to a state of stable condition with complete response or partial response (CR/Stable IM 600). If a patient treated with imatinib 600 mg/day fails to respond or ceases to respond then instead of trying further dose escalation with imatinib, they are switched to treatment with sunitinib (PD with sunitinib). If they respond to sunitinib they will continue with the treatment and move to a state of stable condition with complete response or partial response (CR/Stable with sunitinib). Should they fail to respond to sunitinib or if at some point they cease to respond they continue with best supportive care for the remainder of their life.

In pathway 4 all patients start the treatment with imatinib 600 mg/day and no switching to other treatment is considered. If they respond to imatinib 600 mg/day then they continue with this treatment until the GIST progresses or they die (CR/Stable IM 600). If at any point they do not respond to imatinib 600 mg/day they continue with best supportive care for the remainder of their life.

The remaining care pathways are variants of earlier pathways. Pathway 5 is similar to pathway 3 with respect of combination of escalated dose of imatinib and sunitinib. The main difference being in this case is that the escalated dose is imatinib 800 mg/day. Apart from this difference the pathways are identical. Pathway 6 is similar to pathway 4. However, in this pathway the escalated dose is imatinib 800 mg/day instead of imatinib 600 mg/day. Pathway 7 is similar to pathway 4. In this pathway however instead of being treated with imatinib 600 mg/day patients receive sunitinib. Apart from this change the care pathways are identical (see Appendix 12).

Key assumptions of the modelling exercise

The key assumptions of the model are:

a. The time horizon of the model is 10 years over which time all patients are expected to die and the cycle length is for weeks.
b. The model assumes that patients entering a pathway will remain in that treatment for one cycle only if they do not respond and survive in the treatment arm. In these cases they are

either considered to move to the escalated doses or to another alternative (if allowed by a treatment pathway) or continue with best supportive care for the remainder time horizon of the model.

c. The model assumed that the probabilities of progressing and dying did not change over time. This assumption was made because of the limited data available.

d. The utility of the health outcome from the treatment with imatinib 600 mg/day, imatinib 800 mg/day, and sunitinib are assumed to be the same.

e. All patients failing or not responding to the treatment in any of the treatment arms of the model continue with best supportive care for the remainder of the model time horizon or until they die and are assumed to derive the same utility from the health state of progression.

7.2.2 Data requirements and model inputs

For our model, data on the clinical effectiveness of interventions was based upon the systematic review of clinical effectiveness described earlier. These data were combined within the model with health state utilities data to provide estimates of QALYs for the alternative treatment strategies for GIST patients.

With respect to clinical effectiveness, data were required for the model on the probability of death per cycle and the probability of not responding to treatment per cycle.

Probability of death

As described in the systematic review of effectiveness few data were available for any of the treatments, little of which was based on direct comparisons. Therefore, the data available are imprecise and potentially biased. The direction and magnitude of any bias is unknown. As a consequence the data used to derive probabilities of death for each therapy under medication should be treated cautiously.

- ***Probability of death for best supportive care***

  The data for best supportive care were taken from the three studies[103-105] and pooled weighted estimates suggest that 88.4% (50 out of 58) died during the observation period of 60 months. A monthly rate was derived using an exponential function which assumes the probability of death per month is constant over time. The same value was used in circumstances where patients moved on to best supportive care after previously being treated with imatinib at an

escalated dose or with sunitinib. Alternative data for this parameter were available and these are outlined in Appendix 13, however these data would provide similar, imprecise and potentially biased estimates for this probability.

- ***Probability of death for imatinib for 600mg/day and 800mg/day***

  The data on mortality for the imatinib 600 mg/day treatment groups were taken from the available trial data[37] and 45% (5 out of 11) of those who crossed over to imatinib 600 per day died over the trial period of 60 months. The data on the mortality for 800 mg/day were taken from Blanke and colleagues[39] (where the data suggest that 64.41 % (66 out of 118) died in the Imatinib 800 mg/day group. Again monthly rate was derived as an exponential rate.

- ***Probability of death for sunitinib***

  The mortality data for those treated with sunitinib came from Schutte and colleagues.[80] In this study 193 out of 351 patients receiving sunitinib were still alive after a median survival period of 11.76 months. Monthly mortality rate was derived from this survival rate assuming an exponential rate. In the analysis it has been assumed that the mortality rate for those receiving sunitinib is the same regardless of any prior treatment.

Response rate to the treatment

For our model, response to treatment was also taken to include partial response, complete response and those reported to be in a stable condition.

The response rate to imatinib 600 mg/day was based upon data from the B222[2] trial data.[37] This study reported that 25.5% of patients had responded and remained stable during a median follow-up of 63 months. The same study was also used to provide evidence on the response rate to imatinib 800 mg/day. This study reported that 75 out of 250 patients responded to the treatment with imatinib 800 mg/day and showed partial response or stable condition after a median follow-up of 54 months. For sunitinib the response rate was estimated from the weighted average response rate from two studies.[36,106] In these two studies in total 266 out of 382 patients responded, and simple weighted mean was used to derive the pooled response rate. This response rate was assumed to be unaffected by prior treatment received. The non-response data for each treatment were converted into monthly transition probabilities by assuming an exponential function.

Cost data

Resources used by the selected treatment strategies were identified from relevant sources (e.g. NHS reference costs, the BNF, etc) and the review of economic evaluations. Costs have been considered from a NHS perspective only.

Cost of drugs

We included the costs of drugs, i.e. costs of imatinib 400 mg/day, 600 mg/day, 800 mg/day, and sunitinib 50 mg/day. As the sunitinib treatment process involved taking medications for four weeks and then no medication for the following two weeks, we estimated the yearly medication costs of this drug and then equally proportioned this cost to each month within that year. Data on cost of drugs were obtained from BNF 58.[107] It has been assumed that patients on best supportive care still receive medications and it has been assumed that the cost of these is equivalent to the cost of imatinib at 400 mg/day.

Cost of other resources

Resource use in the treatments were based on the study by Wilson and colleagues[53] which suggested that there are GP visits (£40 per year), outpatient visits including tests (£440 per year), and CT scans (£656 per year) and cost of management of adverse events (£159 per year). These cost estimates for these services used by Wilson and colleagues[53] at 2003 prices were used for our model after adjusting for inflation with HCHS (Hospital and Community Health Services) Index for pay and prices inflator for the year 2008/09.[108] Based on these estimates, the total monthly cost for management with imatinib treatment is £128.16. In the absence of better data these costs have been used for both Imatinib 600 mg/day and 800 mg/day.

For the sunitinib group we have used the resources based on the Pfizer single technology assessment submission[58] for patient monitoring, outpatient and GP visits (£799.73 per year), CT imaging (£336 per year) and management of adverse events (£159 per year). These costs are at 2008 prices and were adjusted to 2009 prices using the same methods as described above. Based on these data the estimated total monthly cost of this care used within the model is £185. For best supportive care, data from the Pfizer submission were again used,[58] the suggested costs in 2008 prices for patient monitoring, outpatient and GP visits was £249 per year, and £105 per year for CT imaging. These costs were inflated to 2009 prices using the same methods described above.

Utility data

There were few data relating to health state utilities. Our model has used data where the health state valuations are derived from the EQ-5D and the values used were taken from Wilson and colleagues[53] and Chabot and colleagues.[91] The utility associated with progression free survival for those responding to imatinib (regardless of dose) was 0.935.[53] The utility for those receiving best supportive care was taken from Chabot and colleagues and was taken to be 0.577.[91] In the absence of alternative data it has been assumed that the utility for those who have not progressed on sunitinib is the same as that assumed for imatinib i.e. 0.935.

Table 15 describes the parameter inputs used within the model. It also describes the sources of data, alternative valuation and data used to inform the probabilistic sensitivity analysis (described in more detail below).

In a sensitivity analysis, the high value of the costs of drugs (imatinib and sunitinib) have been assumed to be similar to the value based on BNF price[107] which we used in our model for the base case analysis. For the lower value, we have taken an average of the price of the higher and lower doses assuming that there may be need to lower the dose in the treatment pathways assumed in our model. For sunitinib, during the sensitivity analysis the price of the lower dose is assumed.

Table 15 Model parameters, values and data sources

Parameters	Description	Value	Low	High	Distribution	Values	Data Source and assumptions
Cost parameters			**For Sensitivity Analysis**				
cImat600	Cost of drugs : imatinib 600	£2406	£2005	£2406			BNF54 (March 2010) Low value is average of imatinib 400 and 600mg.
cImat800	Cost of drugs: imatinib 800	£3208	£2807	£3208			BNF54 (March 2010) Low value is average of imatinib 600 and 800mg
CNott	Cost of Best Supportive Care	£1604	£1283	1604			Include cost of imatinib 400mg (BNF54 March 2010)
CSunb	Cost of drugs: sunitinib	£31398.8	£2092.5	£3138.8			BNF54 (March 2010) Low value is average of reduced dose of sunitinib
OthCostBSC	Other cost and management of treatment in BSC	£50.61					Resource use in the treatment were based on the study by Wilson and colleagues.[53]
OthCostIm	Other cost and management of treatment in imatinib treatment	£128.16					Resource use in the treatment were based on the study by Wilson and colleagues[53] Assumed to be same fro imatinib 600 and imatinib 800
OthCostSun	Other cost and management of treatment in sunitinib treatment	£185.11					Resource use in the treatment were based on the study by Wilson and colleagues[53] and STA Pfizer[58]
Mortality and response to treatment							
deathBSC	Probability of death in the BSC treatment arm	0.014627			Beta	α = 0.8448898 β = 57.775	Pooled weighted rate [103-105]
dth600	Probability of death in imatinib 600 treatment	0.007472			Beta	α = 0.08162 β =10.91838	B2222 study[39]
dth800	Probability of death in imatinib 800 treatment	0.011857			Beta	α = 1.39948 β =116.600	S0033 study[39]
Dthsun	Death due to GIST: sunitinib	0.026706			Beta	α = 9.3284 β =341.62	Schutte 2008[80]
nonrespIm600	Transition Probability of Non response to imatinib 600	0.011743			Beta	α = 0.504949 β =42.495051	B2222 study[39]
nonrespIm800	Transition Probability of Non response to imatinib 800	0.012879			Beta	α = 3.21875 β =246.780	S0033 study [39] and Zalcberg et al 2005

Table 15 Model parameters, values and data sources (cont)

nonrespSun	Transition Probability of Non response to sunitinib	0.080959			Beta	$\alpha = 12.30$ $\beta = 139.6945$	Weighted average response rate [50,106]
uImat600	Utility with imatinib 600	0.935	0.712	0.939			Wilson et al 2005[53]
uImat800	Utility with imatinib 800	0.935	0.712	0.939			Wilson et al 2005[53]
uProg	Utility for Progression Disease	0.577	0.52	0.712			Wilson et al 2005[53]
uSun	Utility with sunitinib treatment	0.935	0.712	0.939			Chabot *et al* 2008[91]
Structural and methodological parameters							
Cycle length	Time period that utilities, costs and probabilities relate to	1month					Assumption
Length of run	Number of cycles model is run for	120 (10 yrs)	72 (6 yrs)	144 (12 yrs)			Assumption
DR	Discount rate	0.002917	0	0.005			NICE guideline

7.2.3 Time horizon for the model

The model looked at the costs and consequences directly attributable to GIST. As reported earlier the typical survival of such patients is relatively short and hence the time horizon of the model was limited to 10 years. The cycle length was one month to reflect the natural history of the condition.

7.2.4 Analysis methods

The results of the model are presented in terms of the incremental cost per QALY. The costs and outcomes were discounted at 3.5% in accordance with NICE. As described below both deterministic and probabilistic sensitivity analyses were conducted with a net benefit framework being used to compare the different treatment strategies.

7.2.5 Sensitivity analysis

Probabilistic sensitivity analyses

Probabilistic analysis of the base case scenario was conducted by assuming a beta distribution of the probability of death and non-response to treatment in the different treatment strategies. The values used to define these distributions are reported in Table 15 and are derived from the data reported in Section 7.2.2.

The beta distribution as defined above might arguably be considered to be too precise and not truly reflect the degree of uncertainty that exists. To examine the uncertainties around the distribution assumed for the base scenario, sensitivity analysis was conducted by assigning a uniform distribution to these parameters, where the low and high value of probability of death and non-response rate were assumed 90% more than and 90% lower than the mean value used in our model. The justification for this distribution was that comparisons of interventions that are based on non-randomised and non-comparative data are potentially biased and that both the magnitude and direction of that bias are uncertain.

Deterministic sensitivity analyses

Sensitivity analysis was conducted with respect to methodological and structural assumptions. First the discount rate for cost and effectiveness was changed to 0% and 6% in the sensitivity analysis. The time horizon was also varied between six and 12 years (data are presented in the results for a six years, and 12 years time horizon).

Sensitivity analysis was also conducted to examine the uncertainties around the values used for the cost of drugs (which are major components of the cost of treatment for different

treatment strategies) and the utility values for the different health states of the model. The values used in the sensitivity analysis are reported in Table 15 above.

A further area of uncertainty relates to the very limited data available for imatinib 600 mg/day. In the base case analysis the effectiveness (in terms of survival and response rates) is better for imatinib 600 mg/day compared with imatinib at 800 mg/day. As this was based on non-randomised, non-comparative data the relative difference is potentially biased. Therefore, in this sensitivity analysis a more conservative assumption was taken that the survival rate and the response rate to the treatment of imatinib 800 mg/day also applied to imatinib 600 mg/day.

7.2.6 Results

Base case analysis

Table 16 shows the mean estimates of cost and effectiveness of the six alternative treatment strategies modelled. As this table shows, effectiveness has been reported in two ways: life years, and QALYs. Path – 4, treatment was imatinib 600 mg/day, has an incremental cost per QALY that was less than £30,000 compared with Path-1: best supportive care. The only other non-dominated or non-extendedly dominated strategy was Path-2 (imatinib 600 mg/day to imatinib 800 mg/day to sunitinib). However, in this case the incremental cost per QALY (compared to the next most costly option (of Path – 4: imatinib 600 mg/day) is in excess of £40,000.

Of note is that in the base case analysis treatment with sunitinib for those who failed with imatinib 400 mg (Path-7) was estimated to have a lower life-expectancy than best supportive care but greater QALYs. The reason for this was that the estimates of survival for sunitinib were based upon limited non-randomised and non-comparative data (as was the case for all the other comparators). Hence, any comparison should be treated cautiously.

The finding that sunitinib was dominated by best supportive care when effectiveness was measured in life years but not dominated when effectiveness was measured in QALYs illustrates the importance of the utility estimates used within the model. Again such data were sparse and particularly for sunitinib, do not reflect the potentially worse side effect profile. Other things remaining unchanged the inclusion of side effects would have reduced the QALYs obtained from pathways containing sunitinib and potentially led to Path - 7 being dominated by best supportive care (at the very least the incremental cost per QALY would have increased from the £272,365 reported in Table 16).

Table 16 Base case analysis and incremental cost-utility of the alternative treatment pathways

Strategies	Cost	Incremental cost	Life years	Incremental life years	QALYS	Incremental QALYs	Incremental cost per QALY
Path-1 Best supportive care	£92,811		4.154		2.397		
Path-7 Sunitinib	£96,688	£3877	3.716	(Dominated)	2.411	0.014	£272,365
Path-4 Imatinib 600mg	£147,060	£50,372	5.211	1.057	4.256	1.845	£27,304
Path-3 Imatinib 600mg to Sunitinib	£149,200	£2,139	5.032	Dominated	4.286	0.030	£71,723
Path 6 Imatinib 800mg	£153,901	£4702	4.506	Dominated	3.635	-0.651	Dominated
Path-5 Imatinib 800mg to Sunitinib	£155,828	£6628	4.336	Dominated	3.659	-0.627	Dominated
Path-2 Imatinib 600 mg to 800 mg to Sunitinib	£172,152	£22,953	5.278	0.067	4.803	0.517	£44,359
With dominated and extendedly dominated options removed							
Path-1 Best supportive care	£92,812		4.154		2.397		
Path-4 Imatinib 600mg	£189,484	£54,249	5.211	1.057	4.256	1.859	£29,181
Path-2 Imatinib 600 mg to 800 mg to Sunitinib	£212,595	£25,092	5.278	0.067	4.803	0.547	£45,850

The results reported in Table 16 are surrounded by considerable imprecision. One of the main sources of the imprecision in the analysis surrounds the clinical effectiveness data. Therefore, a partial probabilistic sensitivity analysis was conducted, with the imprecision surrounding response rates and mortality rates being characterised by Beta distributions. Figure 7 shows the cost-effectiveness acceptability curve and illustrates that the pathway with the highest likelihood of being considered cost-effective when society's willingness to pay for a QALY is less than approximately £25,000 is Path – 1, best supportive care. When society's willingness to pay for a QALY is between approximately £25,000 and £45,000 Path – 4, imatinib 600 mg/day is most likely to be considered cost-effective. Beyond a threshold of approximately £45,000 Path – 2, imatinib 600 mg/day to imatinib 800 mg/day to sunitinib, is most likely to be cost-effective.

Figure 7 Cost-effectiveness acceptability curve for alternative treatments over the ten year time horizon*



* Pathways with a low probability of being cost-effective over the range of willingness to pay for a QALY values considered have not been shown

Sensitivity Analysis

Uncertainty around the distributions used for mortality and response rates

The Beta distributions used to generate Figure 7 above potentially do not fully characterise the extent of the uncertainty surrounding the estimates of mortality and response used within the model. As noted in the methods section this is because the data used come are essentially used as if they came from non-randomised, non-comparative sources, and hence any comparisons drawn may be highly biased. For this reason in this sensitivity analysis uniform distributions were substituted for the beta distributions (Figure 8). It should be noted that these uniform distributions were assumed to be symmetrical around the point estimates used in the base case analysis.

As Figure 8 illustrates, the basic pattern of the cost-effectiveness acceptability curve is the same as that depicted in Figure 7. At low threshold values for the willingness to pay for a QALY Path -1, best supportive care is still the most likely to be considered cost-effective. However, Path – 7 sunitinib is more likely to cost-effective at low thresholds. It should be noted that even though the distributions surrounding mortality weights are very wide in this analysis sunitinib is still associated with a trend toward a slightly higher mortality rate than best supportive care. As previously noted this trend is based upon sparse and potentially unreliable data on the performance of sunitinib. At a threshold value of approximately £36,000 Path – 3 Imatinib 600 mg daily to sunitinib has a similar probability of being

considered as cost-effective as Path – 1, best supportive care and Path – 4, imatinib 600 mg/day. Between a threshold of £36,000 and £48,000 Path – 4, imatinib 600 mg/day is most likely to be cost-effective and beyond that threshold value Path –2, imatinib 600 mg/day to imatinib 800 mg/day to sunitinib is most likely to be cost-effective.

Figure 8 **Cost-effectiveness acceptability curve for alternative treatments over the ten year time horizon assuming uniform distributions for mortality and response rates***



* Pathways with a low probability of being cost-effective over the range of willingness to pay for a QALY values considered have not been shown

Uncertainty surrounding structure and methodological assumptions around distribution

Two different discount rates have been applied to costs and benefit to examine the sensitivity of the results to plausible changes in the discount rate (Table 17). At a 0% discount rate there is no change in the options are dominated or extendedly dominated, and the incremental cost per QALY for Path – 4, imatinib 600 mg/day compared with Path – 1, best supportive care increases to £31,183. The incremental cost per QALY for Path – 2, imatinib 600 mg/day to 800 mg/day to sunitinib compared with Path – 4, imatinib 600 mg/day increases to £54, 715.

When the discount rate was changed to 6%, the incremental cost per QALYs for the non-dominated strategies fall compared with the base case analysis. The key change is that Path – 3 imatinib 600 mg/day to sunitinib is no longer extendedly dominated by Path 4, imatinib 600 mg/day. Furthermore, the incremental cost per QALY for this comparison is less than

£30,000. Overall, the sensitivity analysis around discount rates illustrates that the results are sensitive to the choice of discount rate.

Table 18 reports the results of the sensitivity analysis around the time horizon of the model. When the time horizon is reduced to 6 years (base case = 10 years) the incremental cost per QALYs associated with the non-dominated options increases slightly. When the time horizon increases the incremental cost per QALY for Path 4, imatinib 600 mg/day compared with Path – 1, best supportive care, increases slightly. The incremental cost per QALY for Path – 2, imatinib 600 mg/day to imatinib 800 mg/day to sunitinib compared with Path 4, imatinib 600 mg/day, is virtually unchanged.

Table 17 Sensitivity around the discount rate and length of run

	Strategy	Cost (£)	QALYS	Incremental cost per QALY (£)
Base case e.g. discount rates = 3.5% on Cost and Benefit; time horizon = 10 years	Path-1 Best supportive care	92,811	2.397	
	Path- 7 Sunitinib	96,688	2.411	272,365
	Path-4 Imatinib 600 mg	147,060	4.256	27,304
	Path-3 Imatinib 600 mg to Sun	149,200	4.286	71,723
	Path 6 Imatinib 800 mg	153,901	3.635	Dominated
	Path-5 Imatinib 800 to Sunitinib	155,828	3.659	Dominated
	Path-2 Imatinib 600 mg to 800 to Sunitinib	172,152	4.803	44,359
Sensitivity analysis 1 e.g. discount rates = 0% on Cost and Benefit; time horizon = 10 years	Path-1 Best supportive care	93,137	2.706	
	Path- 7 Sunitinib	97,719	2.672	Dominated
	Path-4 Imatinib 600mg	159,462	4.833	£31,183
	Path-3 Imatinib 600 mg to Sunitinib	163,601	4.859	Ext Dom
	Path 6 Imatinib 800mg	165,641	4.087	Dominated
	Path-5 Imatinib 800 to Sunitinib	169,210	4.105	Dominated
	Path-2 Imatinib 600 mg to 800 to Sunitinib	195,193	5.486	£54,715
Sensitivity analysis 2 e.g. discount rates = 6%; time horizon = 10 years	Path-1 Best supportive care	92,614	2.209	
	Path- 7 Sunitinib	96,007	2.254	Ext Dom
	Path-4 Imatinib 600mg	139,473	3.908	£27,593
	Path-3 Imatinib 600 mg to Sunitinib	140,394	3.940	£28,801
	Path 6 Imatinib 800mg	146,627	3.360	Dominated
	Path-5 Imatinib 800 to Sunitinib	147,542	3.387	Dominated
	Path-2 Imatinib 600 mg to 800mg to Sunitinib	158,271	4.392	£39,480

Ext Dom = extended dominance

Table 18 Sensitivity around the time horizon of the model

	Strategy	Cost (£)	QALYS	Incremental cost per QALY (£)
Base case e.g. discount rates = 3.5% on Cost and Benefit; time horizon = 10 years	Path-1 Best supportive care	92,811	2.397	
	Path- 7 Sunitinib	96,688	2.411	272,365
	Path-4 Imatinib 600 mg	147,060	4.256	27,304
	Path-3 Imatinib 600 to Sunitinib	149,200	4.286	71,723
	Path 6 Imatinib 800 mg	153,901	3.635	Dominated
	Path-5 Imatinib 800 mg to Sunitinib	155,828	3.659	Dominated
	Path-2 Imatinib 600 to 800 mg to Sunitinib	172,152	4.803	44,359
Sensitivity analysis 3 e.g. discount rates = 3.5%; time horizon = 6 years	Path-1 Best supportive care	73,246	1.960	
	Path- 7 Sunitinib	79,720	2.032	Ext Dom
	Path-4 Imatinib 600 mg	114,433	3.402	28,560
	Path-3 Imatinib 600 mg to Sunitinib	117,729	3.455	Ext Dom
	Path 6 Imatinib 800 mg	126,750	3.017	Dominated
	Path-5 Imatinib 800 mg to Sunitinib	129,873	3.066	Dominated
	Path-2 Imatinib 600 to 800 mg to Sunitinib	131,848	3.758	48,969
Sensitivity analysis 4 e.g. discount rates = 3.5%; time horizon = 12 years	Path-1 Best supportive care	98,464	2.510	
	Path- 7 Sunitinib	101,589	2.509	Dominated
	Path-4 Imatinib 600mg	156,943	4.489	29,553
	Path-3 Imatinib 600 mg to Sunitinib	158,421	4.507	Ext Dom
	Path 6 Imatinib 800 mg	161,295	3.790	Dominated
	Path-5 Imatinib 800 mg to Sunitinib	162,637	3.803	Dominated
	Path-2 Imatinib 600 to 800 mg to Sunitinib	183,961	5.093	44,736

Ext Dom = extended dominance

Uncertainty surrounding transition probabilities of survival and response to treatment with imatinib 600 mg/day.

The data available for imatinib given at a dose of 600 mg/day was sparse and what little data there was suggested a superior effectiveness compared with imatinib 800 mg/day. These data

are (i) potentially unreliable because they are based upon non-randomised and non comparative data, and (ii) potentially counter intuitive (in a direct comparison would we expect imatinib 800 mg/day to perform worse than imatinib 600 mg/day?). Therefore, in this sensitivity analysis it was assumed that the mortality and response to treatment with imatinib 600 mg/day was the same as imatinib 800 mg/day.

As Table 19, shows the incremental cost per QALY for Path 4, imatinib 600 mg/day compared with Path – 1, best supportive care falls. This is because the reduction in cost of medications as the probabilities that patients die or make the transition to best supportive care increase, more than compensate for the fall in QALYs. The QALYs associated with Path – 3, imatinib 600 mg/day to imatinib 800 mg/day to sunitinib fall but the incremental cost per QALY compared with Path 4, imatinib 600 mg/day, is virtually unchanged.

Table 19 Changes to mortality and response rates

	Strategy	Cost (£)	QALYS	Incremental cost per QALY (£)
Base case	Path-1 Best supportive care	92,811	2.397	
	Path- 7 Sunitinib	96,688	2.411	272,365
	Path-4 Imatinib 600 mg	147,060	4.256	27,304
	Path-3 Imatinib 600 mg to Sunitinib	149,200	4.286	71,723
	Path 6 Imatinib 800 mg	153,901	3.635	Dominated
	Path-5 Imatinib 800 to Sunitinib	155,828	3.659	Dominated
	Path-2 Imatinib 600 mg to 800 to Sunitinib	172,152	4.803	44,359
Sensitivity analysis 5 Survival rate and response rate to Imatinib 600 mg treatment same as Imatinib 800.	Path-1 Best Supportive Care	92,811	2.397	
	Path- 7 Sunitinib	96,688	2.411	272,365
	Path-4 Imatinib 600 mg	126,074	3.635	24,019
	Path-3 Imatinib 600 mg to Sunitinib	128,001	3.659	80,476
	Path-2 Imatinib 600 mg to 800 to Sunitinib	149,703	4.145	44,603
	Path 6 Imatinib 800 mg	153,901	3.635	Dominated
	Path-5 Imatinib 800 to Sunitinib	155,828	3.659	Dominated

Uncertainty surrounding utility values

The sensitivity of a lower and higher value of utility with the health status of disease progression was examined. In this analysis the lower value was 0.52 and a higher utility value for those patients who progressed with GIST of 0.712 was assumed instead of 0.577 as was used in the base case (Table 20). Reducing the utility value increased the QALYs for treatments that had higher probabilities of response. The incremental cost per QALY for Path - 4, imatinib 600 mg/day compared with Path – 1, best supportive care slightly falls and the incremental cost per QALY for Path –2, imatinib 600 mg/day to imatinib 800 mg/day to sunitinib compared with Path 4, imatinib 600 mg/day falls to approximately £40,000.

Conversely, increasing the utility associated with progressive disease reduced the opportunity for pathways which are clinically more effectiveness to generate additional QALYs. As a consequence in this sensitivity analysis the incremental cost per QALYs for the non-dominated pathways increases.

Table 20 Sensitivity analysis around the utility assumed for disease progression

	Strategy	Cost (£)	QALYS	Incremental cost per QALY (£)
Base case e.g. Utility of Progressive state =0.577	Path-1 Best supportive care	92,811	2.397	
	Path- 7 Sunitinib	96,688	2.411	272,365
	Path-4 Imatinib 600 mg	147,060	4.256	27,304
	Path-3 Imatinib 600 to Sunitinib	149,200	4.286	71,723
	Path 6 Imatinib 800 mg	153,901	3.635	Dominated
	Path-5 Imatinib 800 mg to Sunitinib	155,828	3.659	Dominated
	Path-2 Imatinib 600 to 800 mg to Sunitinib	172,152	4.803	44,359
Sensitivity analysis 6 Utility of Progressive state =0.52	Path-1 Best supportive care	92,811	2.160	
	Path- 7 Sunitinib	96,688	2.242	Ext Dom
	Path-4 Imatinib 600 mg	147,060	4.158	27,156
	Path-3 Imatinib 600 to Sunitinib	149,200	4.219	34,911
	Path 6 Imatinib 800 mg	153,901	3.543	Dominated
	Path-5 Imatinib 800 mg to Sunitinib	155,828	3.596	Dominated
	Path-2 Imatinib 600 to 800 mg to Sunitinib	172,152	4.782	40,759
Sensitivity analysis 7 Utility of Progressive state =0.712	Path-1 Best supportive care	92,811	2.958	
	Path- 7 Sunitinib	96,688	2.812	Dominated
	Path-4 Imatinib 600 mg	147,060	4.488	35,440
	Path-3 Imatinib 600 to Sunitinib	149,200	4.444	Dominated
	Path 6 Imatinib 800 mg	153,901	3.853	Dominated
	Path-5 Imatinib 800 mg to Sunitinib	155,828	3.808	Dominated
	Path-2 Imatinib 600 to 800 mg to Sunitinib	172,152	4.853	68,837

Ext Dom = extended dominance

Uncertainty surrounding the cost of Imatinib and Sunitinib

In this set of sensitivity analyses reductions in the cost of imatinib 600 mg/day, imatinib 800 mg/day and sunatinib are explored (Table 21). Over most of these sensitivity analyses the pathways that are dominated or are extendedly dominated does not change. As would be expected reducing the costs of each medication individually reduces the cost of pathways involving that medication. Over all these sensitivity analyses there are only relatively modest changes in the ICERs reported. One of the more substantive changes is that when the cost of sunitinib is reduced Path – 7, sunitinib becomes the least costly option. This is primarily because this pathway uses the potentially unreliable data on mortality for sunitinib which means that patients on this pathway do not survive long enough to incur higher costs.

Table 21 Sensitivity around the costs of imatinib and sunitinib

	Strategy	Cost (£)	Eff (QALYS)	Incr cost per QALY (£)
Base case:	Path-1 Best supportive care	92,811	2.397	
Imatinib 600 mg	Path- 7 Sunitinib	96,688	2.411	272,365
£2406,	Path-4 Imatinib 600 mg	147,060	4.256	27,304
Imatinib 800mg	Path-3 Imatinib 600 to			
$3208.16,	Sunitinib	149,200	4.286	71,723
Sunitinib £3138.8	Path 6 Imatinib 800 mg	153,901	3.635	Dominated
	Path-5 Imatinib 800 mg to			
	Sunitinib	155,828	3.659	Dominated
	Path-2 Imatinib 600 to 800 mg			
	to Sunitinib	172,152	4.803	44,359
Sensitivity analysis 8	Path-1 BSC	92,811	2.397	
(Change in Imatinib	Path- 7 Sunitinib	96,688	2.411	Ext Dom
600mg Price)	Path-4 Imatinib 600 mg	130,272	4.256	20,150
Imatinib 600 mg	Path-3 Imatinib 600 to			
£2005,	Sunitinib	132,412	4.286	Ext Dom
Imatinib 800mg	Path 6 Imatinib 800 mg	153,901	3.635	Dominated
$3208,	Path-2 Imatinib 600 to 800 mg			
Sunitinib £3138.8	to Sunitinib	155,364	4.803	45,850
	Path-5 Imatinib 800 mg to			
	Sunitinib	155,828	3.659	Dominated
Sensitivity analysis 9	Path-1 Best supportive care	92,811	2.397	
(Change in Imatinib	Path- 7 Sunitinib	96,688	2.411	Ext Dom
800mg Price)	Path 6 Imatinib 800 mg	139,988	3.635	Ext Dom
Imatinib 600 mg	Path-5 Imatinib 800 mg to			
£2406,	Sunitinib	141,915	3.659	Ext Dom

	Strategy	Cost (£)	Eff (QALYS)	Incr cost per QALY (£)
Imatinib 800mg $2807, Sunitinib £31398	Path-4 Imatinib 600 mg	147,060	4.256	29,181
	Path-3 Imatinib 600 to Sunitinib	149,200	4.286	Ext Dom
	Path-2 Imatinib 600 to 800 mg to Sunitinib	166,000	4.803	34,609
Sensitivity analysis 10 (Change in Sunitinib Price) Imatinib 600 mg £2406, Imatinib 800mg $3208, Sunitinib £2092	Path- 7 Sunitinib	87,533	2.411	
	Path-1 Best supportive care	92,811	2.397	Dominated
	Path-3 Imatinib 600 to Sunitinib	144,524	4.286	30,400
	Path-4 Imatinib 600 mg	147,060	4.256	Dominated
	Path-5 Imatinib 800 mg to Sunitinib	151,560	3.659	Dominated
	Path 6 Imatinib 800 mg	153,901	3.635	Dominated
	Path-2 Imatinib 600 to 800 mg to Sunitinib	170,364	4.803	49,940

7.3 Summary

The systematic review of economic evaluations reported in this chapter was not especially informative. This was anticipated at the outset and hence an economic modelling exercise was planned. The modelling exercise compared alternative treatment pathways for patients with unresectable GIST who failed to respond to imatinib 400 mg/day. Over almost all the sensitivity analyses Path - 1, best supportive care, is the least costly and least effective intervention. Similarly, Path – 4, imatinib 600 mg/day, typically has an incremental cost per QALY that is less than £30,000 compared with Path-1: best supportive care. Path-2 (Imatinib 600 mg/day to imatinib 800 mg/day to Sunitinib) is the only other pathway which is not dominated or extendedly dominated over most of the analyses conducted. However, in this case the incremental cost per QALY (compared to the next most costly option (Path – 4: imatinib 600 mg/day) tends to be in excess of £40,000.

When society's willingness to pay for a QALY is less than approximately £25,000 Path – 1, best supportive care is the most cost-effective. When society's willingness to pay for a QALY is between approximately £25,000 and £45,000 Path – 4, imatinib 600 mg/day is most likely to be considered cost-effective. Beyond a threshold of approximately £45,000 Path – 2, imatinib 600 mg/day to imatinib 800 mg/day to sunitinib is most likely to be cost-effective.

The results of the economic analysis are based upon spare data that is potentially biased and are surrounded by considerable imprecision. In particular data for sunitinib and for imatinib 600 mg/day are the most suspect. The analysis has also not considered three main areas of uncertainty due to lack of data:

- Alternative assumptions about how probabilities of death and response change over time; and
- Reductions in utility associated with side effects of treatment.

The impact of making alternative assumptions about how probabilities for death and response change is unknown but it is anticipated that the assumption of constant probabilities over time will exaggerate estimated life expectancy (and hence QALYs and cost) for all pathways. The net impact on relative cost-effectiveness is unclear as it depends upon the magnitude of any changes in both costs and QALYs that might occur.

The net impact of adjusting scores for side effects is also uncertain but it might be expected that it will reduce the QALYs associated with each medication and, although there is limited data available from the systematic review of effectiveness, this reduction may be greater for pathways involving sunitinib because its side-effect profile is believed to be worse than imatinib.

A further factor not considered by the economic model was the cost-effectiveness of treatment with specific gene mutations. Again this was not addressed due to lack of data.

Finally, the economic evaluation has assumed that patients who move on to best supportive care remain on treatment to prevent tumour flare. This has the impact of increasing the cost of best supportive care. It is further assumed that there is no impact on effectiveness (the implicit assumption is that discontinuing the medication would reduce life expectancy). Within the analysis it has been assumed that all patients on best supportive care or moving on to best supportive care after failing to respond on a medication would receive imatinib 400 mg/day. This assumption appears reasonable for Path – 1, best supportive care but may not be appropriate for the other pathways where patients would move on to best supportive care after failing to respond on an escalated dose of imatinib or on sunitinib. Should these patients continue with the last active medication that they received then costs, and incremental costs per QALY would increase.

8 ASSESSMENT OF FACTORS RELEVANT TO THE NHS AND OTHER PARTIES

GISTs are a rare cancer accounting for less than 1% of all cancers of the gastrointestinal tract. NICE guidance on imatinib for the treatment of unresectable and/or metastatic GIST does not recommend an increase in the dose of imatinib for people receiving imatinib who develop progressive disease after initially responding at the 400 mg/day dose.[48] Some guidelines however do advocate dose escalation for such patients, particularly those with KIT exon 9 mutations.[15,109,110]

Since the availability of sunitinib, guidance on the treatment of patients with unresectable and/or metastatic GIST has been adapted to take account of this drug as a possible second line treatment[15] in circumstances where patients either are intolerant to imatinib, or have progressed on treatment with imatinib at a 400 mg/day dose. NICE guidance recommends sunitinib as a treatment option for people with unresectable and/or metastatic malignant GISTs if imatinib treatment has failed because of resistance or intolerance, and the drug cost of sunitinib for the first treatment cycle is met by the manufacturer.

In clinical practice the treatment of patients with unresectable and/or metastatic GIST is generally decided on a case by case basis by multidisciplinary teams. Many clinicians advocate initial dose escalation of imatinib and then consider sunitinib on subsequent progression, although practice will vary depending on the specific needs of individual patients.

9 DISCUSSION

9.1 Statement of principal findings

9.1.1 Clinical effectiveness

This review is a part update of a previous review on imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours (GISTs).[53] This review focused on patients with KIT (CD117) positive unresectable and/or metastatic GISTs whose disease had progressed on treatment with imatinib at a dose of 400 mg/day. Five studies involving 2032 patients on relevant treatment arms, met the inclusion criteria. Of these studies, four involving 318 patients reported imatinib outcomes and one involving 351 patients, who had received a prior imatinib dose of ≤ 400 mg/day reported sunitinib. No studies reporting best supportive care were identified that met our inclusion criteria.

Although the study designs for most of the included trials were RCTs (plus one retrospective cohort study) none of these trials had, as their primary objective, the assessment of the effects of dose escalation following progression on 400 mg/day imatinib. Only a proportion of the overall patient populations received an escalated dose, and these patients were not randomised at the point of dose escalation to receive either an escalated dose of imatinib or remain on 400 mg/day. Therefore the nature of the evidence base for patients who progress on 400 mg/day imatinib and receive escalated doses of 600 or 800 mg/day is observational and therefore open to extensive bias.

The sample sizes involved ranged from 24[73] to 1117[82] participants, and each study had more male than female participants. The vast majority of participants in each study had an ECOG performance status of ≤2, meaning that they were ambulatory and confined to bed for less than 50% of their waking hours.[111] Of the studies that reported the proportion of the study population receiving prior surgery,[37,42,73] most patients had undergone prior surgery for treatment of their disease.

At an escalated imatinib dose of 600 mg/day, between 25.6% (11/43)[37] and 41.7% (5/12)[73] of patients with unresectable and/or metastatic GIST who had previously progressed on a dose of 400 mg/day of imatinib, either developed a partial response or maintained stable disease at the higher dose. At an escalated imatinib of 800 mg/day, the proportions achieving partial response or stable disease ranged between 29.3%[42] to 33.3%.[73] These data were used to inform transition probabilities of non-response to imatinib at escalated doses of 600 mg/day and 800 mg/day respectively. However, response data were not available for patients receiving sunitinib following treatment with imatinib at a dose of ≤400 mg/day. The

economic model was therefore required to use sources excluded from the review of clinical effectiveness on account of failure to report response data separately for those progressing on a 400 mg/day dose, and make the assumption that response was unaffected by prior treatment received. From the data on imatinib, it can be seen that approximately one third of patients progressing on 400mg/day imatinib will respond to escalated doses.

Median overall survival data were not reported for those receiving an escalated imatinib dose of 600 mg/day upon progression at a 400 mg/day dose. Therefore, the economic model calculated the probability of death from the available trial data on median overall survival according to best response, and the proportion of patients receiving escalated doses who will have had a response to imatinib at the initial 400 mg/day dose prior to eventual progression and dose escalation.

For those receiving an escalated imatinib dose of 800 mg/day upon progression, median overall survival was reported to be 19 months (95% CI 13 to 23 months) in the S0033 trial.[39] Median overall survival was not reported for the EORTC-ISG-AGITG study for the population of interest, [redacted] For those receiving sunitinib after a prior imatinib dose of ≤400 mg/day, median overall survival was reported as 22.5 months (95% CI 18.3 to 26.5 months).[82]

Figure 3 provided a visual comparison of the median overall survival times for imatinib at an escalated dose of 800 mg/day and sunitinib, showing overlapping confidence intervals until 33 months from commencement of treatment, at which point the estimated proportion of sunitinib patients surviving appeared to be less than the proportion surviving on the 800 mg/day imatinib dose. [redacted]. It is difficult to draw any conclusions with regard to possible differences in overall survival between imatinib at an escalated dose of 800 mg/day and sunitinib at 50 mg/day (with a four week on/two week off cycle), owing to the lack of data, but as the 95% confidence intervals for median overall

survival overlap, there does not appear to be any significant difference in median overall survival with dose escalation, compared with sunitinib.

Park and colleagues reported that the median time to progression for those receiving an escalated dose of imatinib to 600 mg/day was 1.7 months (range 0.7 to 24.9 months).[73] For studies looking at dose escalation of imatinib to 800 mg/day, progression-free survival ranged from 2.9 months (reported without confidence intervals as "81 days")[42] to 5 months (95% CI 2 to 10 months).[39] A meta-analysis of progression-free survival for patients receiving imatinib at an escalated dose of 800 mg/day was attempted but it was not possible to obtain valid results due to the lack of data available. A visual representation of these data in Figure 4 gives 95% confidence intervals that do not overlap, for all time points between 12 and 21 months, indicating that progression-free survival was signficantly shorter in the EORTC-ISG-AGITG study reported by Zalcberg and colleagues[42] than in the S0033 trial reported by Blanke and colleagues.[39]

Both trials providing information on progression-free survival for patients receiving an escalated dose of imatinib at 800 mg/day reported that between 16.1% (19/118) and 18.8% (25/133) of patients were progression free at the time of the analysis. This represented a proportion of between 52.8% (19/36) and 64.1% (25/39) of all those achieving partial response and stable disease on the escalated dose of 800mg/day. This suggests that a small proportion (i.e. <20%) of those receiving an escalated dose of 800 mg/day imatinib on progression, may maintain their response/stable disease for a median of at least 25 months (i.e. the shorter of the median follow up times reported by these trials), and those who achieve a response or maintain stable disease on the escalated dose may have a greater than 50% likelihood of maintaining this in the longer term.

For those receiving an escalated dose of 800 mg/day, the study by Zalcberg reported a median duration of "stabilisation" among those showing response or stable disease with treatment, of 153 days (range 37 to 574 days).[42] Data were not reported for the treatment duration of patients given sunitnib following failure on imatinib at a dose of ≤400 mg/day. Kang and colleagues reported that treatment duration "did not significantly differ based on the dose of prior imatinib therapy".[76] It was not reported whether this statement was still accurate at the time further analysis was undertaken by Seddon and colleagues. At the time the Seddon and colleagues analysis was undertaken, it was reported that the treatment duration for all patients receiving sunitinib (i.e. regardless of the dose of prior imatinib therapy) was 126 days (range 1 to 618 days).[82] If these data are considered along with the data on median progression-free survival or time to progression, it can be seen that for patients with unresectable and/or

metastatic GIST, the duration of response following either dose escalation of imatinib, or sunitinib treatment, after progression on imatinib at a 400mg/day dose, is likely to be short (i.e. best measured in terms of months rather than years). However it should be noted that the consistency of defintions across studies is unclear, as these were not stated within the study reports, and the use of "duration of treatment" may not be an appropriate substitute in the absence of data on "duration of response", as patients who stop responding may still remain on the study drug to prevent an acceleration of disease and symptoms following withdrawal.

Data on adverse events were not available from any studies where the population of interest received imatinib at 600mg/day, or sunitinib following progression at 400mg/day. For the trials reporting outcomes following dose escalation from 400mg/day to 800mg/day after progression at the lower dose, it was reported that the vast majority (88.4%) of study discontinuations were due to disease progression and not study drug toxicity.[42]

[redacted]

Nevertheless, it was also reported that between 15.6%[74] and 31%[75] of patients receiving an escalated imatinib dose of 800mg/day required a dose reduction. It was also reported that 23.3% (18/77) patients required at least one dose delay.[74] However, it was not possible to take possible dose reductions into account with regard to any of the outcomes. This was because information on the dose provided following reduction, the median duration of any dose delay or dose reduction, and any other factors besides toxicity contributing to any of the dose delays or reductions, were not reported.

These data on discontinuations and dose modifications indicate that whilst disease progression is far more likely than adverse events to contribute to the decision to stop escalated imatinib treatment at the 800 mg/day dose, approximately one third of patients will require dose modifications (i.e. dose reduction or interruption) during treatment at this escalated dose.

With regard to specific adverse events, data were reported by Zalcberg and colleagues showing that a higher proportion of patients with skin rash, nausea, leucopenia, neutropenia and throbocytopenia reported a reduction in the severity of these events compared with the proportion of patients reporting an increase in these events. This reduction was significant in

the case of neutropenia (p=0.002). However, the proportion of patients with oedema, fatigue, dyspnoea and anaemia who reported an increase in severity of these events following dose escalation, was greater than the proportion of patients who reported a reduction in these events. This increase in severity was significant in the case of fatigue (p<0.001) and anaemia (p=0.015).[42]

[redacted] It is difficult to draw any conclusions about specific adverse events from these data, aside from noting that fatigue and anaemia may significantly increase upon dose escalation from 400 mg/day imatinib to 800 mg/day.

The only data available for any of the pre-specified sub-groups of interest, was reported by Debiec-Rychter and colleagues for the EORTC-ISG-AGITG trial which looked at imatinib dose escalation from 400mg/day to 800mg/day following progression at the lower dose. They noted that patients with wild-type, and those with exon 9 mutation, were significantly more likely to have a response to dose escalation than those with exon 11 mutations, but no numerical data were reported for the population of interest.[14]

[redacted] Furthermore, it has been argued that subgroups with certain exon mutations might have improved response and/or survival outcomes if they initially receive an escalated imatinib dose, rather than receiving dose escalation only if there was progression at the 400 mg/day dose.[109]

It was outwith the remit of this review to consider outcomes for patients receiving escalated dosing other than following progression on the initial 400 mg/day dose. The lack of data

available meant it was not possible to assess for specific mutational population subgroups the effects of escalation to an imatinib dose of 800 mg/day following progression at the initial 400 mg/day dose.

9.1.2 Review of cost-effectiveness

The economic component of this study included both a review of the existing economic evaluations and an economic modelling exercise. The evidence from the review of economic evaluations was sparse and there was no published economic evaluation conducted for a UK context which compared the all the interventions for the patient group of interest.

The modelling exercise compared alternative treatment pathways for patients with unresectable GIST who failed to respond to imatinib 400 mg/day. Over almost all the sensitivity analyses Path – 1, best supportive care, is the least costly and least effective intervention. Similarly, Path – 4, imatinib 600 mg/day, typically has an incremental cost per QALY that is less than £30,000 compared with Path–1: best supportive care. Path – 2 (Imatinib 600 mg/day to imatinib 800 mg/day to sunitinib) is the only other pathway which is not dominated or extendedly dominated over most of the analyses conducted. However, in this case the incremental cost per QALY (compared to the next most costly option (Path – 4: imatinib 600 mg/day) tends to be in excess of £40,000.

When society's willingness to pay for a QALY is less than approximately £25,000 Path – 1, best supportive care, is the most cost-effective. When society's willingness to pay for a QALY is between approximately £25,000 and £45,000 Path – 4, imatinib 600 mg/day is most likely to be considered cost-effective. Beyond a threshold of approximately £45,000 Path – 2, imatinib 600 mg/day to imatinib 800 mg/day to sunitinib is most likely to be cost-effective.

9.2 Strengths and limitations of the assessment

In terms of strengths, the review of the evidence base was detailed and thorough. It was unclear from the information provided in a substantial number of abstracts whether the studies met the inclusion criteria and full text papers for all of these reports were obtained and assessed. Non-English language studies were not excluded. Authors were contacted in an attempt to obtain additional information concerning their studies. For the review of economic evaluation, a rigorous systematic approach was adopted. The economic model considered a larger number of plausible alternative treatments and also incorporated both a probabilistic and deterministic estimates of cost effectiveness. The former was limited to clinical effectiveness parameters but this limitation was chosen specifically to draw attention to the uncertainties surrounding these data.

In terms of limitations, there was a dearth of evidence available on the specific population of interest, despite the overall large evidence base on the treatment of GISTs with imatinib or sunitinib. The quality of reporting of dose information in reports of imatinib or sunitinib for GISTs was poor and the data on the population of interest for the studies that were included was non-randomised, non-comparative and therefore observational. Therefore lack of quality data as well as lack of data itself, severely limited both assessments of clinical and cost-effectiveness.

There was also a lack of evidence on quality of life outcomes, which may be of fundamental importance to patients given the potentially palliative nature of treatment following progression, and there was also a lack of evidence on best supportive care. This is important as following the introduction of imatinib and sunitinib, it no longer represents the only treatment option for those with unresectable/metastatic disease. There was little evidence on the response to escalated doses of imatinib based on mutational status, specifically for those who had already failed on an initial imatinib dose of 400 mg/day. It was also not possible to account for the effects of required dose interruptions and reductions, or the effects of sunitinib on those intolerant to imatinib, owing to the lack of available data. This lack of data also prevented an comparative analysis of adverse events between the intervention and comparator treatments.

For sunitinib, it was also necessary to assume that the vast majority of those receiving sunitinib after imatinib treatment at ≤400 mg/day had actually received imatinib at 400 mg/day, and this may not be a valid assumption. However, it was not possible to confirm the validity of the assumption despite contacting the study authors (Personal correspondence, P Reichardt). In addition, much of the evidence base for sunitinib generally relates to its use following the failure of escalated doses of imatinib rather than failure on 400 mg/day, suggesting that the role of sunitinib is seen more as a third line treatment rather than a potential comparator to 600 or 800 mg/day imatinib treatment. This was highlighted by the manufacturer of imatinib in their submission for this Technology Appraisal, and is noted in Chapter 5 of this report.

For the economic model, sufficient sound comparative data for the different plausible treatments was not available, despite conducting an extensive review of relevant studies. Therefore sufficient and appropriate data needed to populate the model were difficult to identify. This led to a number of simplifying assumptions being made with respect to the model and also on the use of data that were potentially unreliable. The model assumes that

patients entering a pathway will remain in that treatment for one cycle only if they do not respond and survive in the treatment arm. In these cases they are either considered to move to the escalated doses or to another alternative (if allowed by a treatment pathway) or continue with best supportive care for the remainder of the model time horizon or until they die. A further simplifying assumption was not to model the complications and side effects of therapy. This latter assumption was made due the very limited evidence available. This is coupled with the assumptions made that the utility associated with stable response or progression did not vary between treatments. One impact of this assumption is that no utility decrement has been assumed for the arguably worse side effect profile of sunitinib. This means that pathways involving sunitinib may overestimate QALYs.

Perhaps a more important limitation is caused by the limited evidence base available. With respect to the clinical effectiveness data used to derive transition probabilities these data, as already noted, were based upon non-randomised, non comparative data. Such data are potentially biased as well as being imprecise. In particular, it is worth noting that point estimates of death and response used within the model may be misleading, for example, the point estimates used suggest that sunitinib has a higher mortality rate than best supportive care.

9.3 Uncertainties

For the assessment of clinical effectiveness:

- The diagnosis of GIST as stated in the final scope document was based on a positive KIT (CD117) test. However this is not a perfect test and in a small (<5%) number of cases a patient can have a GIST despite having a negative KIT (CD117) test.[4,7,25] More recent tests (e.g. PDGRFA and DOG1) may clarify diagnosis. However, the WHO classification of gastrointestinal tumours recommends that a diagnosis of GIST should only apply to those patients testing positive for the KIT (CD117) protein.
- It was not possible to conduct any sub-group analysis for patients with particular mutations, or consider the methods used to identify response (e.g. FDG-PET or CT scanning), or possible factors related to the provision of dose escalated imatinib in an adjuvant or neoadjuvant setting.
- Following progression, the proportion of patients subsequently progressing on escalated doses, who are kept on the study drug on the basis that progression of disease might be slower than if the patient were to be taken off the drug, is not known. It is also not clear whether there is a standard dose used for this purpose. Within the economic model it has been assumed that this would be the case (400 mg/day)

- This review only considered drug treatments that were licensed for patients with GISTs and did not consider other drugs that may be being used in the treatment of GISTs, or licensed drugs that are being used 'off licence' to treat GIST (e.g. imatinib at doses exceeding 800 mg/day, or sunitinib provided in a continuous daily dosing regime).

The economic model has also not considered three main areas of uncertainty due to lack of data:

- Alternative assumption about how probabilities of death and response change over time;
- Reductions in utility associated with side effects of treatment; and
- Impact on cost-effectiveness for people with different gene mutations.

The impact of making alternative assumptions about how probabilities for death and response change is unknown but it is anticipated that the assumption of constant probabilities over time will exaggerate estimated life expectancy (and hence QALYs and cost) for all pathways. The net impact on relative cost-effectiveness is unclear as it depends upon the magnitude of any changes in both costs and QALYs that might occur.

The net impact of adjusting utility scores for side effects is also uncertain but it might be expected that it will reduce the QALYs associated with each medication and, although there is limited data available from the systematic review of effectiveness, this reduction may be greater for pathways involving sunitinib because its side-effect profile is believed to be worse than imatinib.

A further factor not considered by the economic model was the cost-effectiveness of treatment with specific gene mutations. Again this was not addressed due to lack of data.

Finally, the economic evaluation has assumed that patients who move on to best supportive care still receive medication to prevent tumour flare. This has the impact of increasing the cost of increasing the cost of best supportive care. It is further assumed that there is no impact on effectiveness (the implicit assumption is that discontinuing the medication would reduce life expectancy). Within the analysis it has been assumed that all patients on best supportive care or moving on to best supportive care after failing to respond on a medication would receive imatinib 400 mg/day. This assumption appears reasonable for Path – 1, best supportive care only, but may not be appropriate for the other pathways where patients would move on to best supportive care after failing to respond on an escalated dose of imatinib or on

sunitinib. Should these patients continue with the last active medication that they received then costs, and incremental costs per QALY would increase.

10 CONCLUSIONS

10.1 Implications for service provision

- There was very limited evidence available from very few studies on the effects of escalated doses of imatinib 600 mg/day and 800 mg/day or treatment with sunitinib for people with unresectable and/or metastatic GIST whose disease had progressed on the 400 mg/day dose. The evidence that was available was essentially observational in nature and subject to the biases associated with such data, consisting mostly of reporting of subgroups of patients in RCTs that were not designed to assess the effects of dose escalation.
- The limited evidence base suggests that around one third of patients with unresectable and/or metastatic GIST who have failed on a dose of 400 mg/day, may show response or stable disease with escalated doses of imatinib, and those who do respond may have a reasonable chance of maintaining this response over a longer period of time than would otherwise have been the case.
- For all patients receiving either dose escalated imatinib, or sunitinib, median overall survival, where reported, was less than two years.
- Although the results should be interpreted with caution due to the limitations of the evidence base, should society's threshold for willingness to pay be less than £25,000 per QALY a pathway of best supportive care only has the highest probability of being cost-effective. Between a threshold of £25,000 and £45,000 provision of an escalated dose of imatinib would be most likely to be cost-effective. Above a threshold of £45,000 a threshold a pathway of escalated doses of imatinib followed by sunitinib, if necessary, would be most likely to be cost-effective.

10.2 Recommendations for research

Further evidence is needed in order to provide a comprehensive assessment of effectiveness and cost-effectiveness of the alternative treatments for GIST patients who fail on or become resistant to imatinib 400 mg/day. Ideally such data should come from RCTs involving patients who progress on 400 mg/day imatinib, where patients are randomised to 600 mg/day, 800 mg/day, sunitinib, or to remain on 400 mg/day. Dose escalation appears to be used within the NHS already and hence health care professionals may not find it acceptable that their patients could be randomised to 'best supportive care'. Therefore, the following suggested priorities for further research are made:

- An RCT involving patients who progress on 400 mg/day imatinib where patients are randomised to pathways describing alternative combinations of dose escalation with imatinib and the use of sunitinib. The pathways most likely to be cost-effective at thresholds society might be willing to pay and hence potentially the most useful to assess were: dose escalation with imatinib and dose escalation with imatinib followed by sunitinib if necessary. Such studies should as a matter of course include an economic evaluation and measurement of health state utilities.
- Such studies would need to measure outcomes over a sufficiently long time period to capture the main impact on costs and outcomes and in order to avoid the limitation of existing economic evaluations, which relied on extrapolated short-time clinical trial data.
- Where possible further studies should also report outcomes for subgroups of patients with specific KIT mutations.
- There is a dearth of evidence for the utility estimates for the relevant health states of GIST patients. Further UK-relevant information on health state utilities would be useful, collected either as part of a clinical trial, as noted above, or in a stand-alone study.
- With respect to costs, should a further prospective comparative study be conducted the use of health services might usefully be collected. A wider perspective on the consideration of costs might also be informative (e.g. costs that fall on personal social services, which would be relevant for NICE to consider, and costs for patients and their families, which goes beyond NICE's reference case).

11 REFERENCES

1 Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. *Am J Pathol* 1998;152:1259-69.

2 Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. *Am J Surg Pathol* 2004;28:889-94.

3 Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. *Eur J Cancer* 2002;38:S39-S51.

4 Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. *Am J Pathol* 2002;160:1567-72.

5 Duensing A, Medeiros F, McConarty B, Joseph NE, Panigrahy D, Singer S et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). *Oncogene* 2004;23:3999-4006.

6 Heinrich MC, Rubin BP, Longley BJ, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. *Hum Pathol* 2002;33:484-95.

7 Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. *J Clin Oncol* 2003;21:4342-9.

8 Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. *Science* 1998;279:577-80.

9 Rubin BP, Fletcher JA, Fletcher CDM. Molecular insights into the histogenesis and pathogenesis of gastrointestinal stromal tumors. *Int J Surg Pathol* 2000;8:5-10.

10 Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. *Cancer Res* 2001;61:8118-21.

11 Zsebo KM, Williams DA, Geissler EN, Broudy VC, Martin FH, Atkins HL et al. Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. *Cell* 1990;63:213-24.

12 Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N et al. PDGFRA activating mutations in gastrointestinal stromal tumors. *Science* 2003;299:708-10.

13 Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. *Gastroenterology* 2003;125:660-7.

14 Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, Van Oosterom AT et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. *Eur J Cancer* 2006;42:1093-103.

15 *Guidelines for the management of gastrointestinal stromal tumours (GISTs) in Scotland.* Glasgow: Scottish Sarcoma Network; 2009 [accessed February 2010]. URL: http://www.ssn.scot.nhs.uk/protocolsandguidelines/Scottish%20GIST%20guidelines_NOV545_no%.

16 Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. *Am J Surg Pathol* 2009;33:1401-8.

17 West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. *Am J Pathol* 2004;165:107-13.

18 Conlon KC, Casper ES, Brennan MF. Primary gastrointestinal sarcomas: analysis of prognostic variables. *Ann Surg Oncol* 1995;2:26-31.

19 Dematteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. *Ann Surg* 2000;231:51-8.

20 Graadt van Roggen JF, van Velthuysen ML, Hogendoorn PC. The histopathological differential diagnosis of gastrointestinal stromal tumours. *J Clin Pathol* 2001;54:96-102.

21 Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. *Hum Pathol* 2002;33:459-65.

22 Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. *Hum Pathol* 1999;30:1213-20.

23 Miettinen M, Lasota J. Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. *Virchows Arch* 2001;438:1-12.

24 Dematteo RP. The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). *Ann Surg Oncol* 2002;9:831-9.

25 Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. *Am J Surg Pathol* 2005;29:52-68.

26 Nilsson B, Bumming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden. *Cancer* 2005;103:821-9.

27 Tryggvason G, Gislason HG, Magnusson MK, Jonasson JG. Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study. *Int J Cancer* 2005;117:289-93.

28 Reichardt P. Practical aspects of managing gastrointestinal stromal tumours. *Monographs in Gastronintestinal Stromal Tumors* 2003;1:3-8.

29 Lehnert T. Gastrointestinal sarcoma (GIST)--a review of surgical management. *Ann Chir Gynaecol* 1998;87:297-305.

30 Dematteo RP, Heinrich MC, El Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: Before and after STI-571. *Hum Pathol* 2002;33:466-77.

31 Judson I. A guideline for the management of gastrointestinal stromal tumour (GIST). *Sarcoma* 2002;6:83-7.

32 Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. *Ann Oncol* 2005;16:566-78.

33 Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. *Lancet* 2009;373:1097-104.

34 Van den Abbeele AD, Badawi RD, Manola J, Morgan JA, Desai J, Kazanovicz A et al. Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning. *J Clin Oncol* 2004;22 (14 S):3012.

35 Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. *J Surg Oncol* 2009;99:42-7.

36 Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *N Engl J Med* 2002;347:472-80.

37 Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. *J Clin Oncol* 2008;26:620-5.

38 Van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato dP, Dimitrijevic S et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. *Lancet* 2001;358:1421-3.

39 Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. *J Clin Oncol* 2008;26:626-32.

40 Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. *Lancet* 2004;364:1127-34.

41 Gramza AW, Corless CL, Heinrich MC. Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. *Clin Cancer Res* 2009;15:7510-8.

42 Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. *Eur J Cancer* 2005;41:1751-7.

43 Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. *J Clin Oncol* 2007;25:1107-13.

44 Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. *J Clin Oncol* 2007;25:1753-9.

45 Choi H. Response evaluation of gastrointestinal stromal tumors. *Oncologist* 2008;13:4-7.

46 Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. *J Nucl Med* 2004;45:17-21.

47 Van den Abbeele AD. The lessons of GIST--PET and PET/CT: a new paradigm for imaging. *Oncologist* 2008;13 (Suppl 2):8-13.

48 *Gastro-intestinal stromal tumours (GIST) - imatinib. NICE Guidance TA86 [document on the Internet]*. London: National Institute for Health and Clinical Excellence; 2004 [accessed February 2010]. http://guidance.nice.org.uk/TA86/Guidance/pdf/English.

49 *Sunitinib for the treatment of gastrointestinal stromal tumours. NICE Guidance TA179 [document on the Internet]*. London: National Institute for Health and Clinical Excellence; 2009 [accessed February 2010]. URL: http://www.nice.org.uk/nicemedia/pdf/TA179Guidance.pdf.

50 Demetri GD, Van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. *Lancet* 2006;368:1329-38.

51 Pfizer Inc. *Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors. ClinicalTrials.gov Identifier NCT00372567.* ClinicalTrials.gov; 2006 [accessed February 2010]. URL: http://clinicaltrials.gov/.

52 Reddy P. The epidemiologic, health-related quality of life, and economic burden of gastrointestinal stromal tumours. *J Clin Pharm Ther* 2007;32:557-65.

53 Wilson J, Connock M, Song F, Yao G, Fry-Smith A, Raftery J et al. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. *Health Technol Assess* 2005;9:1-142.

54 *Guidelines for the management of gastrointestinal stromal tumours (GISTs)*. London: Association of Upper Gastrointestinal Surgeons of Great Britian and Ireland; 2005 [accessed February 2010]. URL: http://www.augis.org/news_guidelines/management_guidelines.htm.

55 *Imatinib for GIST (Glivec®) [webpage on the Internet]*. Glasgow: Scottish Medicines Consortium; 2002 [accessed February 2010]. URL:ttp://www.scottishmedicines.org.uk/files/GlivecGIST_v2.pdf.

56 O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. *Blood* 2003;101:3597-605.

57 Prenen H, Cools J, Mentens N, Folens C, Sciot R, Schoffski P et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. *Clin Cancer Res* 2006;12:2622-7.

58 *Single Technology Appraisal of Sunitinib for the treatment of gastrointestinal stromal tumours [document on the Internet]*. Sandwich, Kent: Pfizer Ltd; 2008 [accessed February 2010]. http://www.nice.org.uk/guidance/index.jsp?action=download&o=43440.

59 Ahmed N, Ahmedzai S, Vora V, Hillam S, Paz. Supportive care for patients with gastrointestinal cancer. *Cochrane Database of Systematic Reviews* 2004;Art. No.: CD003445. DOI: 10.1002/14651858.CD003445.pub2.

60 Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. *J Clin Oncol* 2008;26:5352-9.

61 Van Glabbeke M, Owzar K, Rankin C, Simes J, Crowley J, GIST Meta-analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumours (GIST): a meta-analysis based on 1640 patients. *J Clin Oncol* 2007;25 (18S):10004.

62 Widmer N, Decosterd LA, Leyvraz S, Duchosal MA, Rosselet A, Debiec-Rychter M et al. Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. *Br J Cancer* 2008;98:1633-40.

63 Novartis. *Glivec - Summary of Product Characteristics [document on the Internet]*. The electronic Medicines Compendium; 2009 [accessed February 2010]. URL: http://emc.medicines.org.uk/history/15014/SPC/GLIVEC+Tablets#03/06/2009%20to%20Current.

64 Rankin C, von Mehren M, Blanke C, Benjamin R, Fletcher CDM, Bramwell V et al. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - phase III Sarcoma Group Study S0033. *J Clin Oncol* 2004;22 (14S):Abstract 9005.

65 *Systematic reviews: CRD's guidance for undertaking systematic reviews in health care [document on the Internet]*. University of York: Centre for Reviews and Dissemination; 2009 [accessed February 2010]. URL: http://www.york.ac.uk/inst/crd/SysRev/!SSL!/WebHelp/SysRev3.htm.

66 Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. *J Clin Epidemiol* 1998;51:1235-41.

67 Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. *J Epidemiol Community Health* 1998;52:377-84.

68 Higgins JP, Green,S, editors. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [document on the Internet]*. The Cochrane Collaboration; 2009 [accessed February 2010]. URL: www.cochrane-handbook.org.

69 Parmar MK, Torri V, Stewary L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. *Stat Med* 1998;17:2815-34.

70 Yusuf S, Peto R, Lewis J, Colins R, Sleight P. Beta blockade during and after myocardial infarction. An overview of randomized trials. *Prog Cardiovasc Dis* 1985;27:335-71.

71 Droitcour J, Silberman G, Chelimsky E. Cross-design synthesis: a new form of meta-analysis for combining results from randomized clinical trials and medical-practice databases. *Int J Technol Assess Health Care* 1993;9:440-9.

72 Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. *J Natl Cancer Inst* 1959;22:719-48.

73 Park I, Ryu MH, Sym SJ, Lee SS, Jang G, Kim TW et al. Dose escalation of imatinib after failure of standard dose in Korean patients with metastatic or unresectable gastrointestinal stromal tumor. *Jpn J Clin Oncol* 2009;39:105-10.

74 Dileo P, Rankin CJ, Benjamin RS, von Mehren M, Blanke C, Bramwell V et al. Incidence and reasons for dose modification of standard-dose vs. high-dose imatinib mesylate (IM) in the Phase III Intergroup Study S0033 of patients (pts) with unresectable or metastatic gastrointestinal stromal tumor (GIST). *J Clin Oncol* 2005;23(16 Suppl):824S.

75 Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY et al. Outcome of patients with advanced gastro-intestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800mg (HD) after progression on 400mg (LO) - an international, intergroup study of the EORTC, ISG and AGITG. *J Clin Oncol* 2004;22 (14S):9004.

76 Kang Y, Reichardt P, Ruka W, Seddon B, Baum C, Demetri G. Efficacy and safety of sunitinib ina worldwide treatment-use trial of gist patients following imatinib failure. *Ann Oncol* 2007;18 (Suppl 7):vii16 - Abstract O-0017.

77 Reichardt P, Kang Y, Ruka W, Seddon B, Nieto A, Breazna A et al. Sunitinib (Su) in A Worldwide Treatment-Use Trial of Patients with Gist: Updated Efficacy and Safety Analysis. *Ann Oncol* 2008;19 (Suppl 8):viii267 - Abstract 869PD.

78 Reichardt P, Kang Y, Ruka W, Seddon B, Guerriero A, Breazna A et al. Detailed analysis of survival and sfety with sunitinib (SU) in a worldwide treatment-use trial of patients with advanced GIST. *J Clin Oncol* 2008;26 (15 Suppl):Abstract 10548.

79 Rutkowski P, Reichardt P, Kang Y, Ruka W, Seddon B, Guerriero A et al. Sunitinib in a worldwide treatment-use trial of patients with imatinib, resistant/intolerant gastrointestinal stromal tumor: Detailed analysis of survival and safety. *Ann Oncol* 2008;19 (Suppl 6):vii12 - Abstract O-013.

80 Schutte J, Reichardt P, Schlemmer M, Wendtner CM, Demetri GD. Efficacy and safety of sunitinib in patients with gastrointestinal stromal tumour resistant or intolerant of prior imatinib therapy: Results from a worldwide treatment-use study. *Onkologie* 2008;31 (suppl 1):77-Abstract OP130.

81 Seddon B, Reichardt P, Ruka W, Kang YK, Baum CM, Demetri GD. Safety and efficacy results of sunitinib from a worldwide treatment. use trial of gastrointestinal stromal tumour (GIST) patients (pts) with resistance or intolerance to prior imatinib therapy. *Eur J Cancer Suppl* 2007;5 (4):405-Abstract 7511.

82 Seddon B, Reichardt P, Kang YK, Ruka W, Nieto A, Breazna A et al. Detailed anlaysis of survival and safety with Sunitinib in a worldwide treatment-use trial of patients with advanced imatinib-resistant/intolerant GIST. *Connective Tissue Oncology Society, 14th Annual Meeting, London, November* 2008. Abstract 34980.

83 An JY, Choi MG, Noh JH, Sohn TS, Kang WK, Park CK et al. Gastric GIST: a single institutional retrospective experience with surgical treatment for primary disease. *Eur J Surg Oncol* 2007;33:1030-5.

84 Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. *Lancet* 2007;370:2011-9.

85 Goerres GW, Stupp R, Barghouth G, Hany TF, Pestalozzi B, Dizendorf E et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. *Eur J Nucl Med Molecul Imag* 2005;32:153-62.

86 Nishida T, Shirao K, Sawaki A, Koseki M, Okamura T, Ohtsu A et al. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202). *Int J Clin Oncol* 2008;13:244-51.

87 Phongkitkarun S, Phaisanphrukkun C, Jatchavala J, Sirachainan E. Assessment of gastrointestinal stromal tumors with computed tomography following treatment with imatinib mesylate. *World J Gastroenterol* 2008;14:892-8.

88 Arends LR, Hunink MG, Stijnen T. Meta-analysis of summary survival curve data. *Stat Med* 2008;27:4381-96.

89 Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. *Health Technol Assess* 2004;8(36):1-61.

90 National Institute for Health and Clinical Excellence. *Guide to the methods of technology appraisal [document on the Internet]*. London: National Institute for Health and Clinical Excellence; 2008 [accessed February 2010]. URL: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf.

91 Chabot I, LeLorier J, Blackstein ME. The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: The example of sunitinib for gastrointestinal stromal tumour. *Eur J Cancer* 2008;44:972-7.

92 Contreras-Hernandez I, Mould-Quevedo JF, Silva A, Salinas-Escudero G, Villasis-Keever MA, Granados-Garcia V et al. A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours. *Br J Cancer* 2008;98:1762-8.

93 Huse DM, von Mehren M, Lenhart G, Joensuu H, Blanke C, Feng W et al. Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours. *Clin Drug Invest* 2007;27:85-93.

94 Mabasa VH, Taylor SCM, Chu CCY, Moravan V, Johnston K, Peacock S et al. Verification of imatinib cost-effectiveness in advanced gastrointestinal stromal tumor in British Columbia (VINCE-BC study). *J Oncol Pharm Pract* 2008;14:105-12.

95 Paz-Ares L, Garcia dM, X, Grande E, Gonzalez P, Brosa M, Diaz S. Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib. *Clin Trans Oncol* 2008;10:831-9.

96 Teich N, Hashizume C, Follador W. Economic Evaluation of Sunitinib Vs. Imatinib in Second Line for Gastrointestinal Tumor (Gist) in Brazil. *Value in Health* 2009;12 (7):A496.

97 Hopkins TG, Marples M, Stark D. Sunitinib in the management of gastrointestinal stromal tumours (GISTs). *Eur J Surg Oncol* 2008;34:844-50.

98 Verweij J, Casali PG, Zalcberg J, Le Cesne A, Reichard P, Blay J et al. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST): interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG abstract. *39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31 - June 3, 2003 Abstract No 3272* 2003;

99 Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg BL, Fletcher J et al. Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients (pts) treated with imatinib mesylate. *J Clin Oncol* 2006;24(18S):Abstract 9528.

100 Motzer RJ, Hoosen S, Bello CL, Christensen JG. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. *Expert Opinion on Investigational Drugs* 2006;15:553-61.

101 Ojeda B, de Sande LM, Casado A, Merino P, Casado MA. Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain. *Br J Cancer* 2003;89:1002-7.

102 *TreeAge Pro [webpage on the Internet]*. Williamstown MA: TreeAge Software Inc; 2009 [accessed February 2010]. URL: http://www.treeage.com/products/overviewPro.html.

103 Artinyan A, Kim J, Soriano P, Chow W, Bhatia S, Ellenhorn JD. Metastatic gastrointestinal stromal tumors in the era of imatinib: improved survival and elimination of socioeconomic survival disparities. *Cancer Epidemiol Biomarkers Prev* 2008;17:2194-201.

104 McGrath PC, Neifeld JP, Lawrence W, Jr., Kay S, Horsley JS, III, Parker GA. Gastrointestinal sarcomas. Analysis of prognostic factors. *Ann Surg* 1987;206:706-10.

105 Pierie JP, Choudry U, Muzikansky A, Yeap BY, Souba WW, Ott MJ. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. *Arch Surg* 2001;136:383-9.

106 Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J et al. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. *J Clin Oncol* 2009;27:439-45.

107 Joint Formulary Committee. *British National Formulary 58.* London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2009.

108 Curtis L. *Unit Costs of Health and Social Care 2009 [document on the Internet]*. Canterbury: Personal Social Services Research Unit.; 2009 [accessed February 2010]. URL: http://www.pssru.ac.uk/uc/uc.htm.

109 Casali PG. Gastrointestinal stromal tumours: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. *Ann Oncol* 2009;20:iv64-iv67.

110 Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. *Journal of the National Comprehensive Cancer Network* 2007;5 Suppl 2:S1-29.

111 Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol* 1982;5:649-55.

12 APPENDICES

APPENDIX 1. SEARCH STRATEGIES

MEDLINE (2000 – September Week 3 2009) EMBASE (2000 – 2009 Week 39) (Medline In Process 25th September 2009)

Ovid Multifile Search URL: https://shibboleth.ovid.com/

```
1 Gastrointestinal Stromal Tumors/ use mesz
2 Gastrointestinal Stromal Tumor/ use emez
3 gastrointestinal neoplasms/ use mesz
4 exp digestive system tumor/ use emez
5 gist.tw
6 ((gastro$ or gastric) adj3 stromal).tw.
7 (3 or 4) and (kit or cd117 or cd 117).tw.
8 (3 or 4) and (stromal or connective or mesenchymal).tw.
9 or/1-2,5-8
10 imatinib.tw,rn.
11 gleevec.tw,rn.
12 glivec.tw,rn.
13 (sti571 or sti 571).tw,rn.
14 or/10-13
15 sunitinib.tw,rn.
16 sutent.tw,rn.
17 (su11248 or su 11248).tw,rn
18 or/15-17
19 dt.fs
20 9 and 19
21 20 not (14 or 18)
22 Palliative Care/
23 ((palliative or support$) adj3 (care or treatment)).tw.
24 (symptom$ adj3 control$).tw.
25 or/21-24
26 9 and 14
27 9 and 18
28 9 and 25
29 or/26-28
30 exp clinical trial/
31 randomized controlled trial.pt.
32 controlled clinical trial.pt.
33 randomization/ use emez
34 randomi?ed.ab.
35 placebo.ab.
36 drug therapy.fs.
37 randomly.ab.
38 trial.ab
39 groups.ab.
40 or/30-39
41 comparative study/ use mesz
42 follow-up studies/ use mesz
43 time factors/ use mesz
44 Treatment outcome/ use emez
45 major clinical study/ use emez
46 controlled study/ use emez
47 clinical trial/ use emez
48 (preoperat$ or pre operat$).mp. use mesz
49 (chang$ or evaluat$ or reviewed or baseline).tw
50 (prospective$ or retrospective$).tw. use mesz
```

```
51 (cohort$ or case series).tw. use mesz
52 (compare$ or compara$).tw. use emez
53 or/41-52
54 29 and (40 or 53)
55 animals/ not (humans/ and animals/)
56 nonhuman/ not (human/ and nonhuman
57 54 not (55 or 56)
58 remove duplicates from 57
59 limit 58 to yr="2000 -Current"
```

Science Citation Index (2000 - 26th September 2009)

Biosis (2000 – 24th September 2009)

ISI Proceedings (2000 – 26th September 2009)

Web of Knowledge URL: http://wok.mimas.ac.uk/

```
#1 ts=gist
#2 ts=((gastric or gastro*) SAME stromal)
#3 ts=((gastric or gastro*) AND (KIT or cd117 or cd 117))
#4 ts=((gastic or gastro*) and mesenchymal)
#5 #1 OR #2 OR #3 OR #4
#6 ts=(imatinib or gleevac or glivec or sti571 or sti 571)
#7 #5 AND #6
#8 ts=(sunitinib or sutent or su11248 or su 11248)
#9 #5 AND #8
#10 ts=(palliative same (care or treatment))
#11 #5 AND #10
#12 ts=(support* SAME (care or treatment))
#13 #5 AND #12
#14 ts=(symptom* SAME control*)
#15 #5 AND #14
#16 #15 OR #13 OR #11 OR #9 OR #7
#17 #16 CPCI-S Timespan=2000-2009
```

CINAHL (September 2009)

EBSCOhost URL: http://web.ebscohost.com/

```
S1   (MH "Gastrointestinal Neoplasms+")
S2   TX gastric or gastro*
S3 S1 OR S2
S4   TX (stromal or connective or mesenchymal)
S5   S3 and S4
S6   TX kit or cd117 or cd 117
S7   S3 and S6
S8   S5 or S7
S9   TX gist
S10   (S8 or S9)
S11  TX (imatinib or gleevec or glivec or sti571 or sti 571)
S12   S10 and S11
S13  TX (sunitinib or sutent or su11248 or su 11248)
S14   S10 and S13
S15   (MH "Palliative Care")
S16   (MH "Hospice and Palliative Nursing
S17   TX (palliative N3 care ) OR (palliative N3 treatment)
S18   TX (support* N3 care ) OR (support* N3 treatment)
S19   TX (symptom* N3 control*)
S20   (S15 or S16 or S17 or S18 or S19)
S21   S10 and S20
S22   S12 OR S14 OR S21
```

Cochrane Library Issue 3, 2009 (CENTRAL and CDSR)

URL: http://www3.interscience.wiley.com/cgi-bin/mrwhome/106568753/HOME

```
#1 MeSH descriptor Gastrointestinal Stromal Tumors, this term only
#2 (gist)
#3 (gastric or gastro*) NEAR/3 stromal
#4 MeSH descriptor Gastrointestinal Neoplasms explode all trees
#5 (kit or cd117 or cd 117) or (stromal or connective or mesenchymal)
#6 (#4 AND #5)
#7 (#1 OR #2 OR #3 OR #6)
#8 (imatinib or gleevec or glivec or sti571 or sti 571) or (sunitinib
or sutent or su11248 or su 11248)
#9 (#7 AND #8)
#10 Any MeSH descriptor with qualifier: DT
#11 (#7 AND #10)
#12 MeSH descriptor Palliative Care, this term only
#13 (symptom* NEAR/3 control*) or (palliative NEAR/3 (care or
treatment)) or (support* NEAR/3 (care or treatment))
#14 (#7 AND ( #12 OR #13 ))
#15 (#9 OR #11 OR #14)
```

DARE and HTA Databases (October 2009)

NHS Centre for Reviews & Dissemination

URL:http://nhscrd.york.ac.uk/welcome.htm

```
# 1 MeSH Gastrointestinal Stromal Tumors EXPLODE 1 2 3
# 2 gist
# 3 ( gastric OR gastro* ) AND ( kit OR cd117 OR cd AND 117 )
# 4 ( gastric OR gastro* ) AND ( stromal OR connective OR mesenchymal
)
# 5 #1 or #2 or #3 or #4
# 6 ( imatinib OR gleevec OR glivec OR sti571 OR sti AND 571 )
# 7 #5 and #6
# 8 ( sunitinib OR sutent OR su11248 OR su AND 11248 )
# 9 #5 and #8
# 10 MeSH Palliative Care EXPLODE 1 2
# 11 palliative
# 12 #5 and (#10 or #11)
# 13 #7 or #9 or #12
```

Health Management Information Consortium (September 2009)

Ovid Multifile Search URL: http://gateway.ovid.com/athens

```
1 gist.tw.
2 ((gastro$ or gastric$) adj3 stromal).tw.
3 gastrointestinal cancer/ 94
4 3 and (kit or CD117 or cd 117).tw.
5 3 and (stromal or connective or mesenchymal).tw.
6 or/1-2,4-5
```

Clinical Trials (Septemember 2009)

URL: ***http://clinicaltrials.gov/ct/gui/c/r***

"GIST":Topic

Current Controlled Trials (September 2009)
URL: http://www.controlled-trials.com/

Gastro% stromal OR GIST

WHO ICTRP (September 2009)
URL: http://www.who.int/ictrp/en/

Gastro% stromal OR GIST

ClinicalStudyResults (September 2009)
URL: http://www.clinicalstudyresults.org/

```
Sutent and GIST
Gleevec and GIST
Glivec and GIST
```

ABPI (September 2009)
URL: www.cmrinteract.com/clintrial

Sutent or gleevec or glivec

IFPMA (September 2009)
URL: http://clinicaltrials.ifpma.org

Sutent or gleevec or glivec

Conference Proceedings

American Society of Clinical Oncology
Annual Meeting, Chicago, 1-5 June 2007
Annual Meeting, Chicago, 30 May – 3 June 2008
Annual Meeting, Orlando, 29 May – 2 June 2009

European Society for Medical Oncology
9th World Congress on Gastrointestinal Cancer,Barcelona,28 June–1 July 2007
10th World Congress on Gastrointestinal Cancer, Barcelona, 25-28 June 2008
33rd Congress, Stockholm, 12-16 September 2008

European Cancer Organisation
ECCO 14: European Cancer Conference, Barcelona, 22-27 September 2007
ECCO 15: European Cancer Conference, Berlin, 24-29 September 2009

APPENDIX 2 FULL PAPER SCREENING TOOL

Escalated dose of imatinib for patients with gastro intestinal stromal tumours **Assessor initials:** **Date:**	
Study identifier (Surname of first author + year of publication)	
Type of study Is the study an RCT in which all participants are randomised to imatinib, sunitinib or best supportive care (either provided in addition to imatinib or sunitinib or as only care)? OR Is the study a non-randomised comparative study on patients using either imatinib or sunitinib or best supportive care? OR Is the study case series or case study of more than one patient on same type of diagnosis?	☐ Yes ☐ Unclear ☐ No ⇩ ⇩ ⇩ Go to next question **Exclude**
Participants in the study Does the study contain participants with KIT (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST)? ☐ Unresectable ☐ Metastatic Does the study state that disease has progressed on treatment with imatinib at a dose of 400 mg/day? ☐ Yes ☐ No	☐ Yes ☐ Unclear ☐ No ⇩ ⇩ ⇩ Go to next question **Exclude**
Doses and other comparisons Does the study contain at least one group using escalated doses of imatinib (600mg or 800mg per day)? OR Does the study contain at least one group using sunitinib within its recommended dose range (i.e. 25-75 mg/day)? OR Does the study contain at least one group receiving best supportive care	☐ Yes ☐ Unclear ☐ No ⇩ ⇩ ⇩ Go to next question **Exclude**
Outcomes reported Does the study report any one of the following outcomes? ☐ Overall response ☐ Overall survival ☐ Disease-free survival ☐ Progression-free survival ☐ Time to treatment failure ☐ Health-related quality of life ☐ Adverse effects of treatment	☐ Yes ☐ Unclear ☐ No ⇩ ⇩ ⇩ Go to next question **Exclude**
Decision	☐ **Include** ☐ **Unclear** ☐ **Exclude** Clarification required

APPENDIX 3 DATA EXTRACTION FORM

Reviewer ID: **Date:**

Administration Details for Study	
Study ID: (Surname of 1st Author and Year of Publication) **Possibly related studies in this review:** **Multicentre Study:** ☐ Yes. Number of centres _____ ☐ No. **Country/countries:** **Funding Details:** Government Private Manufacturer Other (specify)**:** **Additional Info**:	**Study Design:** ☐ - RCT ☐ - Crossover study ☐ - Non-randomised comparative study ☐ - Prospective case series ☐ - Registry-based study **Duration of Study:** **Study start/end dates:** **Length of follow up:**
Aim of Study	
Interventions investigated	
Interventions: ☐ - Imatinib at 600 mg per day ☐ - Imatinib at 800mg per day	**Comparators:** ☐ - Sunitinib (specify dose): ☐ - Best supportive care, defined as: _____ _____

Outcomes Reported	
Outcome:	**Tool Used in Assessment/Outcome defined as:**
☐ - Overall response	
☐ - Overall survival	
☐ - Disease free survival	
☐ - Progression-free survival	
☐ - Time to treatment failure	
☐ - Health-related quality of life	
☐ - Adverse effects of treatment	

Inclusion Criteria

Exclusion Criteria

Characteristics of Participants				
Characteristic	**Intervention 1**	**Comparator 1**	**Comparator 2**	**All**
Enrolled				
Randomised				
Analysed				
Number lost to follow up				
Age (mean/median, SD/IQR/range)				
Sex:	**F:** **M:**	**F:** **M:**	**F:** **M:**	**F:** **M:**
Stage of disease: ☐ - Unresectable ☐ - Metastatic ☐ - Recurrent ☐ - Advanced	No (%) at stage:	No (%) at stage:	No (%) at stage:	No (%) at stage:
Mutations of c-KIT present: ☐ - exon 9 ☐ - exon 11 ☐ - exon 13 ☐ - exon 17	No (%) with mutation	No (%) with mutation	No (%) with mutation	No (%) with mutation
Previous imatinib use: mg/day mg/day mg/day	No (%) on this dose	No (%) on this dose	No (%) on this dose	No (%) on this dose
Used imatinib at mg/day as: ☐ - neoadjuvant treatment ☐ - adjuvant treatment	No (%) affected	No (%) affected	No (%) affected	No (%) affected

Number/proportion of KIT positive patients (if not 100%):

Method of GIST diagnosis (if specified):

Method used to determine progression/response:
☐ - CT scan
☐ - FDG – PET scan

Additional Information on Participants				
Interventions				
Description of intervention (e.g. dose, number of times taken per day, care provided etc)	**Intervention 1**	**Comparator 1**	**Comparator 2**	**All**
Results				
Outcome:	**Intervention 1**	**Comparator 1**	**Comparator 2**	**All**
Overall Response				
Overall Survival				
Disease-free survival				
Progression-free survival				
Time to treatment failure				
Health-related QoL				

Adverse Events				
General Information on Adverse Events:				
Adverse Events Reported	**Intervention 1**	**Comparator 1**	**Comparator 2**	**All**
Additional Study Information				

APPENDIX 4 QUALITY ASSESSMENT TOOL

Table 1 Quality assessment tool of non-randomised studies (comparative studies and case series). Items specific to comparative studies are *in italic*.

Criteria	Yes	No	Unclear	Comments
Participants: sample definition and selection				
1. Were participants a representative sample selected from a relevant patient population?				
2. Were the inclusion/exclusion criteria of participants clearly described?				
3. Were participants entering the study at a similar point in their disease progression?				
4. Was selection of patients consecutive?				
5. Was data collection undertaken prospectively?				
6. Were the groups comparable on demographic characteristics and clinical features?				
Intervention				
7. Was the intervention (and comparison) clearly defined?				
8. Was the intervention undertaken by someone experienced at performing the procedure?				
9. Were the staff, place, and facilities where the patients were treated appropriate for performing the procedure? (e.g. access to back-up facilities)				
Outcome measures				
10. Were all the important outcomes considered?				
11. Were objective (valid and reliable) outcome measure/s used?				
12. Was the assessment of main outcomes blind?				
Follow-up				
13. Was follow-up long enough to detect important effects on outcomes of interest?				
14. Was information provided on non-respondents, dropouts?				

15. Were participants lost to follow-up likely to introduce bias? (e.g. high drop-out rate; *differential drop-out*; no description of those lost)				
16. Was length of follow-up similar between comparison groups?				
Analysis				
17. Were important prognostic factors identified?				
18. Were the analyses adjusted for confounding factors?				

Table 2 Checklist for quality assessment at trial entry if study itself is randomised.

Quality criteria	**Yes**	**No**	**Unclear**	**Comments**
1. Was the allocation sequence adequately generated? (RevMan5, selection bias) • Yes = Adequate, e.g. random number table, use of computer random number generator, shuffling cards or envelopes • No = Inadequate, e.g. use of alternation, case record numbers, birth dates, date of admission • Unclear = Insufficient information to permit judgement of yes or no				
2. Was allocation adequately concealed? (quality of random allocation concealment) • Yes (Adequate, A) = Good attempt at concealment; method should not allow disclosure of assignment (telephone randomisation, third party involvement in allocation procedure etc • Unclear (B) = States concealment but no description given • No (Inadequate, C) = Definitely not concealed (open random numbers tables or quasi-randomised, e.g. day of week, date of birth, alternation) or an attempt at concealment but real chance of disclosure of assignment prior to formal entry (envelopes without third party involvement, random numbers table but procedures not described)				

APPENDIX 5 INFORMATION ON THE REASONS FOR EXCLUSION

Resectable GIST (N=24)

Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. *Clin Cancer Res* 2005;11(11):4182-90.

Aparicio T, Boige V, Sabourin JC, Crenn P, Ducreux M, Le Cesne A et al. Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. *Eur J Surg Oncol* 2004;30(10):1098-103.

Besana-Ciani I. Outcome and long term results of surgical resection for Gastrointestinal Stromal Tumors (GIST). *Scand J Surg* 2003;92(3):195-9.

Bolukbasi H, Nazli O, Tansug T, Bozdag AD, Isgiider AS, Yaman I et al. Gastrointestinal stromal tumors (GISTs): analysis of 20 cases. *Hepatogastroenterology* 2006;53(69):385-8.

Bucher P, Villiger P, Egger JF, Buhler L, Morel P. Results of primary surgical treatment of gastrointestinal stromal tumors. *Gastroenterology* 2004;126(4, Suppl. 2):58.

Casali P, Garrett C, Blackstein M, Shah M, Verweij J, McArthur G et al. A phase III trial of sunitinib in GIST patients following failure of imatinib mesylate: Updated trial results. *Ann Oncol* 2006;17(Suppl 6):21-2.

Date RS, Stylianides NA, Pursnani KG, Ward JB, Mughal MM. Management of gastrointestinal stromal tumours in the Imatinib era: a surgeon's perspective. *World J Surg Oncol* 2008;6:77-81.

Goh B, Chow P, Chuah K, Yap W, Foo K, Wong W. Pathological, radiological and pet scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate: A review of 37 cases. *Ann Oncol* 2006;17(Suppl 6):101-2.

Gupta M, Sheppard BC, Corless CL, MacDonell KR, Blanke CD, Billingsley KG. Outcome following surgical therapy for gastrointestinal stromal tumors. *J Gastrointest Surg* 2006;10(8):1099-105.

Hou YY, Grabellus F, Weber F, Zhou Y, Tan YS, Li J et al. Impact of KIT and PDGFRA Gene Mutations on Prognosis of Patients with Gastrointestinal Stromal Tumors After Complete Primary Tumor Resection. *J Gastrointest Surg* 2009;13(9):1583-92.

Jindal S, Singhal D, Kakodkar R, Gupta S, Soin A, Chaudhary A et al. Management of gastrointestinal stromal tumors: a single center experience in the pre-Imatinib era. *J Gastroenterol Hepatol* 2008;23A:162-A163.

Machado-Aranda D, Malamet M, Chang YJ, Jacobs MJ, Ferguson L, Silapaswan S et al. Prevalence and management of gastrointestinal stromal tumors. *Am Surgeon* 2009;75(1):55-60.

McAuliffe JC, Hunt KK, Lazar AJ, Choi H, Qiao W, Thall P et al. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. *Ann Surg Oncol* 2009;16(4):910-9.

Mudan SS, Conlon KC, Woodruff JM, Lewis JJ, Brennan MF. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. *Cancer* 2000;88(1):66-74.

Nieto EA. Gastrointestinal stromal tumors: Experience in 49 patients. *Clin Translat Oncol* 2006;8(8):594-8.

Nikfarjam M, Kimchi E, Shereef S, Gusani NJ, Jiang Y, Liang J et al. Surgical outcomes of patients with gastrointestinal stromal tumors in the era of targeted drug therapy. *J Gastrointest Surg* 2008;12(11):2023-31.

Nilsson B, Bumming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden. *Cancer* 2005;103(4):821-9.

Nishida T. Phase ii trial adjuvant imatinib mesylate after resection of localized primary high risk GIST. *Eur J Cancer Suppl* 2009;7(2):594.

Nunobe S, Sano T, Shimada K, Sakamoto Y, Kosuge T. Surgery including liver resection for metastatic gastrointestinal stromal tumors or gastrointestinal leiomyosarcomas. *Jpn J Clin Oncol* 2005;35(6):338-41.

Perez EA, Gutierrez JC, Jin X, Lee DJ, Rocha-Lima C, Livingstone AS et al. Surgical outcomes of gastrointestinal sarcoma including gastrointestinal stromal tumors: a population-based examination. *J Gastrointest Surg* 2007;11(1):114-25.

Rutkowski P, Nowecki ZI, Michej W, Debiec-Rychter M, Wozniak A, Limon J et al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. *Ann Surg Oncol* 2007;14(7):2018-27.

Rutkowski P, Nowecki Z, Nyckowski P, Dziewirski W, Grzesiakowska U, Nasierowska-Guttmejer A et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. *J Surg Oncol* 2006;93(4):304-11.

Sujendran V, Fearnhead N, De Pennington N, Warren BF, Maynard ND. Proposals for the management of gastrointestinal stromal tumours of the stomach. *Surg* 2007;5(3):149-53.

Zhan WH. Efficacy and safety of adjuvant post-surgical therapy with imatinib. *J Clin Oncol* 2007;25(18S):Abstract 10045.

Outcomes not reported separately for GIST patients (N=11)

Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, Maki RG et al. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. *Clin Cancer Res* 2007;13(1):170-81.

Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. *N Engl J Med* 2006;354(19):2006-13.

Billemont B. Scrotal cutaneous side effects of sunitinib. *N Engl J Med* 2008;359(9):975-6.

Chugh R, Wathen JK, Maki RG, Benjamin RS, Patel SR, Myers PA et al. Phase II Multicenter Trial of Imatinib in 10 Histologic Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical Model. *J Clin Oncol* 2009;27(19):3148-53.

Fraunfelder FW, Solomon J, Druker BJ, Esmaeli B, Kuyl J. Ocular side-effects associated with imatinib mesylate (Gleevec (R)). *J Ocul Pharmacol Ther* 2003;19(4):371-5.

Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. *Clin Cancer Res* 2008;14(9):2717-25.

Kaneko T, Goto S, Kushima Y, Miyamoto Y, Eriguchi M, Nieda M et al. A report of three patients treated with immunocell therapy with imatinib mesylate. *Anticancer Res* 2004;24(5C):3303-9.

Oudard S, Negrier S, Ferrero JM, Gravis G, Blay JY, Le Cesne A et al. Safety profile of single-agent sunitinib malate from the French Temporary Authorization for Use program (Cohort ATU) in metastatic renal cell carcinoma (MRCC) after failure of treatment with cytokines and gastrointestinal stromal tumor (GIST) patients after failure of imatinib mesylate treatment. *Eur J Cancer Suppl* 2007;5(4):4526.

Polyzos A. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors. *J Steroid Biochem Molecul Biol* 2008;108(3-5):261-6.

Radaelli F, Vener C, Ripamonti F, Iurlo A, Colombi M, Artoni A et al. Conjunctival hemorrhagic events associated with imatinib mesylate. *Int J Hematol* 2007;86(5):390-3.

Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. *Thyroid* 2007;17(4):351-5.

Less than 10 patients in study population (N=46)

Armbrust T. Does imatinib turn recurrent and/or metastasized gastrointestinal stromal tumors into a chronic disease? - Single center experience. *Eur J Gastroenterol Hepatol* 2009;21(7):819-23.

Banzo I, Quirce R, Martinez-Rodriguez I, Jimenez-Bonilla J, Sainz-Esteban A, Barragan J et al. 18F FDG PET/CT in patients with gastrointestinal stromal tumors treated with Imatinib mesylate. *Eur J Nucl Med Molecul Imag* 2007;34(Suppl 2):S298.

Bertolini V, Chiaravalli AM, Klersy C, Placidi C, Marchet S, Boni L et al. Gastrointestinal stromal tumors - frequency, malignancy, and new prognostic factors: The experience of a single institution. *Path Res Pract* 2008;204(4):219-33.

Britten CD, Kabbinavar F, Hecht JR, Bello CL, Li J, Baum C et al. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. *Cancer Chemother Pharmacol* 2008;61(3):515-24.

Bui BN. Trough imatinib plasma levels in patients treated for advanced gastrintestinal stromal tumors evidence of large interpatient variations under treatment with standard doses. *J Clin Oncol* 2008;26:Abstract 10564.

Bulusu V, Fawcett S, Cook N, Hatcher H, Moyle P, Carroll N et al. Size does not matter! Patterns of response and progression in patients (PTS) with metastatic gastro intestinal stromal tumours (GISTS) on imatinib mesylate (IM). *Ann Oncol* 2006;17(Suppl 6):100.

Bulusu VR, Basu BJ, Hatcher H, Parkinson C, Sherbourne K, Earl HM et al. Imatinib mesylate (IM) in locally advanced and metastatic gastrointestinal stromal tumours (GISTs): Cambridge GIST study group experience. *Ann Oncol* 2005;16(suppl 2):311.

Casali P, Fumagalli E, Bello A, George S. Safety and tolerability of sunitinib (SU) initiated 24 h after the last dose of imatinib (IM) in advanced GIST. *J Clin Oncol* 2008;26(5 Suppl):Abstract 10557.

Chen TW, Liu HD, Shyu RY, Yu JC, Shih ML, Chang TM et al. Giant malignant gastrointestinal stromal tumors: recurrence and effects of treatment with STI-571. *World J Gastroenterol* 2005;11(2):260-3.

Chen MY, Bechtold RE, Savage PD. Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate). Am J Roentgenol 2002;179(4):1059-62.

Chen C-W. Surgical management and clinical outcome of Gastro-intestinal stromal tumor of the colon and rectum. *Z Gastroenterol* 2008;46(8):760-5.

Cipolla C, Fulfaro F, Sandonato L, Fricano S, Pantuso G, Grassi N et al. Clinical presentation and treatment of gastrointestinal stromal tumors. *Tumori* 2006;92(4):279-84.

De Giorgi U, Aliberti C, Benea G, Conti M, Marangolo M. Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors. *Clin Cancer Res* 2005;11(17):6171-6.

Gibbons J, Egorin MJ, Ramanathan RK, Fu PF, Mulkerin DL, Shibata S et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: A study by the National Cancer Institute Organ Dysfunction Working Group. *J Clin Oncol* 2008;26(4):570-6.

Gronchi A, Fiore M, Miselli F, Lagonigro MS, Coco P, Messina A et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. *Ann Surg* 2007;245(3):341-6.

Harney J, Wong WI, Short S. A preliminary evaluation of the potential role of FDG-PET to assess response to Glivec (TM) in gastrointestinal stromal tumours (GISTs). *Br J Cancer* 2003;88(Suppl 1):S41.

Hasegawa J, Kanda T, Hirota S, Fukuda M, Nishitani A, Takahashi T et al. Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy. *Int J Clin Oncol* 2007;12(3):212-7.

Hassan I, You YN, Dozois EJ, Shayyan R, Smyrk TC, Okuno SH et al. Clinical, pathologic, and immunohistochemical characteristics of gastrointestinal stromal tumors of the colon and rectum: Implications for surgical management and adjuvant therapies. *Diseases of the Colon & Rectum* 2006;49(5):609-15.

Hsiao HH, Liu YC, Tsai HJ, Chen LT, Lee CP, Chuan CH et al. Imatinib mesylate therapy in advanced gastrointestinal stromal tumors: experience from a single institute. *Kaohsiung J Med Sci* 2006;22(12):599-603.

Kasper B, Kallinowski B, Herrmann T, Lehnert T, Mechtersheimer G, Geer T et al. Treatment of gastrointestinal stromal tumor with imatinib mesylate: a retrospective single-center experience in Heidelberg. *Dig Dis* 2006;24(1-2):207-11.

Lasota J, vel Dobosz AJ, Wasag B, Wozniak A, Kraszewska E, Michej W et al. Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors. *Lab Invest* 2007;87(10):1029-41.

Maehara N, Chijiiwa K, Eto T, Funagayama M, Uchiyama S, Nakashima S et al. Surgical treatment for gastric GIST with special reference to liver metastases. *Hepatogastroenterology* 2008;55(82-83):512-6.

Mearadji A, den Bakker MA, van Geel AN, Eggermont AM, Sleijfer S, Verweij J et al. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis. *Anti -Cancer Drugs* 2008;19(6):607-12.

Mussi C, Schildhaus HU, Gronchi A, Wardelmann E, Hohenberger P. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. *Clin Cancer Res* 2008;14(14):4550-5.

Neagu S, Costea R, Sajin M, Ardelean C, Zarnescu NO. Gastric Stromal Tumors - Histopathological, Clinical and Therapeutical Aspects. *Igcc: Proceedings of the 8th International Gastric Cancer Congress* 2009;85-7.

Nishida T, Kanda T, Nishitani A, Takahashi T, Nakajima K, Ishikawa T et al. Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor. *Cancer Sci* 2008;99(4):799-804.

Nishida T, Takahashi T, Nishitani A, Doi T, Shirao K, Komatsu Y et al. Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene. *Int J Clin Oncol* 2009;14(2):143-9.

Ohnishi K, Sakai F, Kudoh S, Ohno R. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. *Leukemia* 2006;20(6):1162-4.

Petricevic B, Vrbanec D, Belev B, Plestina S, Herceg D, Dedic-Plavetic N. Imatinib mesylate in treatment of advanced gastrointestinal stromal tumours. *Ann Oncol* 2005;16(Suppl 2):313.

Prakash S, Sarran L, Socci N, Dematteo RP, Eisenstat J, Greco AM et al. Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. *J Pediatr Hematol Oncol* 2005;27(4):179-87.

Raut C, Van den Abbeele A, Ramaiya N, Morgan J, George S, Quigley M et al. Pet imaging demonstrates two patterns of response in GIST patients benefiting from long-term sunitinib therapy. *Ann Oncol* 2006;17(Suppl 6):103.

Richter KK, Schmid C, Thompson-Fawcett M, Settmacher U, Altendorf-Hofmann A. Long-term follow-up in 54 surgically treated patients with gastrointestinal stromal tumours. *Langenbecks Arch Surg* 2008;393(6):949-55.

Rutkowski P, Nyckowski P, Grzesiakowska U, Nowecki ZI, Nasierowska-Guttmejer A, Pienkowski A et al. The clinical characteristics and the role of surgery and imatinib treatment in patients with liver metastases from c-Kit positive gastrointestinal stromal tumors (GIST). *Neoplasma* 2003;50(6):438-42.

Salazar LIF, Gago TA, Rubiales AS, Jimenez BV, de la Fuente RA, Hernandez JMG. Gastrointestinal stromal tumors (GIST): clinical aspects. *Rev Esp Enferm Dig* 2007;99(1):19-24.

Scaife CL, Hunt KK, Patel SR, Benjamin RS, Burgess MA, Chen LL et al. Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? *Am J Surg* 2003;186(6):665-9.

Schindler CG, Armbrust T, Gunawan B, Langer C, Fuzesi L, Ramadori G. Gastrointestinal stromal tumor (GIST) -- single center experience of prolonged treatment with imatinib. *Zeitschrift fur Gastroenterologie* 2005;43(3):267-73.

Sym SJ, Ryu MH, Lee JL, Chang HM, Kim TW, Kim HC et al. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). *J Surg Oncol* 2008;98(1):27-33.

Tham C-K. Gastrointestinal stromal tumour in the elderly. *Crit Rev Oncol Hematol* 2009;70(3):256-61.

Tsukuda K, Hirai R, Miyake T, Takagi S, Ikeda E, Kunitomo T et al. The outcome of gastrointestinal stromal tumors (GISTs) after a surgical resection in our institute. *Surg Today* 2007;37(11):953-7.

Van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato dP, Dimitrijevic S et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. *Lancet* 2001;358(9291):1421-3.

Wang CM, Fu H, Zhao GF, Zhou XY, Du CY, Dong RZ et al. Secondary resistance to imatinib in patients with gastrointestinal stromal tumors through an acquired KIT exon 17 mutation. *Molecul Med Rep* 2009;2(3):455-60.

Warakaulle DR, Gleeson F. MDCT appearance of gastrointestinal stromal tumors after therapy with imatinib mesylate. Am J Roentgenol 2006;186(2):510-5.

Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. *Br J Cancer* 2008;99(3):448-54.

Wong DW, Lupton SC, Bhatt L, Gross L, Taniere P, Peake DR et al. Use of imatinib mesylate in gastrointestinal stromal tumours: Pan-Birmingham Cancer Network experience. *Clin Oncol* 2008;20(7):517-22.

Wu A-W. Gastrointestinal stromal tumors of the anorectum - A special entity: GISTs of the anorectum. *Chinese Journal of Cancer Research* 2006;18(1):38-44.

Zhu J, Wang Y, Hou M, Li HY, Zhang J. Imatinib mesylate treatment for advanced gastrointestinal stromal tumor: a pilot study focusing on patients experiencing sole liver metastasis after a prior radical resection. *Oncology* 2007;73(5-6):324-7.

400mg/day IM dose only (N=13)

Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. *J Clin Oncol* 2007;25(9):1107-13.

Bumming P, Andersson J, Meis-Kindblom JM, Klingenstierna H, Engstrom K, Stierner U et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. *Br J Cancer* 2003;89(3):460-4.

Choi H, Charnsangavej C, de Castro FS, Tamm EP, Benjamin RS, Johnson MM et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET finding. Am J Roentgenol 2004;183(6):1619-28.

Delbaldo C, Chatelut E, Re M, Deroussent A, Jambu A, Mackrodt A et al. Inflammatory response affects the pharmacokinetics (PK) and pharmacodynamics (PD) of imatinib and CGP 74588 in patients with advanced gastro-intestinal-sarcoma (GIST). *J Clin Oncol* 2004;22(14):2070.

Dematteo RP, Antonescu CR, Chadaram V, You YN, McCall L, Maki R et al. Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: Safety results from the US Intergroup Phase II trial ACOSOG Z9000. *J Clin Oncol* 2005;23(16):818S.

Kim TW, Ryu MH, Lee H, Sym SJ, Lee JL, Chang HM et al. Kinase mutations and efficacy of imatinib in Korean patients with advanced gastrointestinal stromal tumors. *Oncologist* 2009;14(5):540-7.

Le Cesne A, Rav-Coquard I, Bul B, Duffaud F, Deligny N, Cupissol D et al. Interruption of Imatinib (IM) in responding patients after one year treatment does not influence overall survival of patients with advanced GIST: Updated results of the French Sarcoma Group randomized phase IIIBFR14 trial. *Eur J Cancer Suppl* 2005;3(2):202.

Le Cesne A, Perol D, Ray-Coquard I, Bui B, Duffaud F, Rios M et al. Interruption of imatinib (IM) in GIST patients with advanced disease: Updated results of the prospective French Sarcoma Group randomized phase III trial on survival and quality of life. *J Clin Oncol* 2005;23(16):823S.

Steinert DM, Oyarzo M, Wang X, Choi H, Thall PF, Medeiros LJ et al. Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate. *Cancer* 2006;106(7):1617-23.

Van den Abbeele AD, Badawi RD, Tetrault RJ, Cliche JP, Manola J, Spangler T et al. FDG-PET as a surrogate marker for response to Gleevec (TM) (imatinib mesylate) in patients with advanced gastrointestinal stromal tumors (GIST). *J Nucl Med* 2003;44(5):77.

Widmer N, Decosterd LA, Leyvraz S, Duchosal MA, Rosselet A, Debiec-Rychter M et al. Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. *Br J Cancer* 2008;98(10):1633-40.

Yeh CN, Chen TW, Liu FY, Jan YY, Chen MF. Genetic changes in advanced gastrointestinal stromal tumor (GIST) patients during imatinib mesylate treatment. *Langenbecks Arch Surg* 2006;391(6):615-21.

Yeh CN, Chen TW, Wu TJ, Hsueh S, Jan YY. Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: implications of imatinib mesylate. *World J Gastroenterol* 2006;12(23):3760-5.

No/insufficient data for escalated dose patients (N=66)

Aliberti S, Grignani G, Allione P, Vormola R, Bucci AS, Porrino G et al. Erythrocyte macrocytosis is a rather common, apparently uneventful yet unexplained finding in GIST imatinib (I) chronic therapy. *J Clin Oncol* 2005;23(16):827S.

Allione P, Grignani G, Aliberti S, Scalabrini DR, Schianca FC, Capaldi A et al. Increase of creatine kinase value (CK) correlates with muscoloskeletal complaints (MSC) in GIST patients during imatinib therapy. *J Clin Oncol* 2006;24(18):9509.

An JY, Choi MG, Noh JH, Sohn TS, Kang WK, Park CK et al. Gastric GIST: a single institutional retrospective experience with surgical treatment for primary disease. *Eur J Surg Oncol* 2007;33(8):1030-5.

Barman B, Gupta P, Sen AN, Deb S, Sarkar S, Mukhopadhyay S et al. Imatinib mesylate as first-line therapy in patients with gastro intestinal stomach tumour (GIST): an experience of 24 cases from India. *Ann Oncol* 2005;16(Suppl 2):311.

Benjamin RS, Rankin C, Fletcher C, Blanke C, von Mehren M, Maki R et al. Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: intergroup S0033 early results abstract. 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31 - June 3, 2003. Abstract 3271

Bhattacharjee C, Mukhopadhyay S, Dey S, Basak J, Dutta S, Mukhopadhyay A. Tolerance of imatinib mesylate inpatients with gastro intestinal stromal tumour (GIST) - An Indian experience. *Ann Oncol* 2008;19(Suppl 5):167.

Blanke CD, von Mehren M, Joensuu H, Roberts PJ, Eisenberg B, Heinrich M et al. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients (pts) with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing C-KIT (CD117) . 37th Annual Meeting of the American Society of Clinical Oncology; 12-15 May 2001; San Francisco, California, USA. Abstract 1.

Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg BL, Fletcher J et al. Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients (pts) treated with imatinib mesylate. *J Clin Oncol* 2006;24(18):9528.

Casali PG, Verwell J, Zalcberg J, LeCesne A, Reichardt P, Ray Coquard I et al. Imatinib (Glivec) 400 vs 800 mg daily in patients with gastrointestinal stromal tumours (GIST): a randomized phase III trial from the EORTC Soft Tissue & Bone Sarcoma Group, the Italian Sarcoma Group (ISG) and the Australasian Gastro-Intestinal Trials Group (AGITG). a toxicity report abstract. 38th Annual Meeting of the American Society of Clinical Oncology; 18-21 May 2002; Orlando, Florida, USA. Abstract 413.

Casali PG, Verweij J, Kotasek D, LeCesne A, Reichardt P, Blay JY et al. Imatinib mesylate in advanced Gastrointestinal Stromal Tumors (GIST): survival analysis of the intergroup EORTC/ISG/AGITG randomized trial in 946 patients. *Eur J Cancer Suppl* 2005;3(2):201-2.

Choi D, Yoo EY, Kim KM, Sohn TS, Lee WJ, Lee JY et al. Residual and recurrent gastrointestinal stromal tumors with KIT mutations: findings at first follow-up CT after imatinib treatment. Am J Roentgenol 2009;193(2):W100-W105.

Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with

advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. *Eur J Cancer* 2004;40(5):689-95.

DeMatteo R. Adjuvant imatinib mesylate increases recurrence free survival in patients woth completely resected localized primary gastrintestinal stromal tumor. *J Clin Oncol* 2007;25 (18 Suppl):Abstract 10079.

Demetri GD, Rankin C, Fletcher C, Benjamin RS, Blanke C, Von Mehren N et al. Phase III dose-randomized study of imatinib mesylate (Gleevec, STI571) for GIST: intergroup S0033 early results abstract. 38th Annual Meeting of the American Society of Clinical Oncology; 18-21 May 2002; Orlando, Florida, USA. Abstract 1651.

Demetri GD, Wang Y, Wehrle E, Racine A, Nikolova Z, Blanke CD et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. *J Clin Oncol* 2009;27(19):3141-7.

Dincer S, Akboru H, Teke F, Eren B, Askaroglu B, Demir C et al. Evaluation of Gastrointestinal Stromal Tumor Patients and Imatinib Therapy. *Ann Oncol* 2008;19(Suppl 8):270-1.

Doi T, Nishida T, Hirota S, Sugiyama T, Yamao K, Koseki M et al. Phase II clinical study of STI571 in Japanese (Jpn) patients (pts) with malignant gastrointestinal stromal tumors (GIST): Results of the B 1201 study abstract. 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans,LA, 5-8 June, 2004. Abstract 4078.

Duffaud F, Le Cesne A. Imatinib in the treatment of solid tumours. *Targeted Oncology* 2009;4(1):45-56.

Goerres GW, Stupp R, Barghouth G, Hany TF, Pestalozzi B, Dizendorf E et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. *Eur J Nucl Med Molecul Imag* 2005;32(2):153-62.

Hartmann JT, Heidel F, Stoehlmacher J, Duex M, Izbicki JR, Elsaid A et al. Pattern of progression and its impact on outcome in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: A retrospective multicenter long-term follow-up study. *J Clin Oncol* 2006;24(18):9541.

Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. *J Clin Oncol* 2003;21(23):4342-9.

Heinrich MC, Shoemaker JS, Corless CL, Hollis D, Demetri GD, Bertagnolli MM et al. Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+) . *J Clin Oncol* 2005;23(16S):7.

Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. *J Clin Oncol* 2008;26(33):5360-7.

Hohenberger P. Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST). *J Clin Oncol* 2009;27(15S):Abstract 10550.

Joensuu H, Demetri GD, Heinrich MC, Eisenberg BL, Fletcher JA, Corless CL et al. Up to 6 years follow-up of patients receiving imatinib mesylate (Glivec) to treat unresectable or metastatic gastrointestinal stromal tumors (GISTs). *Eur J Cancer Suppl* 2007;5(4):7506.

Joensuu H, De Braud F, Coco P, De Pas T, Spreafico C, Bono P et al. A phase II, open-label study of PTK787/ZK222584 in the treatment of metastatic gastrointestinal stromal tumors (GISTs) resistant to imatinib mesylate. *J Clin Oncol* 2006;24(18):9531.

Judson IR, Verweij J, Van Oosterom A, Blay JY, Rodenhuis S, van der Graaf W et al. Imatinib (Gleevec) an active agent for gastrointestinal stromal tumours (GIST), but not for other soft tissue sarcoma (STS) subtypes not characterized for KIT and PGDF-R expression: results of EORTC phase II studies abstract. *Proceedings of the American Society of Clinical Oncology* 2002;21 (Pt 1) Abstract 1609.

Kang B. A phase II study of imatibib mesylate as adjuvant treatment for curatively resected high-risk localized GIST. *J Clin Oncol* 2009;27(S) Abstract e21515.

Le Cesne A. Continuous versus interruption of imatinib in responding patients. *J Clin Oncol* 2007;25(18S):Abstract 10005.

Le Cesne A, Van Glabbeke M, Verweij J, Casali P, Zalcberg J, Reichardt P et al. Is a stable disease according to RECIST criteria a real stable disease in GIST patients treated with imatinib mesylate (IM) included in the intergroup EORTC/ISG/AGITG trial? *J Clin Oncol* 2006;24(18):9510.

Le Cesne A, Van Glabbeke M, Verweij J, Casali PG, Findlay M, Reichardt P et al. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. *J Clin Oncol* 2009;27(24):3969-74.

Lee JL, Ryu MH, Chang HM, Kim TW, Kang HJ, Sohn HJ et al. Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response. *Jpn J Clin Oncol* 2006;36(11):704-11.

Li J. Adjuvant therapy with imatinib in gastrointestinal stromal tumor (GIST) patientes with intermediate or high rosk. *J Clin Oncol* 2009;27(15S):Abstract 10556.

Menard C, Blay JY, Borg C, Michiels S, Ghiringhelli F, Robert C et al. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. *Cancer Res* 2009;69(8):3563-9.

Nishida T. Preliminary results of the phase II clinical trial of imatinib mesylate for advanced gastrointestinal stromal tumors in Japan. *Gann Mono Cancer Res* 2004;53:151-7.

Nishida T, Shirao K, Sawaki A, Koseki M, Okamura T, Ohtsu A et al. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202). *Int J Clin Oncol* 2008;13(3):244-51.

Perol D. Does interruption of imatinib in responding GIST patients after one year of treatment influenc the secondary resistance to IM after its reintroduction? *J Clin Oncol* 2008;26(5 Suppl):Abstract 10556.

Phongkitkarun S, Phaisanphrukkun C, Jatchavala J, Sirachainan E. Assessment of gastrointestinal stromal tumors with computed tomography following treatment with imatinib mesylate. *World J Gastroenterol* 2008;14(6):892-8.

Rios M. Interruption of imatinib in GIST patients with advanced disease after one year of treatment. *J Clin Oncol* 2007;25(18S):Abstract 10016.

Romeo S, Debiec-Rychter M, Van Glabbeke M, Van Paassen H, Comite P, Van Eijk R et al. Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. *Clin Cancer Res* 2009;15(12):4191-8.

Ruka W. The outcomes of patients with metastatic/inoperable gastrointestinal stromal tumors (GIST) treated with imatinib - An interim multicenter analysis of Polish Clinical GIST Registry. *Nowotwory* 2005;55(3):195-9.

Rutkowski P, Debiec-Rychter M, Nowecki ZI, Wozniak A, Michej W, Limon J et al. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors. *Med Sci Monitor* 2007;13(11):CR515-CR522.

Rutkowski P, Nowecki ZI, Debiec-Rychter M, Grzesiakowska U, Michej W, Wozniak A et al. Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs). *J Cancer Res Clin Oncol* 2007;133(9):589-97.

Rutkowski P, Nowecki ZI, Grzesiakowska U, Michej W, Debiec-Rychter M, Wozniak A et al. Long-term effects of imatinib therapy and impact of surgery on patients (pts) with CD117(+) gastrointestinal stromal tumours (GIST) without early progression on imatinib. *Society of Surgical Oncology 60th Annual Cancer Symposium* 2007; Poster P280.

Ryu MH, Lee JL, Chang HM, Kim TW, Kang HJ, Sohn HJ et al. Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate. *Jpn J Clin Oncol* 2006;36(1):17-24.

Ryu MH, Kang WK, Bang YJ, Lee KH, Shin DB, Ryoo BY et al. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor. *Oncology* 2009;76(5):326-32.

Ryu M, Lee J, Chang H, Kim T, Kang H, Sohn H et al. Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate. *Eur J Cancer* 2005;3(2, Suppl. S):23.

Ryu MH, Lee JL, Chang HM, Kim TW, Kang HJ, Sohn HJ et al. Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate. *Jpn J Clin Oncol* 2006;36(1):17-24.

Sawaki A. Recurrence after imatinib treatment for patients with gastrointestinal stromal tumor. *J Gastroenterol Hepatol* 2006;21(Suppl 6):A499.

Sciot R, Debiec-Rychter M, Daugaard S, Fisher C, Collin F, Van Glabbeke M et al. Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate. *Eur J Cancer* 2008;44(13):1855-60.

Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). *Eur J Cancer* 2003;39(14):2012-20.

Tamas KR, Papai Z, Vegh EA, Petranyi AE, Szucs Z, Rohanszky M et al. One institutional experience with imatinib mesylate in the treatment of gastrointestinal stromal tumors. *Ann Oncol* 2006;17(Suppl 9):164.

van Erp N, Gelderblom H, Van Glabbeke M, Van Oosterom A, Verweij J, Guchelaar HJ et al. Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC. *Clin Cancer Res* 2008;14(24):8308-13.

Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. *J Clin Oncol* 2005;23(24):5795-804.

Van Glabbeke M, Verweij J, Casali PG, Simes J, Le Cesne A, Reichardt P et al. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). *Eur J Cancer* 2006;42(14):2277-85.

Van Glabbeke M, Owzar K, Rankin C, Simes J, Crowley J, GIST Meta-analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumours (GIST): a meta-analysis based on 1640 patients. *J Clin Oncol* 2007;25(18S):10004.

Van Glabbeke MM, Verweij J, Casali PG, Zalcberg J, Le Cesne A, Reichard P et al. Prognostic factors of toxicity and efficacy in patients with gastro-intestinal stromal tumors (GIST) treated with imatinib: a study of the EORTC-STBSG, ISG and AGITG abstract. *Proceedings of the American Society of Clinical Oncology* 2003;818.

Van Oosterom AT, Judson IR, Verweij J, Stroobants S, Dumez H, Donato dP et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. *Eur J Cancer* 2002;38 Suppl 5S83-S87.

Verweij J, Van Oosterom A, Blay JY, Judson I, Rodenhuis S, van der GW et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.[see comment]. *Eur J Cancer* 2003;39(14):2006-11.

Verweij J, Casali PG, Zalcberg J, Le Cesne A, Reichard P, Blay J et al. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST): interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG abstract. *Proceedings of the American Society of Clinical Oncology* 2003;814.

Verweij J, Casali PG, Kotasek D, Le Cesne A, Reichard P, Judson IR et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. *Eur J Cancer* 2007;43(6):974-8.

Villalobos R. Clinical response to imatinib mesylate in recurrent and metastaic gastrointestinal stromal tumors. *J Clin Oncol* 2007;25(18S):Abstract 20528.

von Mehren M. Imatinib response linked to variations in drug exposure. *Oncology Report* 2008;(FALL):31.

Yeh CN, Chen TW, Lee HL, Liu YY, Chao TC, Hwang TL et al. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital. *Ann Surg Oncol* 2007;14(3):1123-8.

Yildiz I, Mandel NM, Demir G, Ozguroglu M, Toptas T, Buyukunal E et al. Imatinib mesylate response in Gastrointestinal Stromal Tumors: Experience of cerrahpasa medical faculty. *Ann Oncol* 2006;17(Suppl 9):164.

Zekri JM. Relative hypocalcaemia and muscle cramps in patients receiving imatinib for gastrointestinal stromal tumour. *Sarcoma* 2006;2006, Article ID 48948.

IM dose not reported (N=83)

Al Batran SE, Hartmann JT, Heidel F, Stoehlmacher J, Wardelmann E, Dechow C et al. Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients. *Gastric Cancer* 2007;10(3):145-52.

Artinyan A, Kim J, Soriano P, Ellenhorn J. Survival from metastatic gastrointestinal stromal tumors in the era of imatinib. *Ann Surg Oncol* 2008;15(Suppl 2):92.

Bachet JB, Hostein I, Le Cesne A, Brahimi S, Beauchet A, Tabone-Eglinger S et al. Prognosis and predictive value of KIT exon 11 deletion in GISTs. *Br J Cancer* 2009;101(1):7-11.

Bachet J, Hostein I, Le Cesne A, Beauchet A, Brahimi S, Tabone-Eglinger S et al. Gist with deletion of TYR568 and TYR570 of kit have similar prognosis and response to imatinib as those with DELWK557-558, but are mainly extra-gastric. *Ann Oncol* 2008;19(Suppl 6):9.

Bao X, Kamo N, Hao H, Sakurama K, Noma K, Shirakawa Y et al. The upregulation of FAK contributes to tumor progression and a resistance to Imatinib in gastrointestinal stromal tumor. *Proceedings of the American Association for Cancer Research Annual Meeting* 2009:50.

Basu S, Balaji S, Bennett DH, Davies N. Gastrointestinal stromal tumors (GIST) and laparoscopic resection. *Surg Endosc* 2007;21(10):1685-9.

Bearzi I, Mandolesi A, Arduini F, Costagliola A, Ranaldi R. Gastrointestinal stromal tumor. A study of 158 cases: clinicopathological features and prognostic factors. *Analy Quant Cytol Histol* 2006;28(3):137-47.

Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL et al. We should desist using RECIST, at least in GIST. *J Clin Oncol* 2007;25(13):1760-4.

Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL et al. Response of gastrointestinal stromal tumors (GISTs) to imatinib by Choi criteria and response evaluation criteria in solid tumors (RECIST) as surrogates for survival and time to progression. *J Clin Oncol* 2006;24(18):9506.

Blackstein M, Huang X, Demetri G, Casali P, Garrett C, Schoffski P et al. Investigation of soluble kit asa potential surrogate marker for ttp in sunitinib-treated patients with gist. *Ann Oncol* 2007;18(Suppl B):VII16.

Boulos BM, Jajeh A, Nawaz U, Osafo D, Tamkus D, Ogundipe O et al. Retrospective analysis of the use of imatinib mesylate in the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST). *FASEB J* 2007;21(6):A1189.

Bui BN, Le Cesne A, Ray-Coquard I, Duffaud F, Rios M, Adenis A et al. Do patients with initially resected metastatic GIST benefit from 'adjuvant' imatinib (IM) treatment? Results of the prospective BFR14 French Sarcoma Group randomized phase III trial. *J Clin Oncol* 2006;24(18):9501.

Casali PG, Fumagalli E, Messina A, Spreafico C, Comandini D, Camadone A et al. Tumor response to imatinib mesylate in advanced GIST. *J Clin Oncol* 2004;22(14):9028.

Casali PG, Garrett CR, Blackstein ME, Shah M, Verweij J, McArthur G et al. Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. *J Clin Oncol* 2006;24(18):9513.

Cassier P, Fayette J, Ray-Coquard I, Bui B, Duffaud F, Adonis A et al. Outcome of patients with locally advanced gist receiving imatinib mesylate in a prospective trial. *Ann Oncol* 2007;18(Suppl 7):VII105-VII106.

Chevreau C. Outcome of patients with advanced GIST achieving a complete remission. *J Clin Oncol* 2009;27(15S):Abstract 10549.

Choi H, Tamm EP, Macapinlac HA, Faria S, Podoloff DA, Broemeling LD et al. The role of CT density measurement to monitor the gastrointestinal stromal tumors after treatment with STI-571: A quantitative analysis. *Clin Cancer Res* 2001;7(11):233.

Choi H, Faria SC, Benjamin RS, Podoloff DA, Macapinlac HA, Charnsangavej C. Monitoring treatment effects of STI-571 on gastrointestinal stromal tumors (GIST) with CT and PET: A quantitative analysis. *Radiology* 2002;225(Suppl S):583.

Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. *J Clin Oncol* 2007;25(13):1753-9.

Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.[see comment]. *Lancet* 2007;370(9604):2011-9.

Cioffi A. Long term progression-free survval correlates with KIT/PDGFR. *J Clin Oncol* 2007;25(18S):Abstract 10053.

Cioffi A. Outcomes for patients with advanced GUST. *J Clin Oncol* 2008;26(5 Suppl): Abstract 10550.

Davis D, Heymach J, McConkey D, Desai J, George S, Jackson J et al. Receptor tyrosine kinase activity and apoptosis in gastrointestinal stromal tumours: A pharmacodynamic analysis of response to sunitinib malate (SU11248) therapy. *Clin Cancer Res* 2005;11(24):9027S.

De Giorgi U, Aliberti C, Benea G, Kopf B, Marangolo M. Effect of angio-echography with a second-generation contrast agent to assess tumor response to imatinib treatment in patients with advanced gastrointestinal stromal tumor (GIST): Comparison with computerized tomography (CT). *J Clin Oncol* 2004;22(14):4216.

Demetri G, Huang X, Garrett C, Schoffski P, Blackstein M, Shah MH et al. Novel statistical a nalysis og long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs placebo (PL) n advances GIST after imatinib failure. *J Clin Oncol* 2009;26(5 Suppl):10524.

Demetri GD, Desai J, Fletcher JA, Morgan JA, Fletcher CDM, Kazanovicz A et al. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). *J Clin Oncol* 2004;22(14):3001.

Demetri GD, Van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J et al.Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. *Lancet* 2006;368(9544):1329-38

Demetri GD, Heinrich MC, Fletcher JA, Fletcher CD, Van den Abbeele AD, Corless CL et al. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. *Clin Cancer Res* 2009;15(18):5902-9.

Deprimo SE, Huang X, Blackstein ME, Garrett CR, Harmon CS, Schoffski P et al. Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure. *Clin Cancer Res* 2009;15(18):5869-77.

Desai J, Dileo P, Morgan JA, Larsen PR, Chen MH, George S et al. Hypothyroidism may accompany SU11248 therapy in a subset of patients (pts) with metastatic (met) gastrointestinal stromal tumors (GIST) and is manageable with replacement therapy. *J Clin Oncol* 2005;23(16):201S.

Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. *Ann Intern Med* 2006;145(9):660-4.

Dileo P, Morgan JA, Garrett CR, Schutte HJ, Hurwitz H, Rosen LS et al. Updated results from a "treatment-use" trial of sunitinib in advanced gastrointestinal stromal tumor (GIST). *Ann Oncol* 2006;17162-3.

Doi V, Shirao K, Yamada Y, Muro K, Fuse N, Euda E et al. Sunitinib in Japanese patients with GIST after prior treatment with imatinib mesylate: A phase I/II dose-escalation study. *Ann Oncol* 2006;17(Suppl 6):101.

Efthirniou E, Mudan S, Hayes A, Judson I, Thomas M. Pre-operative imatinib for recurrent, metastatic and locally advanced gastrointestinal tumours (GIST). *Ann Oncol* 2008;19(Suppl 6):72.

Ferreira TC, Vieira MR, Salazar M, Nobre-Leitao C. Importance of F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) scan in the evaluation of patients (pts) with gastrointestinal stromal tumour (GIST) under imatinib mesylate (IMT) - One year of experience. *Eur J Nucl Med Molecul Imag* 2004;31(Suppl 2):S335.

Fiore M, Palassini E, Fumagalli E, Pilotti S, Tamborini E, Stacchiotti S et al. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). *Eur J Surg Oncol* 2009;35(7):739-45.

Garrett C, Huang X, Casali P, Schoffski P, Blackstein M, Shah M et al. Long-term survival INA phase III trial of sunitinib in imatinib-resistant/intolerant gastrointestinal stromal tumor with novel statistical analysis to account for crossover. *Ann Oncol* 2008;19(Suppl 6):12.

Gomez D, Al Mukthar A, Menon KV, Toogood GJ, Lodge JP, Prasad KR. Aggressive surgical resection for the management of hepatic metastases from gastrointestinal stromal tumours: a single centre experience. *HPB* 2007;9(1):64-70.

Gong JS, Zuo M, Yang P, Zang D, Zhang Y, Xia L et al. Value of CT in the diagnosis and follow-up of gastrointestinal stromal tumors. *Clin Imaging* 2008;32(3):172-7.

Heinrich MC. Does tumor mutational status correlate with clinical response to imatinib? Commentary. *Nature Clin Pract Oncol* 2006;3(11):600-1.

Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. *J Clin Oncol* 2008;26(33):5352-9.

Hohenberger P, Langer C, Pistorius S, Iesalnieks I, Wardelmann E, Reichardt P. Indication and results of surgery following imatinib treatment of locally advanced or metastatic GI stromal tumors (GIST). *J Clin Oncol* 2006;24(18):9500.

Holdsworth CH, Manola J, Badawi RD, Israel DA, Blanke C, von Mehren M et al. Use of computerized tomography (CT) as an early prognostic indicator of response to imatinib mesylate (IM) in patients with gastrointestinal stromal tumors (GIST). *J Clin Oncol* 2004;22(14):3011.

Hong X, Choi H, Loyer EM, Benjamin RS, Trent JC, Charnsangavej C. Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. *Radiographics* 2006;26(2):481-95.

Janicek MJ, Potter A, Merriam P, Demetri GD. Does pattern of Metastases and early measurable changes after treatment predict therapy effect in gastrointestinal stromal tumor (GIST) on STI571 (Imatinib)? *Radiology* 2002;225(Suppl S):583.

Jin J, Robinson A, Willis J, Hardacre J, Kim J. Does imatinib mesylate (IM) affect longterm outcome in patients with gastrointestinal stromal tumors (GISTs)? *J Am Coll Surg* 2007;205(3):S14.

Judson IR, Casali PG, Garrett CR, Blackstein ME, Shah M, Verweij J et al. Updated results from a phase III trial of sunitinib in advanced gastrointestinal stromal tumor (GIST). *Ann Oncol* 2006;17(Suppl 9):162.

Kaneta T, Takahashi S, Fukuda H, Arisaka Y, Oriuchi N, Hayashi T et al. Clinical significance of performing F-18-FDG PET on patients with gastrointestinal stromal tumors: a summary of a Japanese multicenter study. *Ann Nucl Med* 2009;23(5):459-64.

Kim TW, Ryu MH, Lee H, Lee SS, Sym SJ, Kim MK et al. No relationship between C-kit mutation and response to imatinib in Korean patients with metastatic gastrointestinal stromal tumor. *Ann Oncol* 2006;17(Suppl 9):162.

Kleinbaum EP, Lazar AJ, Tamborini E, McAuliffe JC, Sylvestre PB, Sunnenberg TD et al. Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor. *Int J Cancer* 2008;122(3):711-8.

Kuhlmann KFD, Kerst JM, Cats A, van Coevorden F. Is there a role for post-imatinib surgery in advanced gastrointestinal stromal tumours? *Eur J Gastroenterol Hepatol* 2009;21(3):A3.

Lamuraglia M, Le Cesne A, Chami L, Bonvalot S, Terrier P, Tursz T et al. Dynamic contrast-enhanced Doppler ultrasound (DCE-US) is a useful radiological assessment to early predict the outcome of patients with gastrointestinal stromal tumors (GIST) treated with imatinib (IM). *J Clin Oncol* 2006;24(18):9539.

Lassau N, Lamuraglia M, Chami L, Le Cesne A, Roche A, Leclere L et al. Interest of Doppler-ultrasonography with perfusion software and contrast injection to early evaluation and detection of secondary resistence of gastrointestinal stromal tumors treated with imatinib. *Eur J Cancer Suppl* 2005;3(2):320.

Lassau N, Lamuraglia M, Leclere J, Bonvalot S, Vanel D, Robert C et al. Doppler-Ultrasonography with perfusion software and contrast medium injection as an early evaluation tool of gastro intestinal stromal tumor (GIST) treated by imatinib: Results of a prospective study. *J Clin Oncol* 2004;22(14):9048.

Lee J, Ryu M, Chang H, Kim T, Kang H, Sohn H et al. Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response. *Eur J Cancer* 2005;3(2, Suppl. S):64.

Lichinitser M. Molecular biomarkers and imatinib efficacy in metastatic gastrintestinal stromal tumors. *J Clin Oncol* 2008;26(5 Suppl): Abstract 21500.

Maki R, Fletcher JA, Heinrich M, Morgan JA, George S, Desai J et al. Results from a continuation trial of SU11248 in patients with imatinib (IM) - resistant gastrointestinal stromal tumor (GIST). *J Clin Oncol* 2005;23(16S):9011.

Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. *J Clin Endocrinol Metabol* 2007;92(9):3531-4.

Morgan JA, Demetri GD, Fletcher JA, George S, Desai J, Maki RG et al. Patients with imatinib mesylate-resistant GIST exhibit durable responses to sunitinib malate (SU11248). *Eur J Cancer Suppl* 2005;3(2):421.

Morgan JA, Garrett CR, Schutte HJ, Hurwitz H, Rosen LS, Ruka W et al. Sunitinib for patients (pts) with advanced imatinib (IM)-refractory GIST: Early results from a "treatment-use" trial. *J Clin Oncol* 2006;24(18):9540.

Nishida T, Doi T, Komatsu Y, Ueda E, Baum C, Shirao K. Sunitinib treatment of GIST in Japanese patients after failure of prior imatinis treatment: A phase II trial. *Ann Oncol* 2007;18(Suppl 7):VII110.

Park SS, Ryu JS, Oh SY, Kim WB, Lee JH, Chae YS et al. Surgical outcomes and immunohistochemical features for gastrointestinal stromal tumors (GISTS) of the stomach: with special reference to prognostic factors. *Hepatogastroenterology* 2007;54(77):1454-7.

Pawlik TM, Vauthey JN, Abdalla EK, Pollock RE, Ellis LM, Curley SA. Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. *Arch Surg* 2006;141(6):537-43.

Perez EA, Livingstone AS, Franceschi D, Rocha-Lima C, Lee DJ, Hodgson N et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. *J Am Coll Surg* 2006;202(4):623-9.

Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J et al. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. *J Clin Oncol* 2009;27(3):439-45.

Raut C. Perioperative sunitinib dosing around extensive resections of imatinib-resistant metastatic gastrointestinal stromal tumors. *J Clin Oncol* 2007;25(18S):Abstract 10044.

Raut C. Clinical experience with periopertaive sunitib and extensive resection of imatinib resistant metastatic GIST. *Ann Oncol* 2007;18(Suppl 7):123.

Reichardt P, Kang Y, Ruka W, Seddon B, Baum C, Demetri G. Subpopulation analysis in a world wide ttreatment-use trial of sunitinib (SU) in GIST patients with resistance or intolerance to prior imatinib (IM) therapy. *J Clin Oncol* 2007;25(18S):10022.

Rutkowski P, Nowecki Z, Nyckowski P, Dziewirski W, Nasierowska-Guttmejer A, Grzesiakowska U et al. Surgical treatment of patients (pts) with gastrointestinal stromal tumors (GIST) after imatinib mesylate (IM) therapy. *J Clin Oncol* 2005;23(16):825S.

Rutkowski P, Nowecki ZI, Michej W, Debiec-Rychter M, Limon J, Siedlecki JA et al. The criteria of aggressiveness and other prognostic factors for predicting relapses of primary tumors and imatinib (IM) treatment outcomes in advanced KIT immunopositive gastrointestinal stromal tumors (GIST): A report of the Polish Clinical GIST Registry (PCGR). *J Clin Oncol* 2006;24(18 Suppl):9544.

Ryu MH, Lee JL, Chang HM, Kim TW, Kim HC, Yook JH et al. Surgical resection after imatinib treatment in patients with metastatic or unresectable gastrointestinal stromal tumors. *Ann Oncol* 2006;17(Suppl 9):164.

Schoffski P, Huang X, Casali PG, Garrett CR, Blackstein ME, Shah MH et al. Phase Iii Trial of Sunitinib (Su) in Imatinib (Im)-Resistant/Intolerant Gist with Novel Statistical Analysis of Long-Term Survival to Account for Crossover. *Ann Oncol* 2008;19(Suppl 8):266.

Schurr P, Kohrs D, Reichelt U, Kaifi J, Vashist Y, Bachmann K et al. Repeated surgery improves survival in recurrent gastrointestinal stromal tumors: a retrospective analysis of 144 patients. *Dig Surg* 2009;26(3):229-35.

Shankar S, vanSonnenberg E, Desai J, Dipiro PJ, Van den AA, Demetri GD. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. *Radiology* 2005;235(3):892-8.

Shankar S, Stay RM, vanSonnenberg E, Dipiro PJ, Janicek MJ, Demetri GD. CT features of gastrointestinal stromal tumors following treatment with STI-571. *Radiology* 2002;225(Suppl S):583-4.

Steigen SE, Eide TJ, Wasag B, Lasota J, Miettinen M. Mutations in gastrointestinal stromal tumors--a population-based study from Northern Norway. *APMIS* 2007;115(4):289-98.

Steinert DM, Blakely LJ, Patel SR, Burgess MA, Chen LL, Trent JC et al. Outcomes of gastrointestinal stromal tumors (GIST) and other intra-abdominal sarcomas (IAS) in the era of imatinib therapy. *J Clin Oncol* 2004;22(14):9047.

Tryggvason G. Clinical study on gastrointestinal stromal tumors (GIST) in Iceland, 1990-2003. *Dig Dis Sci* 2007;52(9):2249-53.

Tzen CY. Spectrum and prognostication of KIT and PDGFRA mutation in gastrointestinal stromal tumors. *Eur J Surg Oncol* 2008;34(5):563-8.

Van den Abbeele AD, Badawi RD, Cliche J, Israel DA, Dimitrijevic S, Demetri GD. Response to Imatinib mesylate (GleevecTM) therapy in patients with advanced gastrointestinal stromal tumors (GIST) is demonstrated by F-18-FDG-PET prior to anatomic imaging with CT. *Radiology* 2002;225 (Suppl S): 424.

Van den Abbeele AD, Badawi RD, Manola J, Morgan JA, Desai J, Kazanovicz A et al. Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning. *J Clin Oncol* 2004;22(14):3012.

Vanel D, Albiter M, Shapeero L, Le Cesne A, Bonvalot S, Le Pechoux C et al. Role of computed tomography in the follow-up of hepatic and peritoneal metastases of GIST under imatinib mesylate treatment: a prospective study of 54 patients. *Eur J Radiol* 2005;54(1):118-23.

Zalinski S, Palavecino M, Abdalla EK. Hepatic Resection for Gastrointestinal Stromal Tumor Liver Metastases. *Hematol-Oncol Clinic N Am* 2009;23(1):115.

Intervention not relevant (N=15)

Awasthi R, Forrest J, Toy E, Sarsfield P. A review of gastro-intestinal stromal turnours (GISTs) presenting at a single hospital in a twenty year period. *J Pathol* 2006;208(Suppl. S):54

Bauer S, Hubert C, Heinrich MC, Cohen P, Bertagnolli M, Demetri GD et al. KIT hyperactivation in imatinib-resistant GIST: Implications for salvage therapies. *J Clin Oncol* 2005;23(16):824S.

Bilimoria KY. Small bowel cancer in the United States: Changes in epidemiology, treatment, and survival over the last 20 years. *Ann Surg* 2009;249(1):63-71.

Chirieac LR, Trent JC, Steinert DM, Choi H, Yang Y, Zhang J et al. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate. *Cancer* 2006;107(9):2237-44.

Egberts J-H. Small bowel cancer: Single-centre results over a period of 12 years. *Hepatogastroenterology* 2007;54(73):129-34.

Gupta M, Sheppard BC, Corless CL, Blanke CD, Billingsley KG. Outcome following aggressive surgical therapy for gastrointestinal stromal tumor. *Gastroenterology* 2005;128(4, Suppl. 2):63

Joensuu H, De Braud F, Coco P, De Pas T, Putzu C, Spreafico C et al. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. *Ann Oncol* 2008;19(1):173-7.

Lau S, Lui CY, Yeung YP, Lam HS, Mak KL. Gastrointestinal stromal tumor of rectum: A report of 2 cases. *J Comput Assist Tomogr* 2003;27(4):609-15.

Leahy M, Ray-Coquard I, Verweij J, Le Cesne A, Duffaud F, Hogendoorn PC et al. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study

from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. *Eur J Cancer* 2007;43(2):308-15.

Pauls K, Hohenberger P, Merkelbach-Bruse S, Pietsch T, Heinicke T, Buettner R et al. Correlation of the c-kit mutational status of gastrointestinal stromal tumors with the clinical response to the tyrosine kinase inhibitor imatinib. *Path Res Pract* 2004;200(4):316-7.

Unalp HR, Derici H, Kamer E, Bozdag AD, Tarcan E, Onal MA. Gastrointestinal stromal tumours: outcomes of surgical management and analysis of prognostic variables. *Can J Surg* 2009;52(1):31-8.

Wagner AJ, Yazji S, Morgan JA, Choy E, George S, Hohos M et al. A phase II study of the KIT inhibitor XL820 in patients with advanced gastrointestinal stromal tumors (GIST) resistant to or intolerant of imatinib and/or sunitinib. *Eur J Cancer Suppl* 2008;6(12):67.

Wise SC, Smith BD, Booth R, Kaufman MD, Lu WP, Petillo PA et al. Small molecule modulators of KIT kinase for treatment of gastrointestinal stromal tumors (GIST). Inhibitors of juxtamembrane domain, D816V, T670I and V654A mutant forms. *Proceedings of the American Association for Cancer Research Annual Meeting* 2009:50

Wozniak A, Rutkowski P, Sciot R, De IW, Ruka W, Schoffski P et al. Analysis of genomic imbalances in imatinib-resistant, progressive gastrointestinal stromal tumors by array comparative genomic hybridization (aCGH). *Cell Oncol* 2008;30(3):280-1.

You YQ, Hassan I, Shyyan R, Que FG, Smyrk TC, Donohue JH. Surgical pathology and outcome of gastrointestinal stromal tumors of the stomach. *Gastroenterology* 2004;126(4, Suppl. 2):61

Treatment not evaluated (N=11)

Bumming P, Ahlman H, Andersson J, Meis-Kindblom JM, Kindblom LG, Nilsson B. Population-based study of the diagnosis and treatment of gastrointestinal stromal tumours. *Br J Surg* 2006;93(7):836-43.

Changchien CR, Wu MC, Tasi WS, Tang R, Chiang JM, Chen JS et al. Evaluation of prognosis for malignant rectal gastrointestinal stromal tumor by clinical parameters and immunohistochemical staining. *Dis Colon Rectum* 2004;47(11):1922-9.

Dupart J, Trent JC, Cohen P, Zhang W. Imatinib mesylate activates IGFBP3 expression in gastrointestinal stromal tumors. *Clin Cancer Res* 2005;11(24):8987S.

Dupart JJ, Trent JC, Lee HY, Chiao PJ, Godwin AK, Zhang W. IGFBP3 induces apoptosis in gastrointestinal stromal tumors but does not mediate response to imatinib mesylate. *Proceedings of the American Association for Cancer Research Annual Meeting* 2009;50.

Fernandez A, Sanguino A, Peng Z, Ozturk E, Chen J, Crespo A et al. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. *J Clin Invest* 2007;117(12):4044-54.

Fletcher JA, Corless CL, Liegl B, Fletcher CD, Raut CP, Donsky R et al. KIT mutations and sunitinib resistance in gastrointestinal stromal tumors (GISTs). *Eur J Cancer Suppl* 2007;5(4):7503.

Koay MHE. Gastrointestinal stromal tumours (GISTs): A clinicopathological and molecular study of 66 cases. *Pathology* 2005;37(1):22-31.

Kurtzman D, Malladevan D. Small molecule therapy: Overcoming imatinib resistance in gastrointestinal stromal tumors. *J Investig Med* 2008;56(1):80.

Liegl B, Kepten I, Donsky R, Fletcher CDM, Corless CL, Fletcher JA. Morphologic and molecular heterogeneity in imatinib-resistant GIST. *Mod Pathol* 2008;21(Suppl 1):51.

Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. *Am J Surg Pathol* 2006;30(4):477-89.

Yokoi K, Tanaka N, Shoji K, Ishikawa N, Seya T, Horiba K et al. A study of histopathological assessment criteria for assessing malignancy of gastrointestinal stromal tumor, from a clinical standpoint. *J Gastroenterol* 2005;40(5):467-73.

No relevant outcomes (N=10)

Abecasis MM, Lage P, Salazar M, Freire J, Moreira A, Jorge M et al. Unlike CML patients, patients with gastrointestinal stromal tumors (GIST) treated with imatinib do not develop hematopoietic clonal cytogenetic abnormalities. *Blood* 2004;104(11):4702.

Antonescu CR, Guo T, Arkun K, Dematteo RP, Besmer P. Acquired resistance to imatinib in gastrointestinal stromal tumor (GIST) occurs through secondary gene mutation. *Mod Pathol* 2005;18(Suppl 1):33.

Antonescu CR, Guo T, Arkun K, Dematteo RP, Besmer P. Acquired resistance to imatinib in gastrointestinal stromal tumor (GIST) occurs through secondary gene mutation. *Lab Invest* 2005;85(Suppl 1):33.

Pricl S, Ferrone M, Fermeglia M, Tamborini E, Delia D, Pierotti MA et al. C-kit mutants in GISTs and their interaction with STI 571: Insights from computer simulations and clinical trials. *Abstracts of Papers American Chemical Society* 2003;225(1-2):24.

Raut C, Morgan J, Quigley M, George S, Wagner A, Demetri G et al. Clinical experience with perioperative sunitinib and extensive resection of imatinib-resistant metastatic gist. *Ann Oncol* 2007;18(Suppl 7):VII123.

Rink L. Correlation of gastrointestinal stromal tumor (GIST) gene expression signatures and response to imatinib mesylate in the RTOG ohase II clinicla trial S-0132. *J Clin Oncol* 2009;27(15S):Abstract 10533.

Schoffski P, Huang X, Demetri GD, Casali R, Garrett CR, Blackstein M et al. Assessment of plasma levels of soluble KIT (sKIT) as a potential surrogate marker for TTP in patients (pts) with advanced gastrointestinal stromal tumor (GIST) treated with sunitinib. *Eur J Cancer Suppl* 2007;5(4):7502.

Van den Abbeele A, Melenevsky Y, de Vries D, Manola J, Dileo P, Tetrault R et al. Imaging kinase target inhibition with SU11248 by FDG-PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST). *J Clin Oncol* 2005;23(16):817S.

Van den Abbeele AD, Melenevsky Y, de Vries D, Manola J, Dileo P, Tetrault R et al. FIDG-PET imaging demonstrates kinase target inhibition by sunitinib malate (SU11248) in GIST patients resistant to or intolerant of imatinib mesylate. *Eur J Cancer Suppl* 2005;3(2):202-3.

Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. *Lancet* 2004;364(9440):1127-34.

Other reasons (N=61)

Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. *Ann Surg Oncol* 2007;14(1):14-24.

Artinyan A, Kim J, Soriano P, Chow W, Bhatia S, Ellenhorn JD. Metastatic gastrointestinal stromal tumors in the era of imatinib: improved survival and elimination of socioeconomic survival disparities. *Cancer Epidemiol Biomark Prevent* 2008;17(8):2194-201.

Bakshi CA, Jain RA, Sastry PS, Sainani AR, Advani SH. Imatinib in gastrointestinal stromal tumors. *J Assoc Physicians India* 2004;52403-9.

Basu S, Mohandas KM, Peshwe H, Asopa R, Vyawahare M. FDG-PET and PET/CT in the clinical management of gastrointestinal stromal tumor. *Nucl Med Commun* 2008;29(12):1026-39.

Bauer S, Hartmann JT, Lang H, Antoch G, Dirsch O, Ebeling P et al. Imatinib may enable complete resection in previously unresectable or metastatic GIST. *J Clin Oncol* 2004;22(14):9023.

Bauer S, Hartmann JT, de Wit M, Lang H, Grabellus F, Antoch G et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. *Int J Cancer* 2005;117(2):316-25.

Berman J, O'Leary TJ. Gastrointestinal stromal tumor workshop. *Hum Pathol* 2001;32(6):578-82.

Blay J, George S, Casali P, Le Cesne A, Morgan J, Pokela J et al. Clinical activity and tolerability of continuous daily dosing of sunitinib in patients with advanced GIST. *Ann Oncol* 2007;18(Suppl 7):VII24.

Blay JY, George S, Casali PG, Le Cesne A, Morgan JA, Tyler A et al. Clinical benefit of continuous daily dosing of sunitinib in patients (pts) with advanced gastrointestinal stromal tumor (GIST). *Ann Oncol* 2006;17(Suppl 9):163.

Blay JY, George S, Casali R, Le Cesne A, Morgan JA, Pokela J et al. Continuous daily dosing (CDD) study of sunitinib malate (SU) in patients (pts) with advanced GIST compares favorably with intermittent dosing. *Eur J Cancer Suppl* 2007;5(4):7501.

Blay J, George S, Casali PG, Le Cesne A, Ray-Coquard I, Harmon CS et al. Efficacy, Safety, Pharmacokinetic and Pharmacodynamic Analysis of Sunitinib (Su) Adminstered on A Continuous Daily Dosing (Cdd) Schedule in Patients with Advanced Gist. *Ann Oncol* 2008;19(Suppl 8):267-8.

Blay JY, Berthaud P, Perol D, Ray-Coquard I, Bui B, Duffaud F et al. Continuous vs intermittent imatinib treatment in advanced GIST after one year: A prospective randomized phase III trial of the French Sarcoma Group. *J Clin Oncol* 2004;22(14):9006.

Blay JY, Le Cesne A. Gastrointestinal stromal tumors: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. *Ann Oncol* 2007;1827-9.

Boukovinas IP. Advancing treatment of gastrointestinal stromal tumors (GIST). *Ann Gastroenterol* 2007;20(1):75-7.

Casali P, Furnagalli E, Bello A, George S. Initiation of sunitinis treatment 24 hours following a final dose of imatinib in patients with advanced gastrointestinal stromal tumor: Safety and tolerability. *Ann Oncol* 2008;19(Suppl 8):74.

Das S, Mukhopadhyay S, Garai J, Biswas S, Sarkar R, Ghosh P et al. Tolerance of imatinib mesylate in chronic myeloid leukemia and gastro intestinal stromal tumours patients - An experience from India. *Ann Oncol* 2006;17(Suppl 3):51.

Davis DW, McConkey DJ, Heymach JV, Desai J, George S, Deprimo SE et al. Correlation of receptor tyrosine kinase (RTK) activity and apoptosis with response to sunitinib treatment in patients with gastrointestinal stromal tumor (GIST). *Eur J Cancer Suppl* 2006;4(12):57.

Demetri GD, Van Oosterom AT, Blackstein M, Garrett C, Shah M, Heinrich M et al. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST. *J Clin Oncol* 2005;23(16):308S.

Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CD, Manola J et al. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. *Clin Cancer Res* 2007;13(18 Pt 1):5398-405.

Duffaud F, LeCesne A, Ray-Coquard I, Bompass E, Assi K, Berthaud P et al. Erythropoietin for anemia treatment of patients with GIST receiving imatinib. *J Clin Oncol* 2004;22(14):9046.

Eilber FC, Rosen G, Forscher C, Nelson SD, Dorey F, Eilber FR. Recurrent gastrointestinal stromal sarcomas. *Surg Oncol* 2000;9(2):71-5.

Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. *J Surg Oncol* 2009;99(1):42-7.

Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. *J Clin Oncol* 2006;24(1):25-35.

George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. *Eur J Cancer* 2009;45(11):1959-68.

George S, Casali P, Blay J, Le Cesne A, Tyler A, Quigley M et al. Continuous daily dosing of sunitinib in patients with advanced GIST: Initial results of a phase II study. *Ann Oncol* 2006;17(Suppl 6):28.

George S, Casali PG, Blay J, Le Cesne A, Tyler AR, Quigley MT et al. Phase II study of sunitinib administered in a continuous daily dosing regimen in patients (pts) with advanced GIST. *J Clin Oncol* 2006;24(18):9532.

George S, Blay J, Casali P, Le Cesne A, Morgan J, Pokela J et al. Continuous daily dosing (CDD) of sunitinib malate (SU) compares favorably with intermittent dosing in pts with advanced GIST. *J Clni Oncol* 2007;25(18S):10015.

George S, Blay JY, Casali P, Le Cesne A, Deprimo S, Harmon CS et al. Continuous daily dosing of sunitinib in patients with advanced GIST: updated efficacy safety PK and pharmacodynamic analysis. *J Clin Oncol* 2008;26(5 Suppl):10554.

Gold JS. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. *Ann Surg Oncol* 2007;14(1):134-42.

Gold JS, van der Zwan SM, Gonen M, Maki RG, Singer S, Brennan MF et al. Outcome of metastatic GIST in the era before imatinib mesylate. *Ann Surg Oncol* 2006;13(2):29.

Gronchi A, Fiore M, Bertulli R, Colecchia M, Tamborini E, Pilotti S et al. Surgery of residual disease following imatinib mesylate in advanced gastrointestinal stromal tumors (GIST). *J Clin Oncol* 2005;23(16):825S.

Holdsworth CH, Badawi RD, Manola JB, Kijewski MF, Israel DA, Demetri GD et al. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. Am J Roentgenol 2007;189(6):W324-W330.

Houk BE, Bello CL, Kang D, Amantea M. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. *Clin Cancer Res* 2009;15(7):2497-506.

Houk BE, Bello C, Garrett M, Poland B, Wagg J, Wada R et al. Population pharmacokinetic (PK)-pharmacodynamic (PD) meta-analysis of sunitinib malate (SU11248) efficacy and tolerability endpoints in gastrointestinal stromal tumor (GIST), metastatic renal cell carcinoma (MRCC) and solid tumor patients. *Clin Cancer Res* 2005;11(24):9075S-6S.

Houk BE, Bello C, Cohen D, Kuwabara-Wagg J, Poland B. A sunitinib exposure-effect based meta-analysis of treatment-related adverse events (TRAEs) in patients with metastatic renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST). *Clin Pharmacol Therap* 2008;83(Suppl 1):S53.

Houk B, Bello C, Cohen D, Casali P, Shirao K, Demetri G. An exposure-response-based meta-analysis of the efficacy of sunitinib in patients with gastrointestinal stromal tumor. *Ann Oncol* 2008;19(Suppl 8):11-2.

Houk BE, Bello CL, Demetri GD, Michaelson M, Casali PG, Bukowski RM et al. Comparative efficacy of sunitinib administered on an intermittent or a continuous daily dosing schedule in metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumor (GIST) patients predicted using population PK approaches. *Proceedings of the American Association for Cancer Research Annual Meeting* 2008;49.

Houk B, Kang D, Bello C, Cohen D, Poland B. Impact of demographic and clinical factors on the pharmacokinetics (PK) of sunitinib in patients and healthy volunteers. *Clinical Pharmacology & Therapeutics* 2008;83(Suppl. 1):S53-S54.

Hsieh CB, Shih ML, Yu JC, Lee HS, Chen DW, Chao TY et al. Giant malignant gastrointestinal stromal tumors (> 10cm) - Recurrent factors and effect of STI 571 treatment. *Xxxiii World Congress of the International College of Surgeons* 2002;119-23.

Huang CC, Yang CY, Lai IR, Chen CN, Lee PH, Lin MT. Gastrointestinal stromal tumor of the small intestine: a clinicopathologic study of 70 cases in the postimatinib era. *World J Surg* 2009;33(4):828-34.

Judson I. Imatinib in the treatment of gastrointestinal stromal tumour. *Anal Cell Pathol* 2003;25(5-6):23.

Kang Y, Kang BW, Ryu M, Im S, Park SR, Kang WK et al. A Phase Ii Study of Imatinib Mesylate As Adjuvant Treatment for Curatively Resected High-Risk Localized Gastrointestinal Stromal Tumors with C-Kit Exon 11 Mutation. *Ann Oncol* 2008;19(Suppl 8):169.

Keun PC, Lee EJ, Kim M, Lim HY, Choi DI, Noh JH et al. Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy. *Ann Surg* 2008;247(6):1011-8.

Mabille M, Vanel D, Albiter M, Le Cesne A, Bonvalot S, Le Pechoux C et al. Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!). *Eur J Radiol* 2009;69(2):204-8.

McAuliffe JC, Lazar AJ, Yang D, Steinert DM, Qiao W, Thall PF et al. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate. *Clin Cancer Res* 2007;13(22 Pt 1):6727-34.

Miettinen M, Makhlouf H, Sobin L, Lasota J. Gastrointestinal stromal tumors (GISTs) of the jejunum and ileum - A clinicopathologic, immunohistochemical and molecular genetic study of 906 cases prior to imatinib with long-term follow-up. *Mod Pathol* 2006;19(Suppl. 1):15 A.

Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors (GISTs) of the jejunum and ileum - A clinicopathologic, immunohistochemical and molecular genetic study of 906 cases prior to imatinib with long-term follow-up. *Lab Invest* 2006;86(Suppl 1):56.

Mindikoglu AL, Regev A, Bejarano PA, Martinez EJ, Jeffers LJ, Schiff ER. Imatinib mesylate (Gleevec) hepatotoxicity. *Dig Dis Sci* 2007;52(2):598-601.

Mukhopadhyay A, Barman B, Sen A, Sarkar S, Gupta P, Deb A et al. Tolerance of imatinib mesylate in chronic myeloid leukemia and gastrointestinal stromal tumours patients: an experience from India. *Ann Oncol* 2005;16(Suppl 2):304.

Paul C, Mukhoapdhyay S, Mondal AK, Chitalkar PG, Mukhoapdhyay A. Imatinib mesylate as first line therapy in patients with gastro intestinal stromal tumour (GIST). An experience from India. *Ann Oncol* 2007;18(Suppl 4):40.

Perik PJ, Rikhof B, de Jong FA, Verweij J, Gietema JA, Van der Graaf WT. Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity. *Ann Oncol* 2008;19(2):359-61.

Raut C, Morgan JA, Quigley MT, George S, Wagner AJ, Demetri G et al. Postoperative experience in patients with metastatic GIST are similar in patients while on sunitinib or imatinib. *Eur J Cancer Suppl* 2007;5(4):7522.

Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. *J Clin Oncol* 2006;24(15):2325-31.

Reichardt P, Pink D, Lindner T, Heinrich MC, Cohen PS, Wang Y et al. A phase I/II trial of the oral PKC-inhibitor PKC412 (PKC) in combination with imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM. *J Clin Oncol* 2005;23(16):196S.

Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D et al. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. *Oncologist* 2007;12(1):107-13.

Shen L, Li J, Li J, Gong J, Wu A. Adjuvant Post-Surgery Therapy with Imatinib in Intermediate Or High-Risk Gastrointestinal Stromal Tumour (Gist) Patients: Interim Analysis from A Single Centre Comparison Study. *Ann Oncol* 2008;19(Suppl 8):267.

Siehl J, Thiel E. C-kit, GIST, and imatinib. *Recent Results Cancer Res* 2007;176145-51.

Trent JC, Choi H, Hunt K, Macapinlac H, McConkey D, Charnsangravej C et al. Apoptotic and anti-vascular activity of imatinib in GIST patients. *J Clin Oncol* 2005;23(16):816S.

Ullrich A. Targeted cancer therapies: herceptin and SUTENT. *FEBS Journal* 2008;275(Suppl. 1):11.

Usman M. Hematological and nonhematological toxicities of imatinib mesylate in patients with chronic myeloid leukemia and gastrointestinal stromal tumor. *Ind J Pharmacol* 2007;39(4):192-5.

Wu PC, Langerman A, Ryan CW, Hart J, Swiger S, Posner MC. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era. *Surgery* 2003;134(4):656-65.

Not obtained/received too late (N=47)

ASCO 2007 updates: Sunitinib in the treatment of metastatic renal carcinoma and the gastrointestinal stromal tumors. *Tumori* 2007;93(5 (Suppl)):1-16.

Don't interrupt imatinib in GIST patients. *Oncol News Int* 2007;16(8):1.

Focus on hematology, Gleevec postsurgery sharply reduces GIST recurrences. *Oncol News Int* 2007;16(5):42.

Focus on hematology. Long-term imatinib recommended for metastatic GIST even after complete resection, French study shows. *Oncol News Int* 2006;15(7):30.

Imatinib for the treatment of life-threatening gastrointestinal cancer. *Dtsch Apoth Ztg* 2002;142(7):40-2.

Aliberti S, Grignani G, Bordonaro R. TK-inhibitors in the clinical management of GIST. What's up, what's next? *Supp Palliat Cancer Care* 2006;2(3):143-6.

Anton CR, Balan G. [Gastrointestinal stromal tumors. Actual diagnosis and treatment]. *Revista Medico -Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi* 2005;109(2):223-9.

Baldo S, Rivoire M, Sobrero A, Comandini D, Civalleri D, Stella M et al. [Surgical resection of gastrointestinal stromal tumor after treatment with imatinib: clinical case]. *Supplementi di Tumori: Official Journal of Societa Italiana di Cancerologia* 2005;4(3):S97-Jun.

Beheshti M. The potential value of F-18 FDG PET in comparison to CT in early prediction of response to imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. *Iran J Nucl Med* 2007;15(28):34-42.

Beijnen JH. Recent developments in pharmacotherapy of cancer. *Pharm Weekbl* 2007;142(4):2-7.

Belev B, Vrbanec D, Kralik M, Plestina S, Petricevic B, Sirotkovic-Skerlev M. Gastrointestinal stromal tumors (GIST) - A paradigm of successful targeted therapy of solid tumors. *Acta Med Croatica* 2006;60(5):471-5.

Buchner-Steudel P, Fleig WE. [Diagnosis and conservative treatment of gastrointestinal stromal tumors (GIST)]. *Deutsche Medizinische Wochenschrift* 2004;129(34-35):1808-10.

Cabebe E, Wakelee H. Sunitinib: a newly approved small-molecule inhibitor of angiogenesis. *Drugs of Today* 2006;42(6):387-98.

Casali PG. Selective tyrosine kinase inhibitors - Imatinib in GIST. *Tumori* 2003;S42-S43.

Delmonte L. Good results continue for Gleevec for GIST... Metastatic gastrointestinal stromal tumors. *Oncology Times* 2002;13-4.

Eisenberg B. GIST adjuvant therapy-some answers and more questions. *Nature Reviews Clinical Oncology* 2009;6(8):441-2.

Fath R. Effectiveness of imatinib in GIST continues for the long-term. *Z Gastroenterol* 2006;44(9):

Feldman B. Getting the gist of G.I.S.T.... gastrointestinal stromal tumor. *J GENCA* 2007;17(2):13-7.

Fuerst ML. GIST: molecular tests predict response to imatinib. *Oncology Times* 2005;18.

Gale S. 27th Annual JPMorgan Healthcare Conference - Biogen Idec. *IDrugs* 2009;12(3):140-1.

Gluszek S. R. GIST - Risk of recurrence and dissemination. *Przeglad Gastroenterologiczny* 2008;3(4):176-84.

Gordon JK, Magid SK, Berman E. Elevations in Creatine Kinase Occur Frequently in Patients Treated with Imatinib Mesylate (Gleevec). *Arthritis Rheum* 2008;58(12):25.

Helwick C. Focus on hematology. Good survival with adjuvant imatinib for high-risk GIST. *Oncol News Int* 2008;17(4):28.

Houk BE, Bello C, Cohen DP, Demetri GD, Casali PG, Shirao K. Efficacy of sunitinib in patients with gastrointestinal stromal tumor (GIST): An exposure-response based meta-analysis. *Molecular Cancer Therap* 2007;6(12):3589S.

Jimeno J. Gastrointestinal stromal tumors: Surgical treatment. *Gastroenterologia y Hepatologia Continuada* 2009;8(2):82-6.

Joensuu H. Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec). *Med Klin* 2002;97 Suppl 128-30.

Jost D, Stroszczynski C, Chmelik P, Gaffke G, Schlecht I, Pink D et al. [Morphology of gastrointestinal stromal tumors in advanced stages of the disease: baseline findings before chemotherapy with imatinib]. [German]. *Rofo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin* 2003;175(6):791-8.

Kale SS. A case and literature review of complicated gastrointestinal stromal tumors. *Gastroenterology and Hepatology* 2008;4(9):650-7.

Khadija B. Gastrointestinal stromal tumor: Epidemiology and outcome study in 40 cases. *Tunis Med* 2006;84(1):26-9.

Kitamuru Y, Hirota S, Nishida T. *Gastrointestinal stromal tumors (GIST): A model for molecule-based diagnosis and treatment of solid tumors.* Gann Monograph on Cancer Research no 53: Gastrointestinal Stromal Tumor (GIST): From Pathology to Molecular Target Therapy. Karger; 2004. p. 27-40.

Le Cesne A. C-kit and GIST: Rational use of Glivec in gastrointestinal stromal tumors. *Ann Pathol* 2002;22(SPEC. ISS. 1):S1-S4.

Mansueto G, Longo F. [News on ASCO 2007. Sunitinib in the treatment of metastatic renal carcinoma and gastrointestinal stromal tumors.]. *Tumori* 2007;93(5):Suppl-16.

Masche UP. Sunitinib. *Pharma-Kritik* 2006;28(10):39.

McIntyre JA. Sunitinib malate: Oncolytic drug multitargeted tyrosine kinase inhibitor. *Drugs of the Future* 2005;30(8):785-92.

Mosnier J-F. Gastrointestinal stromal tumors: From gene to treatment. *Hepato-Gastro* 2002;9(6):403-6.

Motzer RJ. Sunitinib. *Drugs* 2006;66(17):2267.

Prenen H, Dumez H, Stefan C, Hoeben A, Wouters C, Van Lierde MA et al. Imatinib for the treatment of patients with unresectable or metastatic malignant KIT-positive gastrointestinal stromal tumours: an open-label Belgian trial. *Acta Gastroenterologica Belgica* 2006;69(4):367-71.

Raccah E, Merimsky O, Kuten A, Apter S, Catane R. [Imatinib mesylate (glivec) as a treatment for gastrointestinal stromal tumor (GIST)--long term follow-up]. *Harefuah* 2007;146(5):329-34.

Rant CP, Hornick JL, Bertagnolli MM. Gastrointestinal Stromal Tumors of Gastric Origin. *Biology of Gastric Cancers* 2009;135-63.

Raut CP. Advanced gastrointestinal stromal tumor: Potential benefits of aggressive surgery combined with targeted tyrosine kinase inhibitor therapy. *Am J Oncol Rev* 2006;5(12):707-12.

Rutkowski P. Gastrointestinal stromal tumors - Clinical and morphological features. *Pol Przegl Chir* 2003;75(4):374-84.

Sanchez MRG. Gastrointestinal stromal tumors: Medical treatment. *Gastroenterologia y Hepatologia Continuada* 2009;8(2):87-90.

Schutte J. Gastrointestinal stromal tumors (GIST) - Systemic treatment with imatinib and treatment monitoring. *Tumor Diagnostik und Therapie* 2004;25(4):174-6.

Sebastian M. Aggressive surgery combined with targeted tyrosine kinase inhibitor therapy in advanced gastrointestinal stromal tumor: A commentary. *Am J Oncol Rev* 2006;5(12):715-6.

Szawlowski AW. Observation results of patients with gastrointestinal stromal tumors (GIST) subjected to surgical treatment: Commentary. *Pol Przegl Chir* 2006;78(5):581-2.

Van den Abbeele AD. FDG-PET to Measure Response to Targeted Therapy: The Example of Gastrointestinal Stromal Tumor and Imatinib Mesylate (Gleevec). *PET Clinics* 2008;3(1):77-87.

Yokoyama A, Dairaku N, Kusano M, Koshita S, Shimada N, Yamagiwa T et al. [Two cases of primary unresectable and/or recurrent gastrointestinal stromal tumors of small intestine presenting hemoperitoneum caused by administration of imatinib mesylate]. *Nippon Shokakibyo Gakkai Zasshi - Japn J Gastroenterol* 2008;105(11):1619-26.

APPENDIX 6 LIST OF INCLUDED STUDIES

Blanke B2222 Study

Primary reference

Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. *J Clin Oncol* 2008;26(4):620-5.

Secondary reference

Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *N Engl J Med* 2002;347(7):472-80

Blanke S0033 Study

Primary reference

Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. *J Clin Oncol* 2008;26(4):626-32.

Secondary references

Dileo P, Rankin CJ, Benjamin RS, von Mehren M, Blanke C, Bramwell V et al. Incidence and reasons for dose modification of standard-dose vs. high-dose imatinib mesylate (IM) in the Phase III Intergroup Study S0033 of patients (pts) with unresectable or metastatic gastrointestinal stromal tumor (GIST). *J Clin Oncol* 2005;23(16 (Suppl)):824S.

Rankin C, von Mehren M, Blanke C, Benjamin R, Fletcher CDM, Bramwell V et al. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - phase III Sarcoma Group Study S0033. *J Clin Oncol* 2004;22(14S):Abstract 9005.

EORTC-ISG-AGITG (62005) Study

Primary reference

Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. *Eur J Cancer* 2005;41(12):1751-7.

Secondary references

Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, Van Oosterom AT et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. *Eur J Cancer* 2006;42(8):1093-103.

Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY et al. Outcome of patients with advanced gastro-intestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800mg (HD) after progression on 400mg (LO) - an international, intergroup study of the EORTC, ISG and AGITG. *J Clin Oncol* 2004;22(14S):9004.

Park 2009

Primary reference

Park I, Ryu MH, Sym SJ, Lee SS, Jang G, Kim TW et al. Dose escalation of imatinib after failure of standard dose in Korean patients with metastatic or unresectable gastrointestinal stromal tumor. *Jpn J Clin Oncol* 2009;39(2):105-10.

Seddon 2008

Primary reference

Seddon B, Reichardt P, Kang YK, Ruka W, Nieto A, Breazna A et al. Detailed anlaysis of survival and safety with Sunitinib in a worldwide treatment-use trial of patients with advanced imatinib-resistant/intolerant GIST. *Connective Tissue Oncology Society, 14th Annual Meeting, London, November* 2008. Abstract 34980.

Secondary references

Kang Y, Reichardt P, Ruka W, Seddon B, Baum C, Demetri G. Efficacy and safety of sunitinib ina worldwide treatment-use trial of gist patients following imatinib failure. *Ann Oncol* 2007;18(Suppl 7):vii16-Abstract O-0017.

Reichardt P, Kang Y, Ruka W, Seddon B, Nieto A, Breazna A et al. Sunitinib (Su) in A Worldwide Treatment-Use Trial of Patients with Gist: Updated Efficacy and Safety Analysis. *Ann Oncol* 2008;19(Suppl 8):viii267-Abstract 869PD.

Reichardt P, Kang Y, Ruka W, Seddon B, Guerriero A, Breazna A et al. Detailed analysis of survival and safety with sunitinib (SU) in a worldwide treatment-use trial of patients with advanced GIST. *J Clin Oncol* 2008;26(15 Suppl):Abstract 10548.

Rutkowski P, Reichardt P, Kang Y, Ruka W, Seddon B, Guerriero A et al. Sunitinib in a worldwide treatment-use trial of patients with imatinib, resistant/intolerant gastrointestinal stromal tumor: Detailed analysis of survival and safety. *Ann Oncol* 2008;19(Suppl 6):vii12-Abstract O-013.

Schutte J, Reichardt P, Schlemmer M, Wendtner CM, Demetri GD. Efficacy and safety of sunitinib in patients with gastrointestinal stromal tumour resistant or intolerant of prior imatinib therapy: Results from a worldwide treatment-use study. *Onkologie* 2008;31(Suppl 1):77-Abstract OP130.

Seddon B, Reichardt P, Ruka W, Kang YK, Baum CM, Demetri GD. Safety and efficacy results of sunitinib from a worldwide treatment. use trial of gastrointestinal stromal tumour (GIST) patients (pts) with resistance or intolerance to prior imatinib therapy. *European Journal of Cancer Supplements* 2007;5(4):405-Abstract 7511.

APPENDIX 7 PROTOCOL

04 September 2009

HTA 09/21/01

1. Title of the project

Imatinib at escalated doses of 600 mg/day or 800 mg/day for the treatment of people with unresectable and/or metastatic gastrointestinal stromal tumours whose disease has progressed on treatment with imatinib at a dose of 400 mg/day: systematic review and economic evaluation

2. Name of TAR team and 'lead'

Aberdeen HTA Group

Jenni Hislop
Research Fellow, Systematic Reviewer
Health Services Research Unit (HSRU)
3rd Floor
University of Aberdeen
Health Sciences Building
Foresterhill
Aberdeen
AB25 2ZD
Tel: 01224 559033
Fax: 01224 554580
E-mail: j.hislop@abdn.ac.uk

Reserve contact:
Graham Mowatt
Senior Research Fellow
Health Services Research Unit (HSRU)
University of Aberdeen
3rd Floor
Health Sciences Building
Foresterhill
Aberdeen
AB25 2ZD
Tel: 01224 552494
Fax: 01224 554580
E-mail: g.mowatt@abdn.ac.uk

3. Plain english summary

GISTs (gastrointestinal stromal tumours) are a rare type of cancerous tumours that most commonly arise in the stomach or small intestine. People will be diagnosed with this type of cancer only if a biopsy of their tumours tests positive for a particular protein (called "KIT" or "CD117"). In around half of all cases it is possible to remove the tumour surgically, however overall at least 50% of those operated on will develop recurrent disease within 5 years. In these patients with recurrence, and other patients with inoperable disease at diagnosis survival beyond a period 2 years is uncommon without

further treatment. The usual treatment for patients with inoperable GISTs is the drug imatinib, prescribed at a dose of 400 mg per day. This treatment is effective in 60-70% of patients, in which it typically provides control of the GISTs for a period of 2-3 years. Approxiamtely 50% of patients will survive 5 or more years with this treatment. However in all patients resistance of the GISTs to imatinib will eventually occur, and the disease will then progress. Genetic differences, for example whether certain mutations in the c-kit or CD117 gene are present in patients or not, may help clincians' understanding of who is more likely to be able to tolerate the drug and/or have least resistance to it. FDG-PET scans may also be useful to detect early response or resistance to imatinib and these measures may allow more individulaised treatment approaches. At present, increasing the dose of imatinib, when 400 mg per day ceases to improve a patient's condition, is not officially recommended (though in practice it is usually tried). An alternative drug (sunitinib) is recommended to be prescribed in cases where imatinib has failed. The only other alternative to these treatments for patients with inoperable GISTs is to provide best supportive care through management of the patient's pain and other symptoms, and attend to their needs and general well-being, without providing treatment to actively fight the cancer itself. However, in reality it is likely that all patients (including those receiving active treatment) will receive supportive care as part of this treatment.

This review will look at two alternative doses of imatinib (600 mg per day and 800 mg per day) and compare these with the current recommended treatment alternatives (i.e. sunitinib and/or best supportive care) for those patients with inoperable GISTs whose disease progresses while on imatinib at a dose of 400 mg per day.

4. Decision problem

Gastrointestinal stromal tumours (GISTs) are tumours of the connective tissue of the gastrointestinal (GI) tract arising in the interstitial cells of Cajal. They are rare cancers and estimated to account for 1% of all tumours arising in the GI tract.[1] It is estimated that the vast majority (between 60 and 70%) will arise in the stomach, though they can also occur in the small bowel (25-35%), colon and rectum (5%), and, to a lesser extent, the oesophagus.[2] Estimates of the number of people affected by GIST vary, but it is thought that the annual incidence is unlikely to exceed 240.[3] However, previous estimates have suggested that it could be as high as 2000 cases per year.[3] The median age at time of first presentation is approximately 60 years.[4] Prognosis for patients with GISTs is highly dependent on the resectability of the tumour and approximately half of GIST patients will have resectable disease at first presentation. GISTs are resistant to 'conventional' oncology treatments of cytotoxic chemotherapy and radiotherapy. For resectable/non-metastatic tumours, prognosis gives a ten year survival rate of 30-50% of patients, and at least 50% will relapse within 5 years,[5] but for unresectable tumours, prognosis is poor with survival generally less than 2 years without further treatment.[6]

For a GIST to be diagnosed, it is widely accepted that a positive test result (at protein level), for the marker KIT (CD117) is required. KIT (CD117) is a tyrosine kinase receptor which provides a major pathogenic drive for the majority of GISTs by promoting tumor growth and inhibiting tumour cell death. There has been some debate on the definition of a GIST, as it has been noted that in extremely rare cases (<5%), a patient can have a GIST despite testing negative for c-Kit protein expression and in most of these cases a mutation of PDGFRAlpha gene has been detected.[7-9] However, the WHO classification of gastrointestinal tumours recommends that a diagnosis of GIST should only apply to those patients testing positive for the KIT (CD117) protein.[10]

Imatinib is manufactured by Novartis under the names Glivec® (in Europe) and Gleevec® (in the USA). Having originally been licensed as a treatment for chronic myeloid leukaemia, it was first licensed for treatment of GIST in 2002, and is now the

standard first line treatment for "locally advanced, inoperable patients and metastatic patients" with GIST.[11] The 2004 NICE Technology Appraisal 86 on the use of imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours recommends 400mg/day as first-line management. At present the NICE guidance does not recommend dose escalation of imatinib for those whose disease progresses after initially responding at the 400 mg per day dose, although dose escalation has been noted to be the standard approach to disease progression, where patient non-adherence or intolerance to imatinib are not factors in disease progression.[11]

The altermative treatments available for unresectable and/or metastatic GISTs are sunitinib (manufactured by Pfizer), and best supportive care. *Sunitinib is recommended for patients with unresectable and/or metastatic GISTs if treatment with imatinib has failed because of resistance or intolerance, and the drug cost for the first treatment cycle will be met by the manufacturer.*[12] Best supportive care is less well defined or standardised in different clinical trials or treatment protocols, and has also been referred to as "active symptom control".[2] It has been said to involve interventions to manage pain; treat fever, anaemia (due to GI haemorrhage) and GI obstruction[1] and can include palliative measures.[13] In a Cochrane review of supportive care for gastrointestinal cancer patients, supportive care was defined as "the multi-professional attention to the individual's overall physical, psychosocial, spiritual and cultural needs".[14] It was argued that this type of care should ethically be made available to all treatment groups, meaning that in practice for GIST patients, treatment with imatinib or sunitinib would not be provided without supportive care as well, though it is possible that treatment with best supportive care could be provided without additional drug treatment with either imatinib or sunitinib.

The survival of patients with GISTs is largely dependent on whether or not the tumour is resectable. For patients with unresectable and/or metastatic disease, the treatment options are imatinib, sunitinib or best supportive care. Guidance is available on the effectiveness of imatinib at the 400 mg per day dose.[1] However assessment is required of the clinical effectiveness of imatinib at higher dosages (i.e. 600 mg per day and 800 mg per day) in patients whose disease has progressed on treatment with the 400 mg dose, given that an estimated 16% of patients will experience primary resistance to imatinib, and all will develop resistance and progressive disease at a later stage.[15] In evaluating the effectiveness of escalated doses of imatinib or other alternate treatments it is also necessary to consider sub-groups of patients with specific gene KIT mutations who may respond differently to treatment, and also note how rapidly, and by what method (e.g. FDG-PET scans), these patients were identified.

This review will assess the clinical and cost-effectiveness of imatinib at escalated doses of 600 mg per day, and 800 mg per day, compared with treatment using sunitinib, or best supportive care, in patients with KIT (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours, whose disease has progressed on treatment with imatinib at a dose of 400 mg per day.

5. Report methods for synthesis of evidence of clinical effectiveness

A systematic review of the evidence of the clinical effectiveness of imatinib at escalated doses of 600 mg per day or 800 mg per day will be undertaken following the general principles of the CRD's guidance for undertaking reviews in health care[16] and reported in accordance with the PRISMA statement.[17]

5.1 Inclusion and exclusion criteria

- *Types of studies*

The types of studies considered will be randomised controlled trials (RCTs), non-randomised comparative studies and case series. If the number of studies meeting our inclusion criteria is sufficiently large, we may consider limiting them by type of study design and taking into account the importance of other factors such as sample size.

Scoping searches have already been conducted and fewer than 40 potentially relevant studies were found looking specifically at either of the named interventions (i.e. imatinib at 600 mg per day or 800 mg per day).

- *Population*

The population considered will be people with KIT (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST), whose disease has progressed on treatment with imatinib at a dose of 400 mg per day.

If there is sufficient evidence, sub-group analysis will be undertaken for those patients with different mutations of CD117, that are likely to affect their response to escalated doses of imatinib. Data will also be recorded on the methods used to identify response or resistance (e.g. FDG-PET or CT scanning), and whether or not imatinib had been prescribed in a neoadjuvant or adjuvant setting for patients with previously resectable GIST.

- *Intervention*

The intervention considered will be imatinib at escalated doses of 600 mg per day and 800 mg per day, being prescribed in addition to best supportive care

- *Comparators*

The comparators considered will be sunitinib, prescribed within its recommended dose range of 27-75 mg, and provided with best supportive care, and best supportive care only. Best supportive care has been defined in Section 4 above.

- *Outcomes*

The following outcomes will be considered:

- Overall response
- Overall survival
- Disease-free survival

- Progression-free survival
- Time to treatment failure
- Health-related quality of life
- Adverse effects of treatment

- *Exclusion criteria*

We will exclude the following types of studies:

- Animal models;
- Preclinical and biological studies;
- Reviews, editorials, opinions;
- Case reports;
- Reports investigating technical aspects of the intervention.

In addition, we may consider excluding non-English language papers, and/or reports published as meeting abstracts, if the evidence base containing English language and/or full text reports is sufficiently large.

5.2 Search strategy

Extensive sensitive electronic searches will be conducted to identify reports of published and ongoing studies on the clinical effectiveness of imatinib The searches will also be designed to retrieve clinical effectiveness studies of the comparator treatments. Databases to be searched will include: Medline, Medline In-Process, Embase, CINAHL, Science Citation Index, Biosis, Health Management Information Consortium, and the Cochrane Controlled Trials Register for primary research and the Database of Abstracts of Reviews of Effects (DARE), the Cochrane Database of Systematic Reviews (CDSR) and the HTA database for relevant evidence synthesis.

A preliminary Medline search strategy is provided in the Appendix and will be adapted for use in the other databases. Current research registers, including Clinical Trials, Current Controlled Trials, NIHR Portfolio, WHO International Clinical Trials Registry Platform, IFPMA Clinical Trials and the ABPI database will be searched to identify ongoing and recently completed trials. Recent conference proceedings of key oncology and gastrointestinal organisations will also be screened and will include the American Society for Clinical Oncology (ASCO), the International Society of Gastrointestinal Oncology (ISGIO), and the National Cancer Research Institute.

In addition, an Internet search using Copernic Agent will be undertaken and will include the websites of key professional organisations, GIST Support International, and the drug manufacturers Pfizer and Novartis.

There will be no language restriction and all databases will be searched from 2000 onwards.

The reference lists of all identified studies and evidence syntheses, as well as submissions from industry and other consultees, will be checked for additional references.

5.3 Data extraction strategy

One reviewer will screen the titles (and abstracts if available) of all reports identified by the search strategy. Full text copies of all studies deemed to be potentially relevant will be obtained, and two reviewers will independently assess them for inclusion. Any disagreements will be resolved by consensus or arbitration by a third party.

A data extraction form will be developed and piloted. One reviewer will extract details of study design, participants, intervention, comparator and outcomes. A second reviewer

will check the data extraction. Any disagreements will be resolved by consensus or arbitration by a third party.

5.4 Quality assessment strategy

Two reviewers will independently assess the methodological quality of the included studies. Any disagreements will be resolved by consensus or arbitration by a third party. Studies will not be included or excluded on the basis of methodological quality.

RCTS will be assessed using the Cochrane Collaboration's tool for assessing risk of bias.[18] The tool addresses six specific domains: sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting and 'other issues'. Non-randomised comparative studies will be assessed using an 18-question checklist, with the same checklist minus four questions used to assess the quality of case series. The checklist for non-randomised studies and case series was adapted from several sources, including the Centre for Reviews and Dissemination's guidance for those carrying out or commissioning reviews,[16] Verhagen and colleagues,[19] Downs and Black[20] and the Generic Appraisal Tool for Epidemiology (GATE). It assesses bias and generalisability, sample definition and selection, description of the intervention, outcome assessment, adequacy of follow-up, and performance of the analysis. The checklist was developed through the Review Body for Interventional Procedures (ReBIP). ReBIP is a joint venture between Health Services Research at Sheffield University and the Health Services Research Unit at the University of Aberdeen and works under the auspices of the National Institute for Health and Clinical Excellence (NICE) Interventional Procedures Programme (IPP).

5.5 Methods of analysis/synthesis

For relevant outcomes from randomised studies, where appropriate, meta-analysis will be employed to estimate a summary measure of effect. Dichotomous outcome data for the overall response outcome will be combined using the Mantel-Haenszel relative risk (RR) method and continuous outcomes will be combined using the inverse-variance weighted mean difference (WMD) method. For the estimates of RR and WMD 95% confidence intervals (CIs) and p-values will be calculated. Chi-squared tests and I-squared statistics will be used to explore statistical heterogeneity across studies. Possible reasons for heterogeneity will be explored using sensitivity analysis. Where there is no obvious reason for heterogeneity, the implications will be explored using random effects methods.

Pooled weighted ratio of median survival will be derived for overall, disease-free and progression-free survival. The hazard ratio (HR) is the most appropriate statistic for time-to-event outcomes (i.e. for time to treatment failure). If available, the HR will be extracted directly from the trial publications. If not reported the HR will be extracted from other available summary statistics or from data extracted from published Kaplan-Meier curves using methods described by Parmar et al.[21] A pooled HR from available RCTs will be obtained by combining the observed (O) minus expected (E) number of events and the variance obtained for each trial using a fixed effects model.[22] A weighted average of survival duration across studies will then be calculated. The chi square test for heterogeneity will be used to test for statistical heterogeneity between studies. If no RCT data are available, but non-randomised studies have reported relevant data for this outcome, assessment of the risk of bias and heterogeneity will be undertaken using meta-regression analysis.

Data on adverse effects of treatment and quality of life (QoL) will be collected and combined, ideally using standardised mean difference to compare QoL, where there are available data to do so.

It is expected that studies with direct comparisons of the intervention and comparators are likely to be limited. If feasible, and appropriate where we have non-randomised evidence, meta-anlysis models will be used to model survival rates for interventions and comparators. A "cross design" approach will be adopted to allow non-randomised evidence to be included, whilst avoiding the strong assumption of the equivalence of studies. This approach will enable evidence from RCTs, non-randomised comparative studies and case-series to be included.[23] Differences between treatments for survival outcomes will be assessed by the corresponding odds ratio and 95% credible intervals. These results will be "unadjusted odds ratios", but meta-analysis models adjusting for study type will also be used. The results from these models will produce "adjusted" odds ratios. WinBUGS software.[24]

If appropriate, and where there is sufficient data to do so, we will consider using a mixed treatment comparison model for indirect comparisons.

Where a quantitative synthesis is considered to be inappropriate or not feasible, a narrative synthesis of results will be provided.

6. Report methods for synthesising evidence of cost-effectiveness

6.1 Economic evaluation

The economic impact of GISTs for the NHS is associated with its incidence rate, and the proportion of patients who may have unresectable disease (and the consequent resource use by the health systems), and burden in terms of patient outcome. Information from the work on an economic model for the UK, mainly from an industry submission, is based on the assumption that the incidence rate is 15 per million population, and 10-30% of all GIST patients are likely to have resectable disease. If these patients (between 80-240 people) are treated with imatinib, the annual drug costs per patient to the NHS, have been estimated at £18,896 and £24,368 for patients on 400 and 600 mg per day, respectively. Other associated yearly costs with the treatment (including the treatment of adverse events) were estimated at £2730. The model estimates suggest that in two years it would cost the NHS £31,160 to treat a patient with imatinib, and in 10 years it would cost the NHS £56,146.[2,25] An estimate suggests that the total yearly costs to the NHS (England and Wales) for treating with imatinib would be between £5.6 million and £11.2 million. The cost to the NHS would differ when patients who fail to progress with imatinib are provided with higher doses, or other alternative treatments, (e.g. treatment with sunitinib). NICE estimates suggest the number of new cases of unresectable and/or metastatic GISTs to be around 240 people per year.[3] The economic impact of different treatment strategies needs thorough investigation for a robust economic evaluation.

- *Objectives*

The aim is to assess the clinical and cost-effectiveness of alternative treatment strategies for people with KIT (CD117) positive unresectable and/or metastatic gastrointestinal tumours (GISTs), whose disease has progressed on treatment with imatinib at a dose of 400 mg per day.

The specific objectives are:

a) To determine, by undertaking a systematic review of the literature, the clinical and cost-effectiveness of using imatinib at an escalated dose of 600 mg per day or 800 mg per day to treat patients with GISTs (whose disease has progressed with imatinib at a dose of 400 mg per day), compared with treating them with sunitinib and best supportive care.

b) To develop an economic model to compare the cost-effectiveness and cost-utility of use of imatinib at a dose of 600 mg per day or 800 mg per day, or use of sunitinib, or best supportive care only, for treating people with KIT (CD117) positive unresectable and/or metastatic gastrointestinal tumours (GISTs) whose disease has progressed on treatment with imatinib at a dose of 400 mg per day.

The economic assessment will be a comparison of alternative treatments for people with GISTs whose disease has progressed in spite of treatment with imatinib at a dose of 400 mg per day, or those whose treatment with imatinib has failed due to resistance or intolerance. The alternative treatments that will be considered are i) treating with escalated doses of 600 mg per day or 800 mg per day, ii) treating with sunitinib (within its recommended dosage) and iii) providing best supportive care to manage symptoms. It should be noted here that best supportive care is often not provided exclusively. For treatment with imatinib, and treatment with sunitinib, it will be assumed that best supportive care would be provided alongside these treatments.

The economic assessment will be based on two components, (i) a systematic review of existing economic evaluations of the above alternative treatments and (ii) an economic evaluation modelling exercise.

- Systematic review of economic evaluations, and cost analyses of alternative treatment strategies used for treatment of GISTs, (particularly for patients whose disease has progressed with imatinib at a dose of 400 mg per day)

The purpose of the review of studies on economic analysis, or economic evaluation, will be to identify published studies and assess their quality and usefulness for comparisons of alternative treatment of GISTs; inform the methodology of the proposed economic model; and identify data on the parameters of the proposed economic model (e.g. utilities for different health states, costs and epidemiological data).

- *Data sought*

With respect to costs, data will be sought to gather information on costs to the health services (NHS) in treating GIST patients and on costs to patients, in order to estimate overall mean-costs. Specific information will also be collected on (a) the cost of treating the different clinical outcomes (e.g. cost of achieving total survival for the GIST patients whose disease has progressed on treatment with imatinib at a dose of 400 mg per day - the base case), (b) the costs of maintaining GIST patients at a disease progression-free state for a specific period of time under alternative treatment strategies, and (c) the cost per life year gained under alternative treatment strategies. Data will be sought on the costs associated with each alternative. For costs to the health services this will include, for example, the mean number of visits to the oncologist, number of laboratory tests and examinations, radiology examination, the number of inpatient days, and the costs of drugs. Costs associated with the treatment of adverse effects[1] will be included within the

[1] Most of the adverse effects noted in the literature include fatigue and fever, hypertension, gastrointestinal illnesses, dermatological, haemorrhagic events etc.

costs of treatment under different strategies, and data will be sought accordingly. Data on costs to patients in seeking care and for best supportive care under different strategies will also be collected.

With respect to effectiveness, data will be sought on the same outcomes (overall survival, disease-free or progression-free survival, adverse effects of the treatments, time to treatment failure or time to tumour progression, and overall response rate) as noted in the review of effectiveness of different strategies (see section 5.1). This will aid comparison of the results of individual economic evaluations with pooled estimates of effectiveness. In addition to this, we will also seek information on the quality adjusted life years (QALYs) associated with each treatment strategy, and for different relevant health states noted.

More specifically we will seek to identify any data on the QALY loss caused by gastro-intestinal cancer or gastrointestinal stromal tumours, tumour progression, and adverse effects of the different treatment strategies.

- *Types of studies*

Economic evaluations and cost analyses comparing the above mentioned alternative treatment strategies will be included. Non-UK studies will also be included provided they report interventions or involve populations relevant to the scope of the study.

- *Search strategy for identification of published reports*

A comprehensive search will be undertaken to identify studies that assess the cost or cost-effectiveness of the alternative treatments used for GISTs. Databases to be searched will include: Medline, Medline In Process, Embase Science Citation Index Health Management Information Consortium, NHS Economic Evaluations database, the HTA database, CEA Registry and RePeC. There will be no language restriction and all databases will be searched from 2000 onwards.

A preliminary Medline search strategy is provided in the Appendix and will be adapted for use in the other databases. In addition, an Internet search using Copernic Agent will be undertaken and will include the websites of key professional organisations, GIST Support International and the drug manufacturers Pfizer and Novartis.

The references lists of all identified studies and evidence syntheses, as well as submissions from industry and other consultees will be checked for additional potentially relevant references.

The description of how the industry submissions will be handled is described in Section 7 below.

- *Quality assessment*

All included studies will be assessed using the guidelines of the Centre for Reviews and Dissemination.[16] Modelling studies will also be quality assessed against the Phillips checklist.[27]

- *Report methods for synthesising evidence of cost-effectiveness*

The titles and abstracts of all published reports, literature and industry submissions identified by the search strategy will be examined to select relevant studies. The full texts of potentially relevant reports, publications and industry submissions will be obtained and assessed in terms of their relevance to the economic evaluation or cost-analysis. Data will be extracted by an economist according to the guidelines produced by the Centre for Reviews and Dissemination for the critical appraisal of economic evaluations. Where the economic evaluation has been based on a modelling exercise, additional data extraction criteria developed by Phillips and colleagues will apply.[26,27]

Data from the included studies on economic analysis and economic evaluation will be summarised in order to identify common results, and to summarise the variations and weaknesses between studies. The studies that use economic modelling will be critically reviewed with regard to, for example, model structure use, parameterisation and how these models have dealt with uncertainty. This critical review will assist us in developing methods that can be used to structure our model.

6.2 Economic modelling

- *Model structure*

The structure of the model will be informed by the modelling studies identified as part of the systematic review of economic evaluations, the review of clinical effectiveness and other existing evidence including previous NICE TARs. We will also draw upon advice from health care professional members of our research team. However, the scope of the study suggests that treatment strategies to be compared in the models are:

i) Treatment of GIST patients (whose disease has progressed on treatment with imatinib at a dose of 400 mg per day) with an escalated dose of 600 mg per day, regulating symptoms with best supportive care

ii) Treatment of GIST patients (whose disease has progressed on treatment with imatinib at a dose of 400 mg per day) with an escalated dose of 800 mg per day, regulating symptoms with best supportive care

iii) Treatment with sunitinib (within its recommended dose range), regulating symptoms with best supportive care

iv) Regulating symptoms with best supportive care only

The model will consider the above treatment strategies as different types of intervention, and will consider the costs and consequences of patients following these different pathways of care. When building the model we will also consider whether the use of FDG-PETs to predict non-response should be built into the model. The inclusion of this imaging technology may alter estimates of cost-effectiveness because (i) it is costly and (ii) it may provide an early indication of non-responders who may benefit from the early introduction of an alternative therapy.

Consideration will be given to estimating relative differences between treatments based on non-directly comparative data, if direct evidence is not identified within the literature.

The model used will be a Markov model, where the following health states will be considered (all are associated with clinical effectiveness); overall survival; treatment failure; time to tumour progression, and progression-free survival. In an earlier HTA of

imatinib at a dose of 400 mg per day,[2] and other studies,[28] the health states within the economic model were (i) “imatinib treatment” with different doses or “sunitinib treatment that stops disease progression, or at least leads to a partial response; (ii) progressive disease, (iii) death. It is likely that the health states used in our model will be similar to these analyses, although the final choice will depend upon advice and also the literature as described in Section 6.1. Where evidence is available, sub-group analysis will be undertaken on patients with different gene mutation types that may affect their response to escalated doses of imatinib.

- *Data requirements*

For our model, data on the relative effectiveness of interventions will be based upon the systematic review. Resource use of the selected treatment strategies, and for baseline (patients whose disease has progressed on treatment with imatinib at a dose of 400 mg/day) will be identified from relevant sources (NHS cost data, NHS tariff), the review of economic evaluations and advice from experts. Data on resource use can generally be classified into different groups: e.g. resource use in the treatment strategy of the escalated doses of imatinib, secondary care resource use related to secondary level of care or services other than the interventions e.g. side-effect management and other associated treatments, laboratory and other examinations, and resource use for other health care. Data/information on unit costs will be obtained from NHS National Reference Costs and from studies that will be identified as described in Section 6.1. Additional focused searching for relevant cost data will also be conducted.

A cost-utility analysis will be conducted, with outcomes estimated in terms of quality-adjusted life years (QALYs) for patients, where EQ-5D health state profile can be used from the information expected to be available from the review of economic evaluation studies on such treatments. Each health state of the state transition model will require a utility estimated using the best available data (EQ-5D, ECOG category mapped to QALY). These data will be identified from the systematic review, additional focused searches and routine data sources. Where necessary we may need to make assumptions in order to use utility values derived from different patient populations.

- *Time horizon for the model*

The model will look at the costs and consequences directly attributable to the events to the GIST patients (whose disease progression takes place in spite of treatment with imatinib at 400 mg per day) and treating them with alternative strategies up to the end of the patient’s lifetime. Although the time horizon used will be the patient’s lifetime, it is expected that this is unlikely to exceed 6 years (the maximum number of years patients are expected to live after they are diagnosed with unresectable and/or metastatic gastrointestinal stromal tumours).

- *Analysis methods*

The results of the model will be presented in terms of a cost-consequence analysis and cost-utility analysis. The cost-consequence analysis will examine the costs and effects on natural and clinical measures. The likely consequences that are expected to be included in the analysis would include overall survival and progression-free survival. In the cost-utility analysis, results will be presented in terms of an incremental cost per QALY, incremental cost per overall survival (life years gained) and incremental cost per months/year of progression-free survival.

Where appropriate, costs and outcomes will be discounted at 3.5% for both the cost-consequence and cost-utility analyses.[26] The economic evaluation will consider the different sub-groups noted earlier.

Both deterministic and probabilistic sensitivity analysis will be conducted for the uncertainty surrounding parameters, and a net benefit framework will be used to compare the different treatment strategies.

7. Handling the company submission(s)

Information from the manufacturer will be considered if submitted in accordance with the 3rd December 2009 deadline set by NICE. Following receipt of the submission, members of the Aberdeen TAR Team will critically appraise sections of the report according to each member's own area of expertise. Studies reported in the manufacturer's submission that meet the inclusion criteria for the review will be data extracted and quality assessed in accordance with the procedures outlined in this protocol, and included in the data analysis.

Any economic evaluations included in the company submission, provided they comply with NICE's guidance on presentation, will be assessed for clinical validity, reasonableness of assumptions and appropriateness of the data used in the economic model, again using the methods outlined in this protocol. Strengths and weaknesses in terms of methodology adopted, reporting of results and conclusions will be described. The default position of the TAR team is that further modelling work will be necessary and if the TAR team judge that the existing economic evidence is not robust then further work will be undertaken, either by adapting what already exists or developing de-novo modelling (as described in Section 6.2). The conclusions derived from the company submission may then be compared with those provided by the review of the other existing evidence and any model we develop so that differences in results can be highlighted. If the model we may develop differs substantively from that submitted by any company, we shall justify any assumptions made.

Any 'commercial in confidence' data taken from a company submission will be reported in accordance with NICE guidelines.

8. Competing interests of authors

None

Reference list

1 *Gastro-intestinal stromal tumours (GIST) - imatinib : guidance TA86 [document on the Internet].* London: National Institute for Health and Clinical Excellence; 2004 [accessed August 2009]. Available from: URL: http://guidance.nice.org.uk/TA86/Guidance/pdf/English.

2 Wilson J, Connock M, Song F, Yao G, Fry-Smith A, Raftery J et al. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. *Health Technol Assess* 2005;9:1-142.

3 *TA86 Gastro-intestinal stromal tumours (GIST) - imatinib: quick reference guide [document on the Internet].* London: National Institute for Health and Clinical Excellence; 2004 [accessed August 2009]. Available from: URL: http://guidance.nice.org.uk/TA86/QuickRefGuide/pdf/English.

4 King DM. The radiology of gastrointestinal stromal tumours (GIST).]. *Cancer Imaging* 2005;5:150-6.

5 Judson I, Leahy M, Whelan J, Lorigan P, Verrill M, Grimer R. A guideline for the management of gastrointestinal stromal tumour (GIST). *Sarcoma* 2002;6:83-7.

6 DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. *Ann Surg* 2000;231:51-8.

7 Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. *J Clin Oncol* 2004;22:3813-25.

8 Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen C-J, Joseph N et al. PDGFRA activating mutations in gastrointestinal stromal tumors. *Science* 2003;299:708-10.

9 Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. *Archiv Pathol Lab Med* 2006;130:1466-78.

10 Hamilton SR. *World Health Organization Classification of Tumours: Pathology and genetics of tumours of the digestive system.* Geneva: IARC Press; 2000.

11 Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY, ESMO Guidelines Working Group. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol* 1920;20:64-7.

12 *Gastrointestinal stromal tumours - sunitinib: final appraisal determination [document on the Internet].* London: National Institute for Health and Clinical Excellence; 2009 [accessed August 2009]. Available from: URL: http://www.nice.org.uk/guidance/index.jsp?action=download&o=45125.

13 *Single Technology Appraisal of Sunitinib for the treatment of gastrointestinal stromal tumours [document on the Internet].* Sandwich, Kent: Pfizer Ltd; 2008 [accessed August 2009]. Available from: URL: http://www.nice.org.uk/guidance/index.jsp?action=download&o=43440.

14 Ahmed N, Ahmedzai S, Vora V, Hillam S, Paz. Supportive care for patients with gastrointestinal cancer. *Cochrane Database of Systematic Reviews* 2004;Art. No.: CD003445. DOI: 10.1002/14651858.CD003445.pub2.

15 Blanke CD, Demetri GD, Von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. *J Clin Oncol* 2008;26:620-5.

16 *Systematic reviews: CRD's guidance for undertaking systematic reviews in health care [document on the Internet].* University of York: Centre for Reviews and Dissemination; 2009 [accessed March 2009]. Available from: URL: http://www.york.ac.uk/inst/crd/SysRev/!SSL!/WebHelp/SysRev3.htm.

17 Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 2009;339:332-9.

18 The Cochrane Collaboration's tool for assessing risk of bias [webpage of the Internet] In: The *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.0.1. The Cochrane Collaboration, 2008. [accessed August 2009] Available from: URL: http://www.cochrane-handbook.org/

19 Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. *J Clin Epidemiol* 1998;51:1235-41.

20 Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. *J Epidemiol Community Health* 1998;52:377-84.

21 Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. *Stat Med* 1998;17:2815-34.

22 Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. *Prog Cardiovasc Dis* 1985;27:335-71.

23 Sutton AJ, Abrams KR. Bayesian methods in meta-analysis and evidence synthesis. *Stat Methods Med Res* 2001;10:277-303.

24 Lunn DG, Thomas A, Best N, Spiegelhalter D. WinBUGS -- a Bayesian modelling framework: concepts, structure, and extensibility. *Stat Comput* 2000;10:325-37.

25 Reddy P, Boci K, Charbonneau C. The epidemiologic, health-related quality of life, and economic burden of gastrointestinal stromal tumours. *J Clin Pharm Therapeut* 2007;32:557-65.

26 National Institute for Health and Clinical ExcellenceNational Institute for Health and Clinical Excellence. *Guide to the methods of technology appraisal [document on the Internet].* London: National Institute for Health and Clinical

Excellence; 2008 [accessed September 2008]. Available from: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf.

27 Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. *Health Technol Assess* 2004;8:1-158.

28 Contreras-Hernandez I, Mould-Quevedo JF, Silva A, Salinas-Escudero G, Villasis-Keever MA, Granados-Garcia V et al. A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours. *Br J Cancer* 2008;98:1762-8.

APPENDIX 8 CHARACTERISTICS OF INCLUDED STUDIES

Study ID	Participants	Intervention(s) and Comparators	Outcomes Summary
Study: B2222Blanke 2008[36,37] **Time Period:** July 2000 to May 2006 **Countries involved:** 2 (Finland, USA) **Number of institutions involved:** 4	**N receiving intervention(s):** 43 **N receiving comparator(s):** 0 **Baseline Characteristics:** Not stated	**Escalated Dose Intervention(s):** Imatinib at 600 mg/day **Comparator(s):** N/A	**N (%) showing response or stable disease:** 11/43 (25.6%)
Study: S0033 Blanke 2008[39,64,74] **Time Period:** December 2000 to [redacted] **Countries involved:** 2 (Canada, USA) **Number of institutions involved:** 148	**N receiving intervention(s):** 118 **N receiving comparator(s):** 0 **Baseline Characteristics:** Not stated	**Escalated Dose Intervention(s):** Imatinib at 800 mg/day **Comparator(s):** N/A	**N (%) showing response or stable disease:** 36/117 (30.8%) **Median overall survival:** 19 months (95% CI 13 to 23 months) **N (%) still alive at data cut-off point:** 42/118 (35.6%) **Median progression-free survival:** 5 months (2 to 10 months) **N (%) still progression free at data cut-off point:** 19/118 (16.1%)

Study: Park 2009 [73] **Time Period:** June 2001 to June 2006 **Countries involved:** 1 (Republic of Korea) **Number of institutions involved:** 1	**N receiving intervention:** 24 **N receiving comparator(s):** 0 **Baseline characteristics:** Age: Median, years (range): 52 (31-73) Sex: N (%) male: 18 (75.0%) N (%) female: 6 (25.0%) ECOG performance status: 0: 4 (16.7%) 1: 18 (75.0%) 2: 2 (8.3%) Primary tumour site: Stomach: 5 (20.8%) Small bowel: 15 (62.5%) Colon or rectum: 3 (12.5%) Omentum: 1 (4.2%) N receiving previous treatment of: Surgery: 20 (83.3%) Conventional chemotherapy: 3(12.5%) Radiofrequency ablation: 1 (4.2%) Transarterial chemoembolization: 1 (4.2%)	**Escalated Dose Intervention(s):** Imatinib at 600 mg/day Imatinib at 800 mg/day **Comparator(s):** N/A	**N (%) showing response or stable disease:** At 600 mg/day - 5/12 (41.6%); at 800 mg/day - 4/12 (33.3%). **Median time to progression:** At 600 mg/day – 1.7 months (range 0.7 to 24.9 months).

	Site(s) of metastases at time of dose escalation: Liver: 20 (83.3%) Peritoneum: 15 (62.5%) Retroperitoneum: 5 (20.8%) N (%) with prior response to standard-dose imatinib of: Partial Response (PR): 9 (37.5%) Stable Disease (SD): 8 (33.3%) Progressive Disease (PD): 7 (29.2%) N (%) whose time to progression (TTP) with standard-dose imatinib was: ≤6 months: 8 (33.3%) >6 months: 16 (66.7%) N (%) given initial escalated dose of imatinib at: 600 mg/day: 12 (50.0%) 800 mg/day: 12 (50.0%)		

Study: Seddon 2008[76-82] **Time Period:** Not stated to December 2007 **Countries involved:** 33 (Not stated) **Number of institutions involved:** 96	**N receiving intervention:** 0 **N receiving comparator(s):** 351 **Baseline Characteristics:** Not stated	**Escalated Dose Intervention(s):** N/A **Comparator(s):** Sunitinib at 50 mg/day in a 6 week cycle of four weeks on, two weeks off treatment.	**Median overall survival:** 90 weeks (95% CI: 73 to 106 weeks) **N (%) still alive at data cut-off point:** 193/351 (55.0%)
Study: Zalcberg 2005[42] **Time Period:** [redacted] to April 2004 **Countries involved:** 13: (Australia, Belgium, Denmark, France, Germany, Italy, The Netherlands, New Zealand, Poland, Singapore, Spain, Switzerland, UK) **Number of institutions involved:** 56	**N receiving intervention:** 133 **N receiving comparator(s):** 0 **Baseline Characteristics:** Age: Median, years (range): 59 (20-85) Sex: N (%) male: 87 (65%) N (%) female: 46 (36%) ECOG performance status: 0: 63 (47%) 1: 49 (37%) 2: 12 (9%) 3: 9 (7%)	**Escalated Dose Intervention(s):** Imatinib at 800 mg/day **Comparator(s):** N/A	**N (%) showing response or stable disease:** 39/133 (29.3%) "Response to cross-over…occurred significantly more often in wild-type cases (83%) compared to KIT exon 11 mutants (7%) (P=0.0012, Fisher exact test), and in KIT exon 9 mutants (57%) compared to KIT exon 11 mutants (P=0.0017, Fisher exact test)" **Median progression-free survival:** 81 days **N (%) still progression free at data cut-off point:** 24/133 (18.8%)

	N (%) whose primary tumour site was: Gastro-intestinal: 109 (82%) Gastric: 34 (26%) Small bowel: 35 (26%) Duodenum: 20 (15%) Other GI: 20 (15%) Other abdominal 20 (15%) Retroperitoneal: 4 (3%) N (%) with time since primary diagnosis of: <12 months: 70 (53%) 12-24 months: 29 (22%) >24 months: 34 (26%) N (%) with site(s) of active disease at study entry in: Site of primary tumour: 50 (38%) Liver: 96 (72%) Lung: 16 (12%) Ascites: 12 (9%) Pleura: 4 (3%) Bone: 3 (2%) Skin: 3 (2%) N (%) receiving previous treatment of: Surgery: 116 (87%) Radiotherapy: 6 (5%) Chemotherapy: 51 (38%)		**Median duration of response:** 153 days (range 37 to 574 days) **N (%) of patients requiring at least one dose reduction**: 12/77 (15.6%) **N (%) of patients requiring at least one dose delay**: 18/77 (23.4%) **N (%) with adverse events:** Oedema: 99/124 (79.8%) Skin rash: 45/124 (36.3%) Fatigue: 102/124 (82.3%) Dyspnoea: 30/124 (24.2%) Infection: 20/124 (16.1%) Nausea: 82/124 (66.1%) Leucopenia: 56/121 (46.3%) Neutropenia: 49/121 (40.5%) Thrombocytopenia: 7/121 (5.8%) Anaemia: 119/121 (98.3%) **N (% with adverse event) reporting decreased severity after crossover:** Oedema: 25/99 (25.3%) Skin rash: 23/45 (51.1%) Fatigue: 21/102 (20.6%) Dyspnoea: 8/30 (26.7%) Infection: 9/20 (45.0%) Nausea: 38/82 (46.3%)

			Leucopenia: 25/56 (44.6%) Neutropenia: 30/49 (61.2%) Thrombocytopenia: 4/7 (57.1%) Anaemia: 15/119 (12.6%) **N (% with adverse event) reporting increased severity after crossover:** Oedema: 33/99 (33.3%) Skin rash: 19/45 (42.2%) Fatigue: 47/102 (46.1%) Dyspnoea: 14/30 (46.7%) Infection: 9/20 (45.0%) Nausea: 26/82 (31.7%) Leucopenia: 16.56 (28.6%) Neutropenia: 13/49 (26.5%) Thrombocytopenia: 2/7 (28.6%) Anaemia: 51/119 (42.9%) **N (% with adverse event) achieving increased severity to grade 3-4 level:** Oedema: 7/99 (7.1%) Skin rash: 2/45 (4.4%) Fatigue: 10/102 (9.8%) Dyspnoea: 1/30 (3.3%) Infection: 1/20 (5.0%) Nausea: 3/82 (3.7%) Leucopenia: 0/56 (0.0%) Neutropenia: 0/49 (0.0%) Thrombocytopenia: 0/7 (0.0%) Anaemia: 17/119 (14.3%)

APPENDIX 9 QUALITY ASSESSMENT OF THE INDIVIDUAL STUDY

Table 1 Quality assessment of the non randomised studies (comparative studies and case series)

Quality Critreia	Study ID			
	Blanke 2008 [37](B2222)	Blanke 2008[39] (S0033)	Park 2009[73]	Zalcberg 2005[42]
Q1: Were participants a representative sample selected from a relevant patient population?	?	?	?	?
Q2: Were the inclusion/exclusion criteria of participants clearly described?	+	+	+	+
Q3: Were participants entering the study at a similar point in their disease progression?	+	+	+	?
Q4: Was selection of patients consecutive?	-	-	-	-
Q5: Was data collection undertaken prospectively?	+	+	+	+
Q6: *Were the groups comparable on demographic characteristics and clinical features?*	N/A	N/A	N/A	N/A
Q7: Was the intervention (and comparison) clearly defined?	+	+	+	+
Q8: Was the intervention undertaken by someone experienced at performing the procedure?	?	?	?	?
Q9: Were the staff, place, and facilities where the patients were treated appropriate for performing the procedure? (e.g. access to back-up facilities)	?	?	?	?
Q10: Were all the important outcomes considered?	-	-	-	-
Q11: Were objective (valid and reliable) outcome measure/s used?	+	+	+	+
Q12: *Was the assessment of main outcomes blind?*	-	-	-	-
Q13: Was follow-up long enough to detect important effects on outcomes of interest?	+	+	?	+
Q14: Was information provided on non-respondents, dropouts?	-	+	?	?
Q15: Were participants lost to follow-up likely to introduce bias? (e.g. high drop-out rate; *differential drop-out*; no description of those lost)	+	?	?	?
Q16: *Was length of follow-up similar between comparison groups?*	N/A	N/A	N/A	N/A
Q17: Were important prognostic factors identified?	?	?	+	-
Q18: *Were the analyses adjusted for confounding factors?*	?	?	-	-

NA, not applicable (items specific to comparative studies)

Table 2 Quality assessment at trial entry if study itself is randomised

Quality criteria	Study ID			
	Blanke 2008 (B2222)	Blanke 2008 (S0033)	Park 2009	Zalcberg 2005
Was the allocation sequence adequately generated?	?	+	N/A	+
Was allocation adequately concealed?	?	?	N/A	-

APPENDIX 10 SEARCH STRATEGIES FOR REVIEW OF ECONOMIC ANALYSIS STUDIES, CEA

MEDLINE (2000 – October Week 4 2009) EMBASE (2000 – 2009 Week 44) (Medline In Process 3rd November 2009)

Ovid Multifile Search URL: https://shibboleth.ovid.com/

```
1 Gastrointestinal Stromal Tumors/ use mesz
2 Gastrointestinal Stromal Tumor/ use emez
3 gastrointestinal neoplasms/ use mesz
4 exp digestive system tumor/ use emez
5 gist.tw.
6 ((gastro$ or gastric) adj3 stromal).tw.
7 (3 or 4) and (kit or cd117 or cd 117).tw.
8 (3 or 4) and (stromal or connective or mesenchymal).tw.
9 or/1-2,5-8
10 exp "costs and cost analysis"/
11 exp economic evaluation/ use emez
12 economics/
13 exp economics,hospital/
14 exp economics,medical/
15 economics,pharmaceutical/
16 exp budgets/
17 exp models, economic/
18 exp decision theory/
19 ec.fs. use mesz
20 monte carlo method/
21 markov chains/
22 exp technology assessment, biomedical/
23 cost$.ti.
24 (cost$ adj2 (effective$ or utilit$ or benefit$ or minimis$))
25 economics model$.tw.
26 (economics$ or pharmacoeconomic$ or pharmo-economic$).ti.
27 (price$ or pricing$).tw.
28 (financial or finance or finances or financed).tw.
29 (value adj2 (money or monetary)).tw.
30 markov$.tw.
31 monte carlo.tw.
32 (decision$ adj2 (tree? or analy$ or model$)).tw.
33 or/10-32
34 9 and 33
35 limit 34 to yr="2000 -Current"
36 quality of life/
37 quality adjusted life year/
38 "Value of Life"/ use mesz
39 health status indicators/ use mesz
40 health status/ use emez
41 sickness impact profile/ use mesz
42 disability evaluation/ use mesz
43 disability/ use emez
44 activities of daily living/ use mesz
45 exp daily life activity/ use emez
46 cost utility analysis/ use emez
47 rating scale/
48 questionnaires/
49 (quality adj1 life).tw.
50 quality adjusted life.tw.
```

```
51 disability adjusted life.tw.
52 (qaly? or qald? or qale? or qtime? or daly?).tw.
53 (euroqol or euro qol or eq5d or eq 5d).tw.
54 (hql or hqol or h qol or hrqol or hr qol).tw.
55 (hye or hyes).tw.
56 health$ year$ equivalent$.tw.
57 (hui or hui1 or hui2 or hui3).tw.
58 (health adj3 (utilit$ or disutili$)).tw.
59 (health adj3 (state or status)).tw.
60 (sf36 or sf 36 or short form 36 or shortform 36).tw.
61 (sf6 or sf 6 or short form 6 or shortform 6).tw.
62 (sf12 or sf 12 or short form 12 or shortform 12).tw.
63 (sf16 or sf 16 or short form 16 or shortform 16).tw.
64 (sf20 or sf 20 or short form 20 or shortform 20).tw.
65 willingness to pay.tw.
66 standard gamble.tw.
67 trade off.tw.
68 conjoint analys?s.tw.
69 discrete choice.tw.
70 or/36-69
71 9 and 70
72  limit 71 to yr="2000 -Current"
73   35 or 72
```

Science Citation Index (2000 - 3rd November 2009)

Web of Knowledge URL: http://wok.mimas.ac.uk/

1 TS=gist
2 TS=((gastric or gastro*) SAME stromal)
3 TS=((gastric or gastro*) SAME (kit or cd117 or cd 117))
4 TS=((gastric or gastro*) SAME mesenchymal)
5 #1 or #2 or #3 or #4
6 #5 and TS=economic*
7 #5 and TS=cost*
8 #5 and TS=(price* or pricing)
9 #5 and TS=(financial or finance*)
10 #5 and TS=(decision* SAME (tree* OR analy* or model*))
11 #5 and TS=markov*
12 #5 and TS=monte carlo
13 #5 and TS=conjoint analys*
14 #5 and TS=discrete choice*
15 #5 and TS=standard gamble
16 #5 and TS=trade off
17 #5 and ts=willingness to pay
18 #5 and TS=(health SAME (indicator* or status or utilit*))
19 #5 and TS=quality of life
20 #5 and TS=quality adjusted life
21 #5 and TS=disability adjusted life
22 #5 and TS=(qaly* or qald* or qale* or qtime* or daly*)
23 #5 and TS=(euroqol* or euro qol* or eq5d or eq 5d)
24 #5 and TS=(hql or hqol or h qol or hrqol or hr qol)

25 #5 and TS=(hye or hyes)
26 #25 OR #24 OR #23 OR #22 OR #21 OR #20 OR #19 OR #18 OR #17 OR #16 OR #15 OR #14 OR #13 OR #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6
#27 #26 CPCI-S Timespan=2000-2009

Health Management Information Consortium (September 2009)
Ovid Multifile Search URL: http://gateway.ovid.com/athens

```
1 gist.tw.
2 ((gastro$ or gastric$) adj3 stromal).tw.
3 gastrointestinal cancer/ 94
4 3 and (kit or CD117 or cd 117).tw.
5 3 and (stromal or connective or mesenchymal).tw.
6 or/1-2,4-5
```

NHS Economic Evaluation Database (October 2009)
HTA Database(October 2009)
NHS Centre for Reviews & Dissemination URL:http://nhscrd.york.ac.uk/welcome.htm

```
# 1 MeSH Gastrointestinal Stromal Tumors EXPLODE 1 2 3
# 2 gist
# 3 ( gastric OR gastro* ) AND ( kit OR cd117 OR cd AND 117 )
# 4 ( gastric OR gastro* ) AND ( stromal OR connective OR mesenchymal )
# 5 #1 or #2 or #3 or #4
```

IDEAS October 2009
RePeC URL: http://ideas.repec.org/

Gist or gastrointestinal stromal

Conference Proceedings

International Society for Pharamoeconomics and Outcomes Research

```
9th Annual European Congress, Copenhagen, October 2006
10th Annual European Congress, Dublin, October 2007
11th Annual European Congress, Athens, November 2008
12th Annual European Congress, Paris, October 2009
11th Annual International Meeting, Philadelphia, May 2006
12th Annual International Meeting, Arlington, May 2007
13th Annual International Meeting, Toronto, May 2008
14th Annual International Meeting, Orlando, May 2009
```

D Websites Consulted [accessed October 2009]

Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland
URL: http://www.augis.org/
Department of Health
URL: http://www.dh.gov.uk/en/index.htm
GIST Support International
URL: http://www.gistsupport.org/
Glivec
URL: http://www.glivec.com/index.jsp
Medicines and Healthcare products Regulatory Agency (MHRA)
URL: http://www.mhra.gov.uk/
National Cancer Institute
URL: http://www.cancer.gov/
National Comprehensive Cancer Network
URL: http://www.nccn.org/index.asp
National Institute for Health and Clinical Excellence (NICE)
URL: http://www.nice.org.uk/nice-web/Cat.asp?c=20
NHS Evidence
URL: http://www.library.nhs.uk/Default.aspx
NHS Knowledge Network Scotland
URL: http://www.knowledge.scot.nhs.uk/home.aspx
Novaritis UK
URL: http://www.novartis.co.uk/
Pfizer UK
URL: **http://www.pfizer.co.uk/Pages/Home.aspx**
Scottish Sarcoma Network
URL:http://www.ssn.scot.nhs.uk/

APPENDIX 11 SUMMARY OF THE INCLUDED ECONOMIC ANALYSIS AND ECONOMIC EVALUATION STUDIES

Study Identification (Identification No.)	Author and year	Chabot 2008[91]
	Intervention studied/comparators	– Best Support Care vs. Sunitinib for Imatinib-resistant or intolerant patients
	Hypothesis/Question	Examine the challenges to undertake cost effectiveness study in oncology using crossover trial, and presented the submission to the Canadian Drug Review (CDR) of a cost –effectiveness evaluation of sunitinib vs. best support care (BSC) for treatment of GIST in patient whoa are imatinib resistant or intolerant
Key Features of the study	Type of Study	Descriptive, and a full economic evaluation (Cost Effectiveness Analysis)
	Target Population/Sample Population	Patients who failed or are intolerant to imatinib
	Context/settings	Canada, hypothetical population at Provincial level
	Dates to which the data of the study relates to	2005
	Source of Effectiveness Data	Clinical effectiveness from Phase III clinical trails (NCT00075218).[50] Health Outcome – QALY based utility measured by EuroQol 5 Dimensions (EQ5D) questionnaire administered on clinical trail patients.
	Modelling	Markov modelling
	Link between effectiveness and costs data	Costs in the model include costs of sunitinib acquisition, and health care resource use for BSC, cost of routine follow-up for patients receiving sunitinib, cost of adverse events, and end-life costs. Information on health care resource use and corresponding unit costs were derived from published literature, medical oncologist and Canadian Government Schedule.
Information on the clinical evidence and effectiveness. Main outcome of the study	Sample Patient /study sample/patient groups	Cohort population in the model
	Study design	Modelling for Cost Utility Analysis
	Effectiveness Analysis	The following trial endpoints were used for the valuation of the outcomes (effectiveness): a. Progression Free Survival (PFS) defined as the time from randomisation to the point when the tumour progressed or death was due to GIST. b. Overall survival(OS) c. Utility, measured by the EQ5D d. treatment related adverse events.
	Effectiveness measures and results/Outcome measures/ Primary endpoints/ outcome and secondary endpoints/outcome? Statistical precision of these outcomes	Sunitinib compared with BSC for the patients who failed or do not respond to imatinib and found sunitinib effective than BSC – in terms OS, PFS, Life Year Gain (LYG), life year saved (LYS) and QALY. Mean survival sunitinib group1.6 years; mean progression-free health state 0.5 years, and 1.1 years with progressive disease. Patients in BSC group spent on average 0.2 years in the progression-free health state and 0.7 years with in progressive disease; and had mean survival of 0.9 years. Sunitinib treatment resulted in 0.7 years of life year gain, and 0.4 QALYs compared

		to BSC. Utilities associated with sunitinib No progression during 4 wks sunitinib: 0.712+- 0.2 Next 2 wks utility improvement 0.081+-0.02 No progression : BSC .781+-.2 Progression : .577 +0.3
	Clinical recommendations and conclusion	The initial CDR recommendation based on the economic evaluation was " not to reimburse" sunitinib in Canada. This was reversed due to the fact that patients who are resistant to imatinib have no other treatment options. Based on review of the quality, safety, and efficacy data, Health Canada concluded that sunitinib had favourable risk/benefit profile for the treatment of GIOST after failure or intolerance of imatinib treatment.
Economic Analysis	Measures of health outcome/ benefits used in the economic analysis	QALY based on EQ5D from UK study[53]
	Direct Costs and its components: Prospective or retrospective (depend on study design). Whether values were imputed in for certain cases How hospital stay was defined, and any classifications were used or not. Costing of complications or side effects. Estimations of unit costs and source/methods.	Cost per 6 week cycle Sunitinib treatment std dose: Can$ 6947.99 Sunitinib treatment reduced dose for adverse event management : Can $ 5210.99 Sunitinib treatment medical follow-up Cycle 1: Can $ 2275.13, Cycle 2 726. 47, Cycle 3+ 1072.11 Terminal Phase – end of life cost Can$ 3752.Cost of serious adverse event with sunitinib $42.84.
	Indirect Costs and its components : Cost of productivity, cost of volunteer care and support for the patient	Not considered
	Currency, year prices	2005 Canadian $
	Statistical Analysis/cost	Mean and standard deviation of the progression and progression free time.
	Sensitivity Analysis	Univariate sensitivity analysis was conducted by varying the most influential model parameters, viz. utility of progression and no progression, overall survival (hazard ratio), progression free survival, positron-emission tomography (PET) at initiation of sunitinib treatment, the cost of palliative care and the cost of PET. The model assumed the cost of acquisition of sunitinib is certain did not vary this in sensitivity analysis. The sensitivity analysis suggests that results of the economic evaluation were most sensitive to health-state utility value and rate of overall survival and progression free survival.

Results/Major Findings	Benefits results from the economic evaluation	Mean QALYs Sunitinib 0.97 BSC: 0.54 ICER ($/Lys): 49, 826 Incremental Cost Utility Ratio: ($/QALYs): 79, 884 These (ICEr, ICUR lies between an estimated thresholds boundaries of $26433 - $132, 166)
	Costs results used in the economic evaluation Cost of treatment, costs to health sector (Cost to NHS) Major determinants of costs, the principle costs drivers	Mean costs Can $ Sunitinib Can $ 46, 125 BSC Can $11,632
	Synthesis of Cost and benefits Any attempt to consider the uncertainty surrounding estimates of effects	Cost effectiveness of sunitinib vs BSC: ICER ($/Lys): 49, 826 ICUR ($/QALYs): 79, 884 SA- sensitivity uncertainty in the OS advantage for sunitinib? As patients were allowed to cross over (?) cross over 70%
	Author Conclusion/Recommendations	Sunitinib cost-effective. The decision of approval for sunitinib from Health Canada was based on the recognition of sunitinb's clinical benefits of the imatinib intolerant group. The paper suggest reliance on cost effectiveness methodology is unsatisfactory. Guidance is needed on how better to reconcile the best available clinical trial data with the cost-effectiveness requirements and the objectives of the prompt access to oncology medicine

Study Identification (Identification No.)	Author and year	Contreras- Hermandez 2008[92]
	Intervention studied/comparators	Sunitinib 50 mg/day, Imatinib 800mg/day and Best Supportive Care
	Hypothesis/Question	Examine the cost effectiveness to compare the alternatives (Imatinib 800, sunitinib 50 mg) as second line of treatment for those who failed or become intolerant with imatinib 400 mg. The study examined whether it is worth for the Mexican insurance system to re-imburse for sunitinib or higher dose of imatinib.
Key Features of the study	Type of Study	Model based (Markov) full economic evaluation (Cost Effectiveness Analysis)
	Target Population/Sample Population	21 advanced GIST patients who were treated at Hospital de Oncologia IMSS, Mexico. Treatment examined over 5 yearsn and a
	Context/settings	Mexico, 21 advanced GIST patients who were treated at Hospital de Oncologia, *Instituto Mexicano del Seguro Social*(IMSS)
	Dates to which the data of the study relates to	January 2005 to 31 Dec 2007,
	Source of Effectiveness Data	Clinical trail and published literature Motzer et al 2006[100]– sunitinib Phase III study and study by Demetri 2006[50] mainly fro survival data and 21 advanced GIST patients who were treated at Hospital de Oncologia, *Instituto Mexicano del Seguro Social*(IMSS) .
	Modelling	Markov model, Model utilized the effectiveness data from Motzer 2006[100] (review of sunitinib treatment) – sunitinib Phase III study and study by Demetri 2006[50]
	Link between effectiveness and costs data	All costs used in the model (except for the cost of sunitinib), were based on the information from IMSS pricing and re-imbursement procedures. For cost of sunitinib, as it was not available in Mexican market at the time of the analysis, the costs information was provided by Pfizer Laboratories. Costs included cost of mean number of visits to the oncologist, laboratory examinations, and radiology procedures, and cost of mean length of stay.,
Information on the clinical evidence and effectiveness. Main outcome of the study	Sample Patient /study sample/patient groups	21 advanced GIST patients who were treated at Hospital de Oncologia, *Instituto Mexicano del Seguro Social*(IMSS) and hypothetical cohort of 1000 patients for modelling exercise
	Study design	Observation study based 21 patients and Markov modelling with a follow period of 5 years treatment horizon
	Effectiveness Analysis	Progression free months, Progression free survival, Life years gained
	Effectiveness measures and results/Outcome measures/ Primary endpoints/ outcome and secondary endpoints/outcome? Statistical precision of these outcomes	Progression free months (PFM) 5.64, and 1.4 years (95% CI, 1.3- 1.6) of life years gain for sunitinib, Imatinib – PFM = 5.28 , and 1.31 LYG (95% C, 1.1-1.4) BSC – PFM =2.52, 1.08 LYG (95% CI, 1.0 – 1.3)
	Clinical recommendations and conclusion	Sunitinib as second line of treatment for those who failed with 400 mg.

Economic Analysis	Measures of health outcome/ benefits used in the economic analysis	Progression free months Life years gained
	Direct Costs and its components	Direct costs estimated from treatment follow up, health systems perspective. Imatinib higher dose: Expected costs per patient US$ 35, 225 (sd 1253) Sunitinib: Expected costs per patient US$ 17, 805 (sd 694.83) Best support care : Expected cost per patient - US$ 2071.86(sd 472.88) Using IMSS data, the estimated annual cost of per patient for medical consultation, hospitalization, laboratory examination, and radiology procedures was $2424.32, $2657.57, $566.99 and $2392.67 respectively.
	Indirect Costs and its components Cost of productivity, cost of volunteer care and support for the patient.	Not taken into consideration
	Currency, year prices	US$, at 2006 prices
	Statistical Analysis/cost (whether parametric or non-parametric boot strap used or to generate the confidence intervals around each difference in costs and differences in total costs	Standard deviation of the mean costs, and mean life years saved, and confidence interval of the mean life years saved.
	Sensitivity Analysis One way or two way	Mote Carlo second order sensitivity analysis, Probabilistic sensitivity analysis conducted. Results from the sensitivity analysis were used to develop the acceptability curve
Results/Major Findings	Benefits results from the economic evaluation	Sunitinib resulted in a mean Progression free months (PFM) of 5.64, and 1.4 years of life years gain (LYG). For Imatinib – PFM = 5.28 , and 1.31 LYG For Best Supportive Care (BSC), PFM =2.52, and LYG was 1.08 years Incrementally, sunitinib yielded a 0.32 LYG when compared to BSC ICER : Sun vs. BSC $15734.23 per patient treated with sunitinib and $ 56612.55 per year of progression free survival, and $ 46108.89 per life year gained
	Costs results used in the economic evaluation	Imatinib higher dose: Expected costs per patient US$ 35, 225 (sd 1253) Sunitinib: Expected costs per patient US$ 17, 805 (sd 694.83) Best support care : Expected cost per patient - US$ 2071.86(sd 472.88) Using IMSS data, the estimated annual cost of per patient for medical consultation, hospitalization, laboratory examination, and radiology procedures was $2424.32, $2657.57, $566.99 and $2392.67 respectively.
	Synthesis of Cost and benefits	Any attempt to consider the uncertainty surrounding estimates of effects
	Author Conclusion/Recommendations	Reimbursing sunitinib over high dose of imatinib would deliver costs savings to the IMSS and greater survival benefits

	Author and year	Mabasa 2008[94]
	Intervention studied/comparators	Imatinib vs no Imatinib (BSC) in GISTs
	Hypothesis/Question	Examine the cost-effectiveness of Imatinib
Key Features of the study	Type of Study	Full economic evaluation (Cost Effective Analysis)
	Target Population/Sample Population	Patients in British Columbia, British Columbia Cancer Agency Patients with Advanced GIST who received imatinib or historical treatment
	Context/settings	BCCA registered patients with advanced GIST, British Columbia, Canada
	Dates to which the data of the study relates to	1996 to 2001 for non Imatinib cases 2002 to 2005 Imatinib Cases. Follow up periods 60 months and 44 months respectively
	Source of Effectiveness Data	Data derived from Medical records of the patients
	Modelling	No modelling, Patient level data used for CEA
	Link between effectiveness and costs data	All costs used were based on the information on the BCCA patients followed and included on an intention treat basis. The mean and median duration of follow-up for the imatinib group was significantly longer than the historical group. Costs of treatment include cost of drugs, cot per cycle of 1 month, and cost of labour and supply (not clearly specified what it include), and cost of counselling. Costing was based on BCCA registry ICER Imatinib vs no imatinib per median life year gain (IC per LYG) ICER Imatinib vs. no imatininb per progression survival)
Information on the clinical evidence and effectiveness. Main outcome of the study	Sample Patient /study sample/patient groups	46 Imatinib Group 47 in no imatinib (historical group)
	Study design	Retrospective follow up case control study based on medical record
	Effectiveness Analysis	Kaplan Meir estimates of overall survival and imatinib and historical groups.
	Effectiveness measures and results/Outcome measures/ Primary endpoints/ outcome and secondary endpoints/outcome? Statistical precision of these outcomes	Median overall survival (months) Imatinib 66.7 No Imatinib (historical group) 7.7 Median Progression Free Survival (months): Imatinib 45.3 months No Imatinib 5.6 months Overall survival at 1 year: Im 95.4% No Imatininb 32.6% Progression free survival at 1 year IM 81.4% No Imatinib 17.4%
	Clinical recommendations and conclusion	Patient receiving imatinib had significantly longer median overall survival and

180

		median progression free survival, higher 1-year overall survival, and 1 year progression free survival compared to the historical group.
Economic Analysis	Measures of health outcome/ benefits used in the economic analysis	Overall survival, progression free survival, and life year gained.
	Direct Costs and its components Prospective or retrospective (depend on study design). Whether values were imputed in for certain cases How hospital stay was defined, and any classifications were used or not. Costing of complications or side effects. Estimations of unit costs and source/methods	Actual cost of drugs, labour and supply IN THIS SECTION REPORT methods and not results The mean costs per patient was $79, 829 Im $1743 in no Im Costs of surgery or radiotherapy not included (though similar in both arms) - Did not include the cost of side effects, cost of health care visits, or supportive care - Cost of drugs presumable include cost of side effects treatment - Did
	Indirect Costs and its components Cost of productivity, cost of volunteer care and support for the patient.	Not included
	Currency, year prices	Canadian Dollar, 2006 price
	Statistical Analysis/cost	(whether parametric or non-parametric boot strap used or to generate the confidence intervals around each difference in costs and differences in total costs
	Sensitivity Analysis	Conducted univariate sensitivity analysis to examine the impact of upper and lower values of the cost of the drugs, the cost of treatment, the utilities of successful treatment and progressive disease, the time horizon, and the annual rate of discount, in their analysis. They used imatinib at a 600 mg/day dose to examine the impact of results variation as an alternative scenario for the sensitivity analysis
Results/Major Findings	Benefits results from the economic evaluation	Mean OS from Imatinib 66.7 months, and historical control group 7.7 months MPFS – 45.3 months vs 5.6 months
	Costs results used in the economic evaluation	Cost of treatment, costs to health sector (Cost to NHS) Major determinants of costs, the principle costs drivers
	Synthesis of Cost and benefits	Conducted the sensitivity analysis.
	Author Conclusion/Recommendations	Imatinib cost-effective in treatment of GIST with an ICER of $15882.

Study Identification (Identification No.)	Author and year	Paz-Ares 2008[95]
	Intervention studied/comparators	Sunitinib (50 mg) with best supportive care (BSC) and BSC alone
	Hypothesis/Question	Assess cost-effectiveness of sunitinib vs best supportive care as second line of treatment.
Key Features of the study	Type of Study	Full economic evaluation 9Cst effectiveness analysis))
	Target Population/Sample Population	Hypothetical cohort of Spanish population with GIST after progression with imatinib. Perspective - Spanish national Health systems
	Context/settings	Patients with advanced unresectable GIST, intolerant to or with diseases progressing during treatment with imatinib
	Dates to which the data of the study relates to	Used Demetri 2006 study
	Source of Effectiveness Data	Used Demetri 2006 study, Expert panel , 3 pathology experts, 3 health economist
	Modelling	Markov Model
	Link between effectiveness and costs data	Data reported by expert panel on number if visits to oncology clinic, laboratory tests, CT scans, nurse visits, and visits to palliative units, and analgesic drugs. Quality of Life obtained from EQ5D scores of A6181004 (Demetri study population).
Information on the clinical evidence and effectiveness. Main outcome of the study	Sample Patient /study sample/patient groups	Hypothetical cohort patients with advanced unresectable GIST, intolerant to or with diseases progressing during treatment with imatinib (same as Dametri study??)
	Study design	Decision Model analysis, based on the trial[50]
	Effectiveness Analysis	Life years gained, QALY Progression free life years Total mean cost per patient Cost per QALY gained ICER .
	Effectiveness measures and results/Outcome measures/ Primary endpoints/ outcome and secondary endpoints/outcome? Statistical precision of these outcomes	Overall survival, life years gained Progression free survival Incidence and treatment of adverse effect
	Clinical recommendations and conclusion	According to oncology thresholds for oncology patients, sunitinib is considered better
Economic Analysis	Measures of health outcome/ benefits used in the economic analysis	Quality of Life obtained from EQ5D scores
	Direct Costs and its components Prospective or retrospective (depend on study design). Whether values were imputed in for certain cases How hospital stay was defined, and any classifications were used or not.	Total mean costs/patients € 23,259 in sunitinib group (including costs of AE)as against € 1, 622 for BSC

	Costing of complications or side effects. Estimations of unit costs and source/methods	
	Indirect Costs and its components Cost of productivity, cost of volunteer care and support for the patient.	Not included
	Currency, year prices	€, 2007 prices
	Statistical Analysis/cost (whether parametric or non-parametric boot strap used or to generate the confidence intervals around each difference in costs and differences in total costs	Deterministic
	Sensitivity Analysis	Univariate sensitivity analysis
Results/Major Findings	Benefits results from the economic evaluation	Patients benefits in life years gains: 1.59 (for sunitinib+BSC) vs .88 (BSC) Progression free life years: 0.50 (in sunitinib) vs 0.24 (BSC) QALY 1 against 0.55
	Costs results used in the economic evaluation Major determinants of costs, the principle costs drivers	Total mean costs/patients € 23,259 as against € 1, 622 Cost of treatment, costs to health sector (Cost to NHS)
	Synthesis of Cost and benefits Any attempt to consider the uncertainty surrounding estimates of effects	Treatment with sunitinib vs BSC resulted in patients benefits of 0.26 PFLY, 0.71 LY gained and .45 QALY's gained with the cost difference of € 21,637/per patient between both treatment . ICER of sunitinib vs. BSC i. per life years gained €30,242 ii. per month of progression free survival € 4,090 per QALY gained €49, 090 Univariate sensitivity analysis The most important variables: Overall survival hazard ratio Cost of sunitinib Utility value during active treatment and after progression Yes considered the uncertainty surrounding estimates of effects Considering ta +- 25% variation on the overall survival hazard ratio (HR), the parameter most influencing the model results, the ICER/QALY gained would oscillate between €39,201 and €62,806.
	Author Conclusion/Recommendations	Sunitinib can be considered cost-effective vs BSC with acceptable cost per LY gained, and QALY gained. Notes the limitation is using a extrapolated survival curve And hence instead of LYG and QALY surrogate measures

Study Identification (Identification No.)	Author and year	Huse 2007 [93]
	Intervention studied/comparators	Imatinib in the treatment of Advanced GIST
	Hypothesis/Question	Estimated the cost effectiveness if imatinib mesylate in treatment of unresectable GIST using trails data elsewhere and using them US context
Key Features of the study	Type of Study	Cost-effectiveness modelling for decision analysis
	Target Population/Sample Population	Advanced GIST patients
	Context/settings	USA, Imatinib mesylate treatment vs no treatment of advanced hypothetical GIST population in US
	Dates to which the data of the study relates to	Mostly trial data used Demetri (2002) trial data and Blanke Trail data) and Phase II clinical trail data
	Source of Effectiveness Data	Demetri (2002) trail data and Blanke Trail data
	Modelling	Decision modelling
	Link between effectiveness and costs data	Imatinib cost: Pharmacy's Fundamental references, 2005, and Physicians Desk references 2005 Cost of medical management for pancreatic cancer was used in absence of data for GIST management. Cost data for diseases specific For palliative care – since GIST specific palliative care data not available, information on palliative care for pancreatic cancer was used.
Information on the clinical evidence and effectiveness. Main outcome of the study	Sample Patient /study sample/patient groups	Hypothetical cohort population with advanced GIST
	Study design	Decision model
	Effectiveness Analysis	QALY
	Effectiveness measures and results/Outcome measures/ Primary endpoints/ outcome and secondary endpoints/outcome? Statistical precision of these outcomes	Used from UK study (William) Utilities 0.875 for progressive disease and (lower bound .75 – 1.00 upper) 0.935 for successful treatment (.4 – 1.00)
	Clinical recommendations and conclusion	Imatinib is cost-effective in advanced GIST patient.
Economic Analysis	Measures of health outcome/ benefits used in the economic analysis	QALY, overall survival, Cost, cost per life gained and cost per QALY gained.
	Direct Costs and its components Prospective or retrospective (depend on study design). Whether values were imputed in for certain cases How hospital stay was defined, and any classifications were used or not.	

	Costing of complications or side effects. Estimations of unit costs and source/methods source/methods	
	Indirect Costs and its components : Cost of productivity, cost of volunteer care and support for the patient	Not included
	Currency, year prices	US$ 2005 price
	Statistical Analysis/cost (whether parametric or non-parametric boot strap used or to generate the confidence intervals around each difference in costs and differences in total costs	
	Sensitivity Analysis	One way sensitivity analysis
Results/Major Findings	Benefits results from the economic evaluation	Effectiveness QALYS – 4.15 for Imatinib 2.23 for untreated Difference (treated- untreated) 1.92 The net discounted cost of achieving the survival benefit of (2.2 QALY, PV of 1.9 QALY) is $US 74 39 per imatinib-treated patients. CER – US$ 38 723
	Costs results used in the economic evaluation Cost of treatment, costs to health sector (Cost to NHS) Major determinants of costs, the principle costs drivers	Imatinib Treatment US$ 416 255 Untreated US $ 341 886 Weekly cost of imatinib: $US 685 (685-1028) Weekly costs of care successfully treated patients: US$ 359 (226-492) Weekly cost of care for progressive disease US$2575 (1700-3450) Utilities, successful treatment and progressive disease 0.935, 0.875 Time horizon (y) 10, 20 yrs in sensitivity analysis Major cost drivers- cost of drugs
	Synthesis of Cost and benefits Any attempt to consider the uncertainty surrounding estimates of effects	The cost –effectiveness ratio was most sensitive to variation in the cost estimates and time horizon for the analysis. CER ratios were estimated for the upper and lower bound of the of the parameters
	Author Conclusion/Recommendations	Over 10 yrs time horizon, imatinib treatment increases mean quality adjusted survival from 2.4 to 4.6 QALYs, this gain of 2.2 QALYs (undiscounted) with PV of 1.92 QALYs.Net undiscounted costs of achieving this survival benefit is $US 74 369 per imatinib treated patient, yielding a cost-effectiveness ratios of US$38 723 per QALY.

Study Identification (Identification No.)	Author and year	Teich 2009[96]
	Intervention studied/comparators	Sunitinib vs Imatinib 800, and BSC for those who failed with Imatinib 400
	Hypothesis/Question	What the cost-effectiveness of sunitinib vs imatinib in secon line for GIST in Brazil
Key Features of the study	Type of Study	Model Analysis
	Target Population/Sample Population	Cohort population failed with imatinib 400
	Context/settings	
	Dates to which the data of the study relates to	??, 2005? Price
	Source of Effectiveness Data	
	Modelling	Markov Model
	Link between effectiveness and costs data	Cost per LY gains, cost per progression free life years ICER
Information on the clinical evidence and effectiveness. Main outcome of the study	Sample Patient /study sample/patient groups	Cohort population number 1000?
	Study design	Modelling
	Effectiveness Analysis	In comparison with BSC sunitinib increases life LY and PFLY by 0.3 and .26 years respectively With incremental costs off R$86,756 (US$61, 968 PPP 2005) In comparison to Imatinib, sunitinib was more effective and cost –effective with increased Ly 0.02 and PFLY gained of 0.47 and less costly over 6 years
	Effectiveness measures and results/Outcome measures/	Primary endpoints/ outcome and secondary endpoints/outcome? Statistical precision of these outcomes
	Clinical recommendations and conclusion	
Economic Analysis	Measures of health outcome/ benefits used in the economic analysis	
	Direct Costs and its components	Prospective or retrospective (depend on study design). Whether values were imputed in for certain cases How hospital stay was defined, and any classifications were used or not. Costing of complications or side effects. Estimations of unit costs and source/methods
	Indirect Costs and its components	Cost of productivity, cost of volunteer care and support for the patient.
	Currency, year prices	
	Statistical Analysis/cost	(whether parametric or non-parametric boot strap used or to generate the confidence intervals around each difference in costs and differences in total costs
	Sensitivity Analysis	One way? Two-way?
Results/Major Findings	Benefits results from the economic evaluation	
	Costs results used in the economic evaluation	Cost of treatment, costs to health sector (Cost to NHS) Major determinants of costs, the principle costs drivers
	Synthesis of Cost and benefits	Any attempt to consider the uncertainty surrounding estimates of effects
	Author Conclusion/Recommendations	Sunitinib is cost-effective when compare with imatinib 800 and BSC

Study Identification (Identification No.)	Author and year	Wilson 2005[53]
	Intervention studied/comparators	Cot-effectiveness of imatinib in the treatment of unresectable and .or metastatic KIT positive GIST relative to current standard practice
	Hypothesis/Question	Assess the clinical cot-effectiveness of imatinib in the treatment of unresectable and .or metastatic KIT positive GIST relative to current standard practice
Key Features of the study	Type of Study	Systematic review of clinic effectiveness and analysis economic evaluation
	Target Population/Sample Population	Hypothetical cohort population with unresectable GIST in UK
	Context/settings	UK. NHS perspectives
	Dates to which the data of the study relates to	2004?
	Source of Effectiveness Data	Trials Novartis model from clinical trial (??? Need to mention)
	Modelling	Markov modelling, Reporting results from two modelling work 1. Novartis model 2. Birmingham model
	Link between effectiveness and costs data	ICER, cots per QALY
Information on the clinical evidence and effectiveness. Main outcome of the study	Sample Patient /study sample/patient groups	Trials patient – 147 patients with malignant unresectable and/or metastatic GISTs with the median follow up 25 months. Modelled for 10 years
	Study design	Open-label mutlicentre trial compared two imatinib does 400 or 600 mg.
	Effectiveness Analysis	The survival rate was 88% after 1 yr and 78% after 2 years
	Effectiveness measures and results/Outcome measures/	Primary endpoints/ outcome and secondary endpoints/outcome? Statistical precision of these outcomes
	Clinical recommendations and conclusion	Te survival rate was 88% after 1 yr and 78% after 2 years
Economic Analysis	Measures of health outcome/ benefits used in the economic analysis	QALYs from ECOG performance of the trial patient
	Direct Costs and its components Prospective or retrospective (depend on study design). Whether values were imputed in for certain cases How hospital stay was defined, and any classifications were used or not. Costing of complications or side effects. Estimations of unit costs and source/methods	Prospective as trial data Values were not imputed as patients data were used from trials Cost of side effects were available from patients data available from patients data **From Novartis model** Drug cost of imatinib £20,000 Costs of outpatient visit £440 per year Cost of CT scan £656 for imatinib patients and £82 for patients with progressive disease. Cost of GP visit per year £40 Cost of management of adverse events£159 per year (range from £127.20 to £190.80 Costs discounted at 6% (sensitivity – 3% and 6%) QALY discounted at 1.5% (SA 1.5% to 3%)

		Birmingham model developed for this report **4 wks** Cost of averse event £12.23 Cost of imatinib 400 mg - £1,453.54 Cost of imatinib 600 mg - £1874.49 Costs of no treatment (BSC) £43.23 Cost of Terminal disease (death)£2,730 Discounted rate for cost .0046154 Discounted rate fro QALY .0011538 Other costs for imatinib-treated patients £87.38 Utility for imatininb 0.935 Utility for progressive state 0.875 Using incidence rate used by Novartis (15 per million population) and assuming 10-30 % of all GIST patients expected to have matestaic and/or unrestable disease, the number of patients treated with for metastatic and /or unresectable diseases would be between 80 to 240, and the budgetary impact on NHS is estimated between £2.4 and £ 11.8 million per year. The annual costs to NHS per patient at £20, 400 per.
	Indirect Costs and its components Cost of productivity, cost of volunteer care and support for the patient.	Not included
	Currency, year prices	£ 2004 (?) prices
	Statistical Analysis/cost (whether parametric or non-parametric boot strap used or to generate the confidence intervals around each difference in costs and differences in total costs	
	Sensitivity Analysis	
Results/Major Findings	Benefits results from the economic evaluation	The cost per QALY ranged from £51,515 to £98,889 after 2 yrs an from £27, 331 to 44,236 after 5 years and from £21,404 to £449,76 after 10 yrs Results from Birmingham model Costs per QALs gained by imatinib treatment are £70, 206, £51,514, £36, 479 and £25,859 at 2, 3, 5 and 10 years ICER changes depending the whether Weibull or exponential distribution is used Weibull ICER - £26,427 Exponential ICER £21707

	Costs results used in the economic evaluation Cost of treatment, costs to health sector (Cost to NHS) Major determinants of costs, the principle costs drivers	**From Novartis model** Drug cost of imatinib £20,000 Costs of outpatient visit £440 per year Cost of CT scan £656 for imatinib patients and £82 for patients with progressive disease. Cost of GP visit per year £40 Cost of management of adverse events£159 per year (range from £127.20 to £190.80 Weekly cost of Imatinib (pooled trail data) £420.38 (420.38 -£370.38 – 400 mg per ay start dose.) Other costs per imatinib treated patients £ 1136 (£1786 - £570) Others costs per progressive disease patients £562 (£1498 -£233)patient Utillities Imatinib treated 0.935 (.900 to .935) Progressive 0.875 (.875 **Birmingham model developed for this report** **4 wks** Cost of averse event £12.23 Cost of imatinib 400 mg - £1,453.54 Cost of imatinib 600 mg - £1874.49 Costs of no treatment (BSC) £43.23 Cost of Terminal disease (death)£2,730 Discounted rate for cost .0046154 Discounted rate fro QALY .0011538 Othe costs for imatinib-treated patients £87.38 Utility for imatininb 0.935 Utility for progressive state 0.875
	Synthesis of Cost and benefits Any attempt to consider the uncertainty surrounding estimates of effects	Yes costs, discount rate, cost for acquisition of drugs
	Author Conclusion/Recommendations	The Novartis model suggested that the costs per QALY gained ranged from £31,5151 to £98,889 at 2 years, from £27,331 to £44, 236 at 5 years and from £21,404 to £33,976 at 10 years. This range of estimates may still not reflect the uncertainty, since the estimates after 2 years are mainly based on mathematical extrapolation beyond observed data. The results from Birmingham model confirms the finding s of the Novarits model. Because there were no directly controlled trials the results for the model cannot very conclusive due to the uncretanities.

Study Identification (Identification No.)	Author and year	Reddy 2007[52]
	Intervention studied/comparators	NA
	Hypothesis/Question	NA
Key Features of the study	Type of Study	Systematic Review to identify, summarize, and evaluate published studies and abstract describing the epidemiologic, HRQOL and economic impact of GIST 2000-2006. 34 puiblication 29 provided data on epidemiology One provided cost data, Three reported HRQOL One reported cost and HRQOL
	Target Population/Sample Population	NA
	Context/settings	NA
	Dates to which the data of the study relates to	
	Source of Effectiveness Data	
	Modelling	
	Link between effectiveness and costs data	
Information on the clinical evidence and effectiveness. Main outcome of the study	Sample Patient /study sample/patient groups	
	Study design	
	Effectiveness Analysis	
	Effectiveness measures and results/Outcome measures/	Primary endpoints/ outcome and secondary endpoints/outcome? Statistical precision of these outcomes
	Clinical recommendations and conclusion	
Economic Analysis	Measures of health outcome/ benefits used in the economic analysis	Performance stated were assessed using ECOG scale performance take from Dametri study
	Direct Costs and its components Prospective or retrospective (depend on study design). Whether values were imputed in for certain cases How hospital stays was defined, and any classifications were used or not. Costing of complications or side effects. Estimations of unit costs and source/methods	
	Indirect Costs and its components	Cost of productivity, cost of volunteer care and support for the patient.
	Currency, year prices	

	Statistical Analysis/cost	(whether parametric or non-parametric boot strap used or to generate the confidence intervals around each difference in costs and differences in total costs
	Sensitivity Analysis	One way? Two-way?
Results/Major Findings	Benefits results from the economic evaluation	
	Costs results used in the economic evaluation Cost of treatment, costs to health sector (Cost to NHS) Major determinants of costs, the principle costs drivers	The acquisition costs of imatinib was estimated at $18 per 100 mg. tablet in USA and € 23 in France Annual cost $ 32 850 in USA And € 41 975 in France (assuming 50% of patients each received 400 or 600 mg per day UK study Annual drug cost £20,000 Outpatient visits including lab tests £440 GP visits: £40 CT scans: £656 for imatinib patients And £82 for patients with progressive disease Management of adverse events: £159 (range £127-191) Another study (model base Williams) Annual costs of imatinib was £18896 and £24 368 for patients on 400 and 600 mg daily respectively.
	Synthesis of Cost and benefits Any attempt to consider the uncertainty surrounding estimates of effects	Total costs with imatinib over 2 yrs £30 295 for 10 yrs - £47 521 BSC - £1949 at 2 yrs and £4047 at 10 yrs. Cost QALY gained £85 224 after 2 yrs and £29 after 10 yrs Two year total costs were £31 160 compared with £56 146 at 10yrs with imatinib vs £1998 and £4230 at 2 and 10 yrs with BSC. The cost per QALy gain varied from £45 533 to £70 206 at 2 years and 21 £708 to £25 859 at 10 years
	Author Conclusion/Recommendations	

Study Identification (Identification No.)	Author and year	Hopkins 2008[97]
	Intervention studied/comparators	Sunitinib and Imatinib, and placebo (different studies reviewed)
	Hypothesis/Question	Review the new development in cancer therapeutics drugs
Key Features of the study	Type of Study	Review
	Target Population/Sample Population	GIST patients, patients with diseases resistant to imatinib 800 mg or intolerant of imatinib sample not applicable
	Context/settings	Settings of the clinical trials for sunitinib. Three trials Phase three 56 sites Europe, America, Asia and Australia
	Dates to which the data of the study relates to	2003, 2004, 2005 and another 2009
	Source of Effectiveness Data	Reviewed from all the study mentioned
	Modelling	Not applicable
	Link between effectiveness and costs data	Nat relevant
Information on the clinical evidence and effectiveness. Main outcome of the study	Sample Patient /study sample/patient groups	Mark 2005 - 97 Demetri 2006 207 and 105 (placebo) George 2007 - 60
	Study design	
	Effectiveness Analysis	
	Effectiveness measures and results/Outcome measures/	Primary endpoints/ outcome and secondary endpoints/outcome? Statistical precision of these outcomes
	Clinical recommendations and conclusion	Initial results for use of sunitinib is promising- however to early to draw conclusion Important to consider the secondary resistance in GIST Mutational status should be determined before treatment in order to decide the initial dosage of kinase inhibitor

Economic Analysis	Measures of health outcome/ benefits used in the economic analysis	Referred to SMC study
	Direct Costs and its components (Prospective or retrospective (depend on study design). Whether values were imputed in for certain cases How hospital stay was defined, and any classifications were used or not. Costing of complications or side effects. Estimations of unit costs and source/methods	Not relevant – did not used or refer to studies with Costing of the intervention. Refer to SMC study Drug costs for one 6 week cycle of sunitinib 50 mg - £3304 for the 4-2 regimen – 4 cycle costing over £1300
	Indirect Costs and its components : Cost of productivity, cost of volunteer care and support for the patient.	Not considered as the study referred did not used
	Currency, year prices	Drug costs at 2006 prices
	Statistical Analysis/cost	(whether parametric or non-parametric boot strap used or to generate the confidence intervals around each difference in costs and differences in total costs
	Sensitivity Analysis	One way? Two-way?
Results/Major Findings	Benefits results from the economic evaluation	
	Costs results used in the economic evaluation. Cost of treatment, costs to health sector (Cost to NHS) Major determinants of costs, the principle costs drivers	Drugs costs – UK - NHS The total costs was not reported for the study reviewed. The costs are not from study reviewed
	Synthesis of Cost and benefits: Any attempt to consider the uncertainty surrounding estimates of effects	There was not complete economic evaluation neither referred nor modelled in this study. So synthesising not relevant. No
	Author Conclusion/Recommendations	No recommendation on from economic evaluation

APPENDIX 12 MODEL STRUCTURE




Path-2
Im 600 to 800 to Sun
--- Markov Information
Term : _stage =lengthof_run
PD initial treatment
Im 600
--- Markov Information
Init Cost: 0.5 * (cImat600+OthCostIm)
Incr Cost: 1*(cImat600+OthCostIm)/(1+DR)^_stage
Final Cost: 0.5 * ((cImat600+OthCostIm)/(1+DR)^_stage)
Init Eff: 0.5 * ((1/12)*uImat600/(1+DR)^_stage)
Incr Eff: (1/12)*uImat600/(1+DR)^_stage
Final Eff: 0.5 * ((1/12)*uImat600/(1+DR)^_stage)
1
survive
#
response
#
CR/Stable Im 600
no response
nonrespIm600
PD at Imb 800
die due to GIST
dth600
Death
CR/Stable
Im 600
--- Markov Information
Init Cost: 0
Incr Cost: 1*(cImat600+OthCostIm)/((1+DR)^_stage)
Final Cost: 0.5 * (1*(cImat600+OthCostIm)/((1+DR)^_stage))
Init Eff: 0.5 * ((1/12)*uImat600/((1+DR)^_stage))
Incr Eff: (1/12)*uImat600/((1+DR)^_stage)
Final Eff: 0.5 * ((1/12)*uImat600/((1+DR)^_stage))
.0
survive
#
response
#
CR/Stable Im 600
no response
nonrespIm600
PD at Imb 800
die due to GIST
dth600
Death
PD at Imb 800
--- Markov Information
Init Cost: 0
Incr Cost: 1*(cImat800+OthCostIm)/((1+DR)^_stage)
Final Cost: 0.5 * (cImat800+OthCostIm)/((1+DR)^_stage)
Init Eff: 0.5 * ((1/12)*uImat800/((1+DR)^_stage))
Incr Eff: (1/12)*uImat800/((1+DR)^_stage)
Final Eff: 0.5 * ((1/12)*uImat800/((1+DR)^_stage))
.0
survive
#
response
#
CR/Stable Imb 800
no response
nonrespIm800
PD with Sun
die due to GIST
dth800
Death
CR/Stable Imb 800
--- Markov Information
Init Cost: 0
Incr Cost: 1*(cImat800+OthCostIm)/((1+DR)^_stage
Final Cost: 0.5 * ((cImat800+OthCostIm)/((1+DR)^_stage)
Init Eff: 0.5 * (((1/12)*uImat800)/((1+DR)^_stage))
Incr Eff: ((1/12)*uImat800)/((1+DR)^_stage)
Final Eff: 0.5 * (((1/12)*uImat800)/((1+DR)^_stage))
.0
survive
#
response
#
CR/Stable Imb 800
no response
nonrespIm800
PD with Sun
die due to GIST
dth800
Death
PD with Sun
--- Markov Information
Init Cost: 0
Incr Cost: 1*(cSunb+OthCostSun)/((1+DR)^_stage)
Final Cost: 0.5 * (OthCostSun)/((1+DR)^_stage))
Init Eff: 0.5 * (((1/12)*uSun)/((1+DR)^_stage))
Incr Eff: ((1/12)*uSun)/((1+DR)^_stage)
Final Eff: 0.5 * (((1/12)*uSun)/((1+DR)^_stage))
.0
survive
#
response
#
CR/stable with Sun
no response
nonrespSun
PD No treat/BSC
die due to GIST
dthsun
Death
CR/stable with Sun
--- Markov Information
Init Cost: 0
Incr Cost: 1*(cSunb+OthCostSun)/((1+DR)^_stage)
Final Cost: 0.5 *(cSunb+OthCostSun)/((1+DR)^_stage)
Init Eff: 0.5 * (((1/12)*uSun)/((1+DR)^_stage))
Incr Eff: ((1/12)*uSun)/((1+DR)^_stage)
Final Eff: 0.5 * (((1/12)*uSun)/((1+DR)^_stage))
.0
survive
#
response
#
CR/stable with Sun
no response
nonrespSun
PD No treat/BSC
die due to GIST
dthsun
Death
PD No treat/BSC
--- Markov Information
Init Cost: 0
Incr Cost: 1*(cNott+othCostBSC/((1+DR)^_stage))
Final Cost: 0.5 * (cNott+othCostBSC/((1+DR)^_stage))
Init Eff: 0.5 * ((1/12)*uProg/((1+DR)^_stage))
Incr Eff: (1/12)*uProg/((1+DR)^_stage)
Final Eff: 0.5 * ((1/12)*uProg/((1+DR)^_stage))
0
survive
#
PD No treat/BSC
die due to GIST
deathBSC
Death
Death
--- Markov Information
Init Cost: 0
Incr Cost: 0
Final Cost: 0
Init Eff: 0
Incr Eff: 0
Final Eff: 0
0


Path-3
Imatinib 600 to
Sunitinib
--- Markow Information
Term :
PD with initial
treatment Im 600
--- Markow Information
Init Cost: 0.5 * (cImat600+OthCostIm)
Incr Cost: 1*(cImat600+OthCostIm)/(1+DR)^_stage
Final Cost: 0.5 * ((cImat600+OthCostIm)/(1+DR)^_stage)
Init Eff: 0.5 * ((1/12)*uImat600/((1+DR)^_stage))
Incr Eff: (1/12)*uImat600/((1+DR)^_stage)
Final Eff: 0.5 * ((1/12)*uImat600/((1+DR)^_stage))
1
survive
#
response
#
CR/Stable with Im 600
no response
nonrespIm600
PD with Sunitinib
die due to GIST
dth600
Death
CR/Stable
with Im 600
--- Markow Information
Init Cost: 0
Incr Cost: 1*(cImat600+OthCostIm)/(1+DR)^_stage
Final Cost: 0.5 *(cImat600+OthCostIm)/(1+DR)^_stage
Init Eff: 0.5 * (((1/12)*uImat600)/((1+DR)^_stage))
Incr Eff: ((1/12)*uImat600)/((1+DR)^_stage)
Final Eff: 0.5 * (((1/12)*uImat600)/((1+DR)^_stage))
0
survive
#
response
#
CR/Stable with Im 600
no response
nonrespIm600
PD with Sunitinib
die due to GIST
dth600
Death
PD with Sunitinib
--- Markow Information
Init Cost: 0
Incr Cost: 1*(cSunb+OthCostSun)/((1+DR)^_stage)
Final Cost: 0.5*(cSunb+OthCostSun)/((1+DR)^_stage)
Init Eff: 0.5 * ((1/12)*uSun/((1+DR)^_stage))
Incr Eff: (1/12)*uSun/((1+DR)^_stage)
Final Eff: 0.5 * ((1/12)*uSun/((1+DR)^_stage))
0
survive
#
reponse
#
CR/Stable with Sun
no response
nonrespSun
PD No treat/BSC
die due to GIST
dthsun
Death
CR/Stable with Sun
--- Markow Information
Init Cost: 0
Incr Cost: 1*(cSunb+OthCostSun)/((1+DR)^_stage)
Final Cost: 0.5 *(cSunb+OthCostSun)/((1+DR)^_stage)
Init Eff: 0.5 * (((1/12)*uSun)/((1+DR)^_stage))
Incr Eff: ((1/12)*uSun)/((1+DR)^_stage)
Final Eff: 0.5 * (((1/12)*uSun)/((1+DR)^_stage))
0
survive
#
response
#
CR/Stable with Sun
no response
nonrespSun
PD No treat/BSC
die due to GIST
dthsun
Death
PD No treat/BSC
--- Markow Information
Init Cost: 0
Incr Cost: 1*(cNott+othCostBSC/((1+DR)^_stage))
Final Cost: 0.5 *(cNott+othCostBSC/((1+DR)^_stage))
Init Eff: 0.5 * ((1/12)*uProg/(1+DR)^_stage)
Incr Eff: (1/12)*uProg/(1+DR)^_stage
Final Eff: 0.5 * ((1/12)*uProg/(1+DR)^_stage)
0
survive
#
PD No treat/BSC
die due to GIST
deathBSC
Death
Death
--- Markow Information
Init Cost: 0
Incr Cost: 0
Final Cost: 0
Init Eff: 0
Incr Eff: 0
Final Eff: 0
0


Path-4
Imatinib 600mg
--- Markov Information
Term : _stage =lengthof_run
PD with initial
treatment Im 600
--- Markov Information
Init Cost: 0.5*(cImat600+OthCostIm)
Incr Cost: 1*(cImat600+OthCostIm)/(1+DR)^_stage
Final Cost: 0.5*(1*(cImat600+OthCostIm)/(1+DR)^_stage)
Init Eff: 0.5 * ((1/12)*(uImat600/(1+DR)^_stage))
Incr Eff: (1/12)*(uImat600/(1+DR)^_stage)
Final Eff: 0.5 * ((1/12)*(uImat600/(1+DR)^_stage))
1
survive
#
response
#
CR/Stable with Im 600
no response
nonrespIm600
PD No treat/BSC
die due to GIST
dth600
Death
CR/Stable
with Im 600
--- Markov Information
Init Cost: 0
Incr Cost: 1*(cImat600+OthCostIm)/(1+DR)^_stage
Final Cost: 0.5*(cImat600+OthCostIm)/(1+DR)^_stage
Init Eff: 0.5 * ((1/12)*(uImat600/(1+DR)^_stage))
Incr Eff: (1/12)*(uImat600/(1+DR)^_stage)
Final Eff: 0.5 * ((1/12)*(uImat600/(1+DR)^_stage))
0
survive
#
response
#
CR/Stable with Im 600
no response
nonrespIm600
PD No treat/BSC
die due to GIST
dth600
Death
PD No treat/BSC
--- Markov Information
Init Cost: 0
Incr Cost: 1*(cNott+othCostBSC/((1+DR)^_stage))
Final Cost: 0.5*(cNott+othCostBSC/((1+DR)^_stage))
Init Eff: 0.5 * ((1/12)*(uProg)/(1+DR)^_stage)
Incr Eff: (1/12)*(uProg)/(1+DR)^_stage
Final Eff: 0.5 * ((1/12)*(uProg)/(1+DR)^_stage)
0
survive
#
PD No treat/BSC
die due to GIST
deathBSC
Death
Death
--- Markov Information
Init Cost: 0
Incr Cost: 0
Final Cost: 0
Init Eff: 0
Incr Eff: 0
Final Eff: 0
0


Path-5
Imatinib 800 to
Sunitinib
--- Markov Information
Term :
PD with intial
treatment Im 800
--- Markov Information
Init Cost: 0.5*(cImat800+OthCostIm)
Incr Cost: 1*(cImat800+OthCostIm)/(1+DR)^_stage
Final Cost: 0.5*(1*(cImat800+OthCostIm)/(1+DR)^_stage)
Init Eff: 0.5 * (((1/12)*uImat800)/((1+DR)^_stage))
Incr Eff: ((1/12)*uImat800)/((1+DR)^_stage)
Final Eff: 0.5 * (((1/12)*uImat800)/((1+DR)^_stage))
1
survive
#
response
#
CR/Stable with Im 800
no response
nonrespIm800
PD with Sun
die due to GIST
dth800
Death
CR/Stable
with Im 800
--- Markov Information
Init Cost: 0
Incr Cost: 1*(cImat800+OthCostIm)/(1+DR)^_stage
Final Cost: 0.5*(cImat800+OthCostIm)/(1+DR)^_stage
Init Eff: 0.5 * (((1/12)*uImat800)/((1+DR)^_stage))
Incr Eff: ((1/12)*uImat800)/((1+DR)^_stage)
Final Eff: 0.5 * (((1/12)*uImat800)/((1+DR)^_stage))
0
survive
#
response
#
CR/Stable with Im 800
no response
nonrespIm800
PD with Sun
die due to GIST
dth800
Death
PD with Sun
--- Markov Information
Init Cost: 0
Incr Cost: 1*(cSunb+OthCostSun)/((1+DR)^_stage)
Final Cost: 0.5*(cSunb+OthCostSun)/((1+DR)^_stage)
Init Eff: 0.5 * (((1/12)*uSun)/((1+DR)^_stage))
Incr Eff: ((1/12)*uSun)/((1+DR)^_stage)
Final Eff: 0.5 * (((1/12)*uSun)/((1+DR)^_stage))
0
survive
#
response
#
CR/stable with Sun
no response
nonrespSun
PD No treat/BSC
die due to GIST
dthsun
Death
CR/stable
with Sun
--- Markov Information
Init Cost: 0
Incr Cost: 1*(cSunb+OthCostSun)/((1+DR)^_stage)
Final Cost: 0.5 * (cSunb+OthCostSun)/((1+DR)^_stage)
Init Eff: 0.5 * ((1/12)*uSun)
Incr Eff: ((1/12)*uSun)/((1+DR)^_stage)
Final Eff: 0.5 * (((1/12)*uSun)/((1+DR)^_stage))
0
#
response
#
CR/stable with Sun
no response
nonrespSun
PD No treat/BSC
die due to GIST
dthsun
Death
PD No treat/BSC
--- Markov Information
Init Cost: 0
Incr Cost: 1*(cNott+othCostBSC)/((1+DR)^_stage))
Final Cost: 0.5*(cNott+othCostBSC)/((1+DR)^_stage))
Init Eff: 0.5 * ((1/12)*(uProg/(1+DR)^_stage))
Incr Eff: (1/12)*(uProg/(1+DR)^_stage)
Final Eff: 0.5 * ((1/12)*(uProg/(1+DR)^_stage))
0
survive
#
PD No treat/BSC
die due to GIST
deathBSC
Death
Death
--- Markov Information
Init Cost: 0
Incr Cost: 0
Final Cost: 0
Init Eff: 0
Incr Eff: 0
Final Eff: 0
0


Path 6
Imatinib 800mg
--- Markow Information
Term : _stage= lengthof_run
PD with initial
treatment Im 800
--- Markow Information
Init Cost: 0.5*(cImat800+OthCostIm)
Incr Cost: 1*(cImat800+OthCostIm)/((1+DR)^_stage
Final Cost: 0.5*(cImat800+OthCostIm)/((1+DR)^_stage
Init Eff: 0.5 * (((1/12)*uImat800)/((1+DR)^_stage))
Incr Eff: ((1/12)*uImat800)/((1+DR)^_stage)
Final Eff: 0.5 * (((1/12)*uImat800)/((1+DR)^_stage))
1
survive
#
response
#
CR/Stable with Im 800
no response
nonrespIm800
PD No treat/BSC
die due to GIST
dthIm800
Death
CR/Stable with
Im 800
--- Markow Information
Init Cost: 0
Incr Cost: 1*(cImat800+OthCostIm)/((1+DR)^_stage
Final Cost: 0.5*(cImat800+OthCostIm)/((1+DR)^_stage)
Init Eff: 0.5 * (((1/12)*uImat800)/((1+DR)^_stage))
Incr Eff: ((1/12)*uImat800)/((1+DR)^_stage)
Final Eff: 0.5 * (((1/12)*uImat800)/((1+DR)^_stage))
0
survive
#
response
#
CR/Stable with Im 800
no response
nonrespIm800
PD No treat/BSC
die due to GIST
dthIm800
Death
PD No treat/BSC
--- Markow Information
Init Cost: 0
Incr Cost: 1*(cNott+othCostBSC)/((1+DR)^_stage))
Final Cost: 0.5*(cNott+othCostBSC)/((1+DR)^_stage))
Init Eff: 0.5 * ((1/12)*uProg/((1+DR)^_stage))
Incr Eff: (1/12)*uProg/((1+DR)^_stage)
Final Eff: 0.5 * ((1/12)*uProg/((1+DR)^_stage))
0
survive
#
PD No treat/BSC
die due to GIST
deathBSC
Death
Death
--- Markow Information
Init Cost: 0
Incr Cost: 0
Final Cost: 0
Init Eff: 0
Incr Eff: 0
Final Eff: 0
0


Path- 7
Sunitinib
--- Markov Information
Term : _stage =lengthof_run
PD with initial
treatment Sun
--- Markov Information
Init Cost: 0.5*(cSunb+OthCostSun)
Incr Cost: 1*((cSunb+OthCostSun)/((1+DR)^_stage)
Final Cost: 0.5*((cSunb+OthCostSun)/((1+DR)^_stage)
Init Eff: 0.5 * (((1/12)*uSun)/((1+DR)^_stage))
Incr Eff: ((1/12)*uSun)/((1+DR)^_stage)
Final Eff: 0.5 * (((1/12)*uSun)/((1+DR)^_stage))
1
survive
#
response
#
CR/Stable with Sun
no response
nonrespSun
PD No treat/BSC
die due to GIST
dthsun
Death
CR/Stable
with Sun
--- Markov Information
Init Cost: 0
Incr Cost: 1*(cSunb+OthCostSun)/((1+DR)^_stage)
Final Cost: 0.5 * (1*(cSunb+OthCostSun)/((1+DR)^_stage))
Init Eff: 0.5 *((1/12)*uSun/(1+DR)^stage)
Incr Eff: (1/12)*uSun/(1+DR)^stage
Final Eff: 0.5 * ((1/12)*uSun/(1+DR)^stage)
0
survive
#
response
#
CR/Stable with Sun
no response
nonrespSun
PD No treat/BSC
die due to GIST
dthsun
Death
PD No treat/BSC
--- Markov Information
Init Cost: 0
Incr Cost: 1*(cNott+othCostBSC/(1+DR)^_stage)
Final Cost: 0.5 *(cNott+othCostBSC/(1+DR)^_stage)
Init Eff: 0.5 * ((1/12)*(uProg/(1+DR)^_stage))
Incr Eff: (1/12)*(uProg/(1+DR)^_stage)
Final Eff: 0.5 * ((1/12)*(uProg/(1+DR)^_stage))
0
survive
#
PD No treat/BSC
die due to GIST
deathBSC
Death
Death
--- Markov Information
Init Cost: 0
Incr Cost: 0
Final Cost: 0
Init Eff: 0
Incr Eff: 0
Final Eff: 0
0

APPENDIX 13 ALTERNATIVE BEST SUPPORTIVE CARE SURVIVAL ESTIMATES

Source	Year	Definition of population for which survival outcome is given	Number in sample	Follow-Up Time	Median OS	% Survivng
Conlon[18]	1995	Those not having a complete resection	38	5 years		0%
DeMatteo [19][De Mestier[111]	2000 2005	Metastatic (inc 28/94 who had complete resection)	94	14 months	19 months	<30% at 1 year
DeMatteo[19]	2000	Those not having a complete resection	86	14 months	12 months	
Demetri[50]	2006	Receiving placebo after median prior IM dose of 800mg	105	7.2 months		62.5%
Nilsson[26]	2005	Those with overtly malignant GISTs	29		1.4 years	5/29
von Mehren [112]	2006	Those who had metastic GIST or recurrence after primary resection			6 months to 18 months	
Plaat[113]	2000	Those with malignant GIST (18/26 had metastatic disease)	26	 2 years 5 years	28 months	 58.5% 13.0%
Pidhorecky[114]	2000	Those undergoing palliative surgical procedure/biopsy Those with unresectable metastatic GIST	11	5 years	15 months 40 months	10%
Comandone[115]		Metastatic GIST			6 months	
Pierie [104]	2001	Those with incomplete resection (41% had metastatic disease)	69	3 years 5 years		13% 9%
Duffaud [116]	2003	Those with unresectable disease			10 to 20 months	
Cohen[117]	2002	Those with metastatic or recurrent disease			12 to 19 months	
Totman[118] /Van Oosterom [38]	2001	Those with unresectable or metastatic sarcoma (inc GIST)			53 weeks	
Katz [119]	2008	Those who could not undergo complete resection			9 to 12 months	
Trent [120]	2003	Those with advanced/metastatic GIST treated with temozolomide, of which none responded	17	2 years	26.4 months	62%†
Le Cesne[121] /Verweij[40]	2009/2004	Those presenting with incurable advanced disease		2 years	10.25 months†	25%
McGrath[103]	1987	Those with partial resection Those with distant metastases	21 28	5 years 5 year	9 months 10 months	10% 0%
Dougherty[122]	1991	Presenting with unresectable disease	15	2.167 years 2.75 years 4.167	12 months	3/15 2/15 1/15
Artiynan [102]	2008	Those with metastatic GIST	140	3 years 3 years 11 months	12 months	24% 21%